# 世界卫生组织基本药物示范清单：第22份清单（2021年）

![](<../.gitbook/assets/0 (1)>)

WHO/MHP/HPS/EML/2021.02

**© World Health Organization 2021**

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; [https://creativecommons.org/licenses/by-nc-sa/3.0/igo)](https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: _“_This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization [(http://www.wipo.int/amc/en/mediation/rules/)](http://www.wipo.int/amc/en/mediation/rules/).

**Suggested citation**. World Health Organization Model List of Essential Medicines **** – **** 22nd List, 2021. Geneva: World

Health Organization; 2021 (WHO/MHP/HPS/EML/2021.02). Licence: [CC BY-NC-SA 3.0 IGO.](https://creativecommons.org/licenses/by-nc-sa/3.0/igo/)

**Cataloguing-in-Publication (CIP) data.** CIP data are available at **** [http://apps.who.int/iris.](http://apps.who.int/iris/)

**Sales, rights and licensing.** To purchase WHO publications, see **** [http://apps.who.int/bookorders. ](http://apps.who.int/bookorders)**To** submit requests **** for commercial use and queries on rights and licensing, see [http://www.who.int/about/licensing.](http://www.who.int/about/licensing)

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, **** figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply **** the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of WHO.

The recommendations contained in this publication are based on the advice of independent experts, who have considered the best available evidence, a risk–benefit analysis and other factors, as appropriate. This publication may include recommendations on the use of medicinal products for an indication, in a dosage form, dose regimen, population or other use parameters that are not included in the approved labelling. Relevant stakeholders should familiarize themselves with applicable national legal and ethical requirements. WHO does not accept any liability for the procurement, distribution and/or administration of any product for any use.

![](../.gitbook/assets/1)WHO Model List of Essential Medicines – 22nd List (2021) Explanatory notes

![](../.gitbook/assets/2)

The **core list** presents a list of minimum medicine needs for a basic health-care system, listing the most efficacious, safe and cost–effective medicines for priority conditions. Priority conditions are selected on the basis of current and estimated future public health relevance, and potential for safe and cost-effective treatment.

Where the **\[c]** symbol is placed next to an individual medicine or strength of medicine on the core list it signifies that there is a specific indication for restricting its use to children.

The **complementary list** presents essential medicines for priority diseases, for which specialized diagnostic or monitoring facilities, and/or specialist medical care, and/or specialist training are needed. In case of doubt medicines may also be listed as complementary on the basis of consistent higher costs or less attractive cost-effectiveness in a variety of settings.

Where the _**\[c]**_ symbol is placed next to an individual medicine or strength of medicine on the complementary list it signifies that the medicine(s) require(s) specialist diagnostic or monitoring facilities, and/or specialist medical care, and/or specialist training for their use in children.

The **square box symbol ()** is intended to indicate therapeutic alternatives to the listed medicine that may be considered for selection in national essential medicines lists. Alternatives may be individual medicines, or multiple medicines within a pharmacological class or chemical subgroup, defined at the 4th level of the [Anatomical Therapeutic Chemical (ATC) classification, ](https://www.whocc.no/atc\_ddd\_index/)which have similar clinical effectiveness and safety. The listed medicine should be the example of the class or subgroup for which there is the best evidence for effectiveness and safety. In some cases, this may be the first medicine that is licensed for marketing; in other instances, subsequently licensed compounds may be safer or more effective. Where there is no difference in terms of efficacy and safety data, the listed medicine should be the one that is generally available at the lowest price, based on international drug price information sources. Not all square box listings are applicable to medicine selection for children. A square box is not used to indicate alternative generic brands of the same small molecule medicines, nor alternative biosimilars of biological medicines. However, the selection and use of quality-assured generics and biosimilars of essential medicines at country level is recommended.

National lists should not use a similar symbol and should be specific in their final selection, which would depend on local availability and price.

![](<../.gitbook/assets/3 (1)>)

The **a** symbol indicates that there is an age or weight restriction on use of the medicine; details for each medicine can be found in Table 1.1.

The presence of an entry on the Essential Medicines List carries no assurance as to pharmaceutical quality. It is the responsibility of the relevant national or regional drug regulatory authority to ensure that each product is of appropriate pharmaceutical quality (including stability) and that, when relevant, different products are interchangeable.

For recommendations and advice concerning all aspects of the quality assurance of medicines see the WHO website [https://www.who.int/teams/health-product-and-policy-standards/standards-and-specifications/norms-and-standards-for-pharmaceuticals/guidelines/quality-assurance](https://www.who.int/teams/health-product-and-policy-standards/standards-and-specifications/norms-and-standards-for-pharmaceuticals/guidelines/quality-assurance)

Medicines and dosage forms are listed in alphabetical order within each section and the order of listing does not imply preference for one form over another. Standard treatment guidelines should be consulted for information on appropriate dosage forms.

The main terms used for dosage forms in the Essential Medicines List can be found in Table 1.2.

Definitions of many of these terms and pharmaceutical quality requirements applicable to the different categories are published in the current edition of _The International Pharmacopoeia._ [https://www.who.int/teams/health-product-and-policy-standards/standards-and-specifications/norms-and-standards-for-pharmaceuticals/pharmacopoeia.](https://www.who.int/teams/health-product-and-policy-standards/standards-and-specifications/norms-and-standards-for-pharmaceuticals/pharmacopoeia)

**WHO Model List of Essential Medicines – 22nd List (2021)**

**1. ANAESTHETICS, PREOPERATIVE MEDICINES AND MEDICAL GASES**

**1.1 General anaesthetics and oxygen**

**1.1.1 Inhalational medicines**

| halothane                                                                  | **Inhalation.**                                                          |   |
| -------------------------------------------------------------------------- | ------------------------------------------------------------------------ | - |
|                                                                            |                                                                          |   |
| isoflurane                                                                 | **Inhalation.**                                                          |   |
|                                                                            |                                                                          |   |
| nitrous oxide                                                              | **Inhalation.**                                                          |   |
|                                                                            |                                                                          |   |
| oxygen                                                                     | **Inhalation** (medical gas).                                            |   |
|                                                                            |                                                                          |   |
| **1.1.2 Injectable medicines**                                             |                                                                          |   |
|                                                                            |                                                                          |   |
| ketamine                                                                   | **Injection:** 50 mg/mL (as hydrochloride) in 10 mL vial.                |   |
|                                                                            |                                                                          |   |
|  propofol                                                                 |                                                                          |   |
| Therapeutic alternatives:                                                  | **Injection:** 10 mg/mL; 20 mg/mL.                                       |   |
| - thiopental                                                               |                                                                          |   |
|                                                                            |                                                                          |   |
| **1.2 Local anaesthetics**                                                 |                                                                          |   |
|                                                                            |                                                                          |   |
|  bupivacaine                                                              | **Injection:** 0.25%; 0.5% (hydrochloride) in vial.                      |   |
| **Injection for spinal anaesthesia:** 0.5% (hydrochloride) in              |                                                                          |   |
| Therapeutic alternatives to be reviewed (2023)                             |                                                                          |   |
| 4 mL ampoule to be mixed with 7.5% glucose solution.                       |                                                                          |   |
|                                                                            |                                                                          |   |
|                                                                            | **Injection:** 1%; 2% (hydrochloride) in vial.                           |   |
|  lidocaine                                                                | **Injection for spinal anaesthesia:** 5% (hydrochloride) in              |   |
| Therapeutic alternatives to be reviewed (2023)                             | 2 mL ampoule to be mixed with 7.5% glucose solution.                     |   |
|                                                                            |                                                                          |   |
|                                                                            | **Topical forms:** 2% to 4% (hydrochloride).                             |   |
|                                                                            |                                                                          |   |
|                                                                            | **Dental cartridge:** 2% (hydrochloride) + epinephrine 1:80 000.         |   |
| lidocaine + epinephrine (adrenaline)                                       | **Injection:** 1%; 2% (hydrochloride or sulfate) + epinephrine 1:200 000 |   |
|                                                                            |                                                                          |   |
|                                                                            | in vial.                                                                 |   |
|                                                                            |                                                                          |   |
| _**Complementary List**_                                                   |                                                                          |   |
|                                                                            |                                                                          |   |
| _ephedrine_                                                                | _**Injection:** 30 mg/mL (hydrochloride) in 1 mL ampoule._               |   |
| _(For use in spinal anaesthesia during delivery, to prevent hypotension)._ |                                                                          |   |
|                                                                            |                                                                          |   |
|                                                                            |                                                                          |   |
| **1.3 Preoperative medication and sedation for short-term procedures**     |                                                                          |   |
|                                                                            |                                                                          |   |
| atropine                                                                   | **Injection:** 1 mg (sulfate) in 1 mL ampoule.                           |   |
|                                                                            |                                                                          |   |
|                                                                            | **Injection:** 1 mg/mL.                                                  |   |
|  midazolam                                                                | **Oral liquid:** 2 mg/mL **\[c]**.                                       |   |
|                                                                            |                                                                          |   |
| Therapeutic alternatives to be reviewed (2023)                             | **Tablet:** 7.5 mg; 15 mg.                                               |   |
|                                                                            |                                                                          |   |
|                                                                            |                                                                          |   |
| morphine                                                                   | **Injection:** 10 mg (sulfate or hydrochloride) in 1 mL ampoule.         |   |
|                                                                            |                                                                          |   |

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 1**

**WHO Model List of Essential Medicines – 22nd List (2021)**

**1.4 Medical gases**

|          | **Inhalation**                                                        |   |
| -------- | --------------------------------------------------------------------- | - |
| oxygen\* | For use in the management of hypoxaemia.                              |   |
|          |                                                                       |   |
|          | \*No more than 30% oxygen should be used to initiate resuscitation of |   |
|          | neonates less than or equal to 32 weeks of gestation.                 |   |

**2. MEDICINES FOR PAIN AND PALLIATIVE CARE**

**2.1 Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)**

| acetylsalicylic acid                                                 | **Suppository:** 50 mg to 150 mg.                                         |   |
| -------------------------------------------------------------------- | ------------------------------------------------------------------------- | - |
| **Tablet:** 100 mg to 500 mg.                                        |                                                                           |   |
|                                                                      |                                                                           |   |
|                                                                      |                                                                           |   |
|                                                                      | **Oral liquid:** 200 mg/5 mL.                                             |   |
| ibuprofen **a**                                                      | **Tablet:** 200 mg; 400 mg; 600 mg.                                       |   |
|                                                                      | **a** Not in children less than 3 months.                                 |   |
|                                                                      |                                                                           |   |
|                                                                      | **Oral liquid:** 120 mg/5 mL; 125 mg/5 mL.                                |   |
|                                                                      | **Suppository:** 100 mg.                                                  |   |
| paracetamol\*                                                        | **Tablet:** 100 mg to 500 mg.                                             |   |
|                                                                      |                                                                           |   |
|                                                                      | \*Not recommended for anti-inflammatory use due to lack of proven         |   |
|                                                                      | benefit to that effect.                                                   |   |
|                                                                      |                                                                           |   |
| **2.2 Opioid analgesics**                                            |                                                                           |   |
|                                                                      |                                                                           |   |
| codeine                                                              | **Tablet:** 30 mg (phosphate).                                            |   |
|                                                                      |                                                                           |   |
|                                                                      | **Transdermal patch:** 12 micrograms/hr; 25 micrograms/hr; 50             |   |
| fentanyl\*                                                           | micrograms/hr; 75 micrograms/hr; 100 micrograms/hr                        |   |
|                                                                      |                                                                           |   |
|                                                                      | \*For the management of cancer pain                                       |   |
|                                                                      |                                                                           |   |
|                                                                      | **Granules (slow release; to mix with water):** 20 mg to 200 mg           |   |
|                                                                      | (morphine sulfate).                                                       |   |
|  morphine                                                           | **Injection:** 10 mg (morphine hydrochloride or morphine sulfate) in 1 mL |   |
| ampoule.                                                             |                                                                           |   |
|                                                                      |                                                                           |   |
| Therapeutic alternatives:                                            | **Oral liquid:**                                                          |   |
| - hydrormorphone                                                     |                                                                           |   |
| **Tablet (slow release):** 10 mg to 200mg (morphine hydrochloride or |                                                                           |   |
| - oxycodone                                                          |                                                                           |   |
|                                                                      | morphine sulfate).                                                        |   |
|                                                                      | **Tablet (immediate release):** 10 mg (morphine sulfate).                 |   |
|                                                                      |                                                                           |   |

![](<../.gitbook/assets/4 (1)>) ![](../.gitbook/assets/5)

_**Complementary list**_

_**Tablet:** 5 mg; 10 mg (hydrochloride)_

_**Oral liquid:** 5 mg/5 mL; 10 mg/5 mL (hydrochloride)_

_methadone\*_

_**Concentrate for oral liquid:** 5 mg/mL; 10 mg/mL (hydrochloride)_

_\*For the management of cancer pain._

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 2**

**WHO Model List of Essential Medicines – 22nd List (2021)**

**2.3 Medicines for other common symptoms in palliative care**

| amitriptyline                             | **Tablet:** 10 mg; 25 mg; 75 mg.                                     |   |
| ----------------------------------------- | -------------------------------------------------------------------- | - |
|                                           |                                                                      |   |
| cyclizine **\[c]**                        | **Injection:** 50 mg/mL.                                             |   |
| **Tablet:** 50 mg.                        |                                                                      |   |
|                                           |                                                                      |   |
|                                           |                                                                      |   |
|                                           | **Injection:** 4 mg/mL (as disodium phosphate salt) in 1 mL ampoule. |   |
| dexamethasone                             | **Oral liquid**: 2 mg/5 mL.                                          |   |
|                                           | **Tablet:** 2 mg **\[c]**; 4 mg.                                     |   |
|                                           |                                                                      |   |
|                                           | **Injection:** 5 mg/mL.                                              |   |
| diazepam                                  | **Oral liquid:** 2 mg/5 mL.                                          |   |
| **Rectal solution:** 2.5 mg; 5 mg; 10 mg. |                                                                      |   |
|                                           |                                                                      |   |
|                                           | **Tablet:** 5 mg; 10 mg.                                             |   |
|                                           |                                                                      |   |
| docusate sodium                           | **Capsule:** 100 mg.                                                 |   |
| **Oral liquid:** 50 mg/5 mL.              |                                                                      |   |
|                                           |                                                                      |   |
|                                           |                                                                      |   |
| fluoxetine **a**                          | **Solid oral dosage form:** 20 mg (as hydrochloride).                |   |
| **a** > 8 years.                          |                                                                      |   |
|                                           |                                                                      |   |
|                                           |                                                                      |   |
|                                           | **Injection:** 5 mg in 1 mL ampoule.                                 |   |
| haloperidol                               | **Oral liquid:** 2 mg/mL.                                            |   |
|                                           | **Solid oral dosage form:** 0.5 mg; 2mg; 5 mg.                       |   |
|                                           |                                                                      |   |
| hyoscine butylbromide                     | **Injection:** 20 mg/mL.                                             |   |
|                                           |                                                                      |   |
| hyoscine hydrobromide **\[c]**            | **Injection:** 400 micrograms/mL; 600 micrograms/mL.                 |   |
| **Transdermal patches:** 1 mg/72 hours.   |                                                                      |   |
|                                           |                                                                      |   |
|                                           |                                                                      |   |
| lactulose **\[c]**                        | **Oral liquid:** 3.1 to 3.7 g/5 mL.                                  |   |
|                                           |                                                                      |   |
| loperamide                                | **Solid oral dosage form:** 2 mg.                                    |   |
|                                           |                                                                      |   |
|                                           | **Injection:** 5 mg/mL (hydrochloride) in 2 mL ampoule.              |   |
| metoclopramide                            | **Oral liquid:** 5 mg/5 mL**.**                                      |   |
|                                           | **Solid oral form:** 10 mg (hydrochloride).                          |   |
|                                           |                                                                      |   |
|                                           | **Injection:** 1 mg/mL; 5 mg/mL.                                     |   |
| midazolam                                 | **Oral liquid:** 2mg/mL **\[c].**                                    |   |
|                                           | **Solid oral dosage form:** 7.5 mg; 15 mg.                           |   |
|                                           |                                                                      |   |
|  ondansetron **a**                       | **Injection:** 2 mg base/mL in 2 mL ampoule (as hydrochloride).      |   |
| Therapeutic alternatives:                 | **Oral liquid:** 4 mg base/5 mL.                                     |   |
| - dolasetron                              | **Solid oral dosage form:** Eq 4 mg base; Eq 8 mg base.              |   |
| - granisetron                             |                                                                      |   |
|                                           |                                                                      |   |
| - palonosetron                            | **a** > 1 month.                                                     |   |
| - tropisetron                             |                                                                      |   |
|                                           |                                                                      |   |
| senna                                     | **Oral liquid:** 7.5 mg/5 mL.                                        |   |
|                                           |                                                                      |   |

![](<../.gitbook/assets/6 (1)>) ![](../.gitbook/assets/7) ![](<../.gitbook/assets/8 (1)>) ![](<../.gitbook/assets/9 (1)>)

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 3**

**WHO Model List of Essential Medicines – 22nd List (2021)**

**3. ANTIALLERGICS AND MEDICINES USED IN ANAPHYLAXIS**

| dexamethasone             | **Injection:** 4 mg/mL (as disodium phosphate salt) in 1 mL ampoule.        |   |
| ------------------------- | --------------------------------------------------------------------------- | - |
|                           |                                                                             |   |
| epinephrine (adrenaline)  | **Injection:** 1 mg/mL (as hydrochloride or hydrogen tartrate) in 1 mL      |   |
| ampoule.                  |                                                                             |   |
|                           |                                                                             |   |
|                           |                                                                             |   |
| hydrocortisone            | **Powder for injection:** 100 mg (as sodium succinate) in vial.             |   |
|                           |                                                                             |   |
|  loratadine\*            | **Oral liquid:** 1 mg/mL.                                                   |   |
| Therapeutic alternatives: | **Tablet:** 10 mg.                                                          |   |
| - cetirizine              | _\*There may be a role for sedating antihistamines for limited indications_ |   |
| - fexofenadine            | _(EMLc)._                                                                   |   |
|                           |                                                                             |   |
|  prednisolone            | **Oral liquid:** 5 mg/mL **\[c]**.                                          |   |
| Therapeutic alternatives: |                                                                             |   |
| **Tablet:** 5 mg; 25 mg.  |                                                                             |   |
| - prednisone              |                                                                             |   |
|                           |                                                                             |   |
|                           |                                                                             |   |

**4. ANTIDOTES AND OTHER SUBSTANCES USED IN POISONINGS**

**4.1 Non-specific**

| charcoal, activated                          | **Powder.**                                                             |   |
| -------------------------------------------- | ----------------------------------------------------------------------- | - |
|                                              |                                                                         |   |
| **4.2 Specific**                             |                                                                         |   |
|                                              |                                                                         |   |
| acetylcysteine                               | **Injection:** 200 mg/mL in 10 mL ampoule.                              |   |
| **Oral liquid:** 10% **\[c]**; 20% **\[c]**. |                                                                         |   |
|                                              |                                                                         |   |
|                                              |                                                                         |   |
| atropine                                     | **Injection:** 1 mg (sulfate) in 1 mL ampoule.                          |   |
|                                              |                                                                         |   |
| calcium gluconate                            | **Injection:** 100 mg/mL in 10 mL ampoule.                              |   |
|                                              |                                                                         |   |
| methylthioninium chloride                    | **Injection:** 10 mg/mL in 10 mL ampoule.                               |   |
| (methylene blue)                             |                                                                         |   |
|                                              |                                                                         |   |
|                                              |                                                                         |   |
| naloxone                                     | **Injection:** 400 micrograms (hydrochloride) in 1 mL ampoule.          |   |
|                                              |                                                                         |   |
| penicillamine                                | **Solid oral dosage form:** 250 mg.                                     |   |
|                                              |                                                                         |   |
| potassium ferric hexacyano-ferrate(II) -2H2O | **Powder for oral administration.**                                     |   |
| (Prussian blue)                              |                                                                         |   |
|                                              |                                                                         |   |
|                                              |                                                                         |   |
| sodium nitrite                               | **Injection:** 30 mg/mL in 10 mL ampoule.                               |   |
|                                              |                                                                         |   |
| sodium thiosulfate                           | **Injection:** 250 mg/mL in 50 mL ampoule.                              |   |
|                                              |                                                                         |   |
| _**Complementary List**_                     |                                                                         |   |
|                                              |                                                                         |   |
| _deferoxamine_                               | _**Powder for injection:** 500 mg (mesilate) in vial._                  |   |
|                                              |                                                                         |   |
| _dimercaprol_                                | _**Injection in oil:** 50 mg/mL in 2 mL ampoule._                       |   |
|                                              |                                                                         |   |
| _fomepizole_                                 | _**Injection:** 5 mg/mL (sulfate) in 20 mL ampoule or 1 g/mL (base) in_ |   |
| _1.5 mL ampoule._                            |                                                                         |   |
|                                              |                                                                         |   |
|                                              |                                                                         |   |
| _sodium calcium edetate_                     | _**Injection:** 200 mg/mL in 5 mL ampoule._                             |   |
|                                              |                                                                         |   |
| _succimer_                                   | _**Solid oral dosage form:** 100 mg._                                   |   |
|                                              |                                                                         |   |

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 4**

**WHO Model List of Essential Medicines – 22nd List (2021)**

**5. ANTICONVULSANTS/ANTIEPILEPTICS**

|                                                             | **Oral liquid:** 100 mg/5 mL.                                           |   |
| ----------------------------------------------------------- | ----------------------------------------------------------------------- | - |
| carbamazepine                                               | **Tablet (chewable):** 100 mg; 200 mg.                                  |   |
|                                                             | **Tablet (scored):** 100 mg; 200 mg.                                    |   |
|                                                             |                                                                         |   |
| diazepam                                                    | **Gel or rectal solution:** 5 mg/mL in 0.5 mL; 2 mL; 4 mL tubes.        |   |
|                                                             |                                                                         |   |
|                                                             | **Tablet:** 25 mg; 50 mg; 100 mg; 200 mg.                               |   |
|                                                             | **Tablet (chewable, dispersible):** 2 mg; 5 mg; 25 mg; 50 mg; 100 mg;   |   |
| lamotrigine\*                                               | 200 mg.                                                                 |   |
|                                                             | \*For use as adjunctive therapy for treatment-resistant partial or      |   |
|                                                             | generalized seizures.                                                   |   |
|                                                             |                                                                         |   |
|  lorazepam                                                 |                                                                         |   |
| Therapeutic alternatives:                                   | **Injection:** 2 mg/mL in 1 mL ampoule; 4 mg/mL in 1 mL ampoule.        |   |
| - diazepam (injection)                                      |                                                                         |   |
|                                                             |                                                                         |   |
| - midazolam (injection)                                     |                                                                         |   |
|                                                             |                                                                         |   |
|                                                             | **Injection:** 0.5 g/mL in 2 mL ampoule (equivalent to 1 g in 2 mL; 50% |   |
|                                                             | weight/volume); 0.5 g/mL in 10 mL ampoule (equivalent to 5 g in 10      |   |
| magnesium sulfate\*                                         | mL; 50% weight/volume).                                                 |   |
|                                                             |                                                                         |   |
|                                                             | \*For use in eclampsia and severe pre-eclampsia and not for other       |   |
|                                                             | convulsant disorders.                                                   |   |
|                                                             |                                                                         |   |
|                                                             | **Solution for oromucosal administration:** 5 mg/mL; 10 mg/mL.          |   |
| midazolam                                                   | **Ampoule\*:** 1 mg/mL; 10 mg/mL.                                       |   |
| \*For buccal administration when solution for oromucosal    |                                                                         |   |
|                                                             |                                                                         |   |
|                                                             | administration is not available.                                        |   |
|                                                             |                                                                         |   |
|                                                             | **Injection:** 200 mg/mL (sodium).                                      |   |
| phenobarbital                                               | **Oral liquid:** 15 mg/5 mL.                                            |   |
|                                                             | **Tablet:** 15 mg to 100 mg.                                            |   |
|                                                             |                                                                         |   |
|                                                             | **Injection:** 50 mg/mL (sodium) in 5 mL vial.                          |   |
|                                                             | **Oral liquid:** 25 mg to 30 mg/5 mL.\*                                 |   |
| phenytoin                                                   | **Solid oral dosage form:** 25 mg; 50 mg; 100 mg (sodium).              |   |
| **Tablet (chewable):** 50 mg.                               |                                                                         |   |
|                                                             |                                                                         |   |
|                                                             | \*The presence of both 25 mg/5 mL and 30 mg/5 mL strengths on the       |   |
|                                                             | same market would cause confusion in prescribing and dispensing and     |   |
|                                                             | should be avoided.                                                      |   |
|                                                             |                                                                         |   |
| valproic acid (sodium valproate)\*                          | **Oral liquid:** 200 mg/5 mL.                                           |   |
| _\*Avoid use in pregnancy and in women and girls of child-_ |                                                                         |   |
|                                                             |                                                                         |   |
| _bearing potential, unless alternative treatments are_      | **Tablet (crushable):** 100 mg.                                         |   |
| _ineffective or not tolerated because of the high risk of_  | **Tablet (enteric-coated):** 200 mg; 500 mg.                            |   |
| _birth defects and developmental disorders in children_     |                                                                         |   |
| _exposed to valproate in the womb._                         |                                                                         |   |
|                                                             |                                                                         |   |

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 5**

**WHO Model List of Essential Medicines – 22nd List (2021)**

_**Complementary List**_

| _ethosuximide_                                    | _**Capsule:** 250 mg._                                                  |   |
| ------------------------------------------------- | ----------------------------------------------------------------------- | - |
| _**Oral liquid:** 250 mg/5 mL._                   |                                                                         |   |
|                                                   |                                                                         |   |
|                                                   |                                                                         |   |
| _valproic acid (sodium valproate)\*_              |                                                                         |   |
| _\*Avoid use in pregnancy and in women and girls_ |                                                                         |   |
| _of child-bearing potential, unless alternative_  | _**Injection:** 100 mg/mL in 4 mL ampoule; 100 mg/mL in 10 mL ampoule._ |   |
| _treatments are ineffective or not tolerated_     |                                                                         |   |
|                                                   |                                                                         |   |
| _because of the high risk of birth defects and_   |                                                                         |   |
| _developmental disorders in children exposed to_  |                                                                         |   |
| _valproate in the womb._                          |                                                                         |   |
|                                                   |                                                                         |   |
| **6. ANTI-INFECTIVE MEDICINES**                   |                                                                         |   |
|                                                   |                                                                         |   |
| **6.1 Anthelminthics**                            |                                                                         |   |
|                                                   |                                                                         |   |
| _**6.1.1 Intestinal anthelminthics**_             |                                                                         |   |

| albendazole                                                     | **Tablet (chewable):** 400 mg.                      |   |
| --------------------------------------------------------------- | --------------------------------------------------- | - |
|                                                                 |                                                     |   |
| ivermectin                                                      | **Tablet (scored):** 3 mg.                          |   |
|                                                                 |                                                     |   |
| levamisole                                                      | **Tablet:** 50 mg; 150 mg (as hydrochloride).       |   |
|                                                                 |                                                     |   |
| mebendazole                                                     | **Tablet (chewable):** 100 mg; 500 mg.              |   |
|                                                                 |                                                     |   |
| niclosamide                                                     | **Tablet (chewable):** 500 mg.                      |   |
|                                                                 |                                                     |   |
| praziquantel                                                    | **Tablet:** 150 mg; 600 mg.                         |   |
|                                                                 |                                                     |   |
| pyrantel                                                        | **Oral liquid:** 50 mg/mL (as embonate or pamoate). |   |
| **Tablet (chewable):** 250 mg (as embonate or pamoate).         |                                                     |   |
|                                                                 |                                                     |   |
|                                                                 |                                                     |   |
| _**6.1.2 Antifilarials**_                                       |                                                     |   |
|                                                                 |                                                     |   |
| albendazole                                                     | **Tablet (chewable):** 400 mg.                      |   |
|                                                                 |                                                     |   |
| diethylcarbamazine                                              | **Tablet:** 50 mg; 100 mg (dihydrogen citrate).     |   |
|                                                                 |                                                     |   |
| ivermectin                                                      | **Tablet (scored):** 3 mg.                          |   |
|                                                                 |                                                     |   |
| _**6.1.3 Antischistosomals and other antitrematode medicines**_ |                                                     |   |
|                                                                 |                                                     |   |
| praziquantel                                                    | **Tablet:** 600 mg.                                 |   |
|                                                                 |                                                     |   |
| triclabendazole                                                 | **Tablet:** 250 mg.                                 |   |
|                                                                 |                                                     |   |
| _**Complementary List**_                                        |                                                     |   |
|                                                                 |                                                     |   |
|                                                                 | _**Capsule:** 250 mg._                              |   |
| _oxamniquine\*_                                                 | _**Oral liquid:** 250 mg/5 mL._                     |   |
|                                                                 | _\*For use when praziquantel treatment fails._      |   |
|                                                                 |                                                     |   |
| _**6.1.4 Cysticidal medicines**_                                |                                                     |   |
|                                                                 |                                                     |   |
| _**Complementary List**_                                        |                                                     |   |
|                                                                 |                                                     |   |
| _albendazole_                                                   | _**Tablet (chewable):** 400 mg._                    |   |
|                                                                 |                                                     |   |
| _mebendazole_                                                   | _**Tablet (chewable):** 500 mg._                    |   |
|                                                                 |                                                     |   |
| _praziquantel_                                                  | _**Tablet:** 500 mg; 600 mg._                       |   |
|                                                                 |                                                     |   |

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 6**

**WHO Model List of Essential Medicines – 22nd List (2021)**

**6.2 Antibacterials**

To assist in the development of tools for antibiotic stewardship at local, national and global levels and to reduce antimicrobial resistance, the Access, Watch, Reserve (AWaRe) classification of antibiotics was developed – where antibiotics are classified into different groups to emphasize the importance of their appropriate use.

**ACCESS GROUP ANTIBIOTICS**

This group includes antibiotics that have activity against a wide range of commonly encountered susceptible pathogens while also showing lower resistance potential than antibiotics in the other groups. Selected Access group antibiotics are recommended as essential first or second choice empiric treatment options for infectious syndromes reviewed by the EML Expert Committee and are listed as individual medicines on the Model Lists to improve access and promote appropriate use. They are essential antibiotics that should be widely available, affordable and quality assured.

**WATCH GROUP ANTIBIOTICS**

This group includes antibiotic classes that have higher resistance potential and includes most of the highest priority agents among the [Critically Important Antimicrobials for Human Medicine ](https://apps.who.int/iris/handle/10665/312266)and/or antibiotics that are at relatively high risk of selection of bacterial resistance. These medicines should be prioritized as key targets of stewardship programs and monitoring. Selected Watch group antibiotics are recommended as essential first or second choice empiric treatment options for a limited number of specific infectious syndromes and are listed as individual medicines on the Model Lists.

**RESERVE GROUP ANTIBIOTICS**

This group includes antibiotics and antibiotic classes that should be reserved for treatment of confirmed or suspected infections due to multi-drug-resistant organisms. Reserve group antibiotics should be treated as “last resort” options. Selected Reserve group antibiotics are listed as individual medicines on the Model Lists when they have a favourable risk-benefit profile and proven activity against “Critical Priority” or “High Priority” pathogens identified by the [WHO Priority](https://apps.who.int/iris/handle/10665/311820) [Pathogens List, ](https://apps.who.int/iris/handle/10665/311820)notably carbapenem resistant _Enterobacteriaceae_. These antibiotics should be accessible, but their use should be tailored to highly specific patients and settings, when all alternatives have failed or are not suitable. These medicines could be protected and prioritized as key targets of national and international stewardship programs involving monitoring and utilization reporting, to preserve their effectiveness.

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 7**

**WHO Model List of Essential Medicines – 22nd List (2021)**

_**6.2.1 Access group antibiotics**_

|                                   | **Injection:** 250 mg/mL (as sulfate) in 2 mL vial.                                       |                                |   |
| --------------------------------- | ----------------------------------------------------------------------------------------- | ------------------------------ | - |
|                                   |                                                                                           |                                |   |
| amikacin                          | **FIRST CHOICE**                                                                          | **SECOND CHOICE**              |   |
| − _High-risk febrile neutropenia_ | − _Sepsis in neonates and children_ **\[c]**                                              |                                |   |
|                                   |                                                                                           |                                |   |
|                                   | − _Pyelonephritis or prostatitis (severe)_                                                |                                |   |
|                                   |                                                                                           |                                |   |
|                                   | **Powder for injection**: 250 mg; 500 mg; 1 g (as sodium) in vial.                        |                                |   |
|                                   | **Powder for oral liquid:** 125 mg/5 mL; 250 mg/5 mL (as trihydrate) **\[c]**.            |                                |   |
|                                   | **Solid oral dosage form:** 250 mg; 500 mg; 1g (as trihydrate).                           |                                |   |
|                                   |                                                                                           |                                |   |
|                                   | **FIRST CHOICE**                                                                          | **SECOND CHOICE**              |   |
|                                   | − _Community acquired pneumonia (mild_                                                    | − _Acute bacterial meningitis_ |   |
|                                   | _to moderate)_                                                                            |                                |   |
| amoxicillin                       | − _Community acquired pneumonia_                                                          |                                |   |
| _(severe)_ **\[c]**               |                                                                                           |                                |   |
|                                   |                                                                                           |                                |   |
|                                   | − _Complicated severe acute_                                                              |                                |   |
|                                   | _malnutrition_ **\[c]**                                                                   |                                |   |
|                                   | − _Exacerbations of COPD_                                                                 |                                |   |
|                                   | − _Otitis media_                                                                          |                                |   |
|                                   | − _Pharyngitis_                                                                           |                                |   |
|                                   | − _Progressive apical dental abscess_                                                     |                                |   |
|                                   | − _Sepsis in neonates and children_ **\[c]**                                              |                                |   |
|                                   | − _Sinusitis_                                                                             |                                |   |
|                                   | − _Uncomplicated severe acute_                                                            |                                |   |
|                                   | _malnutrition_ **\[c]**                                                                   |                                |   |
|                                   |                                                                                           |                                |   |
|                                   | **Powder for injection:** 500 mg (as sodium) + 100 mg (as potassium salt); 1000 mg (as    |                                |   |
|                                   | sodium) + 200 mg (as potassium salt) in vial.                                             |                                |   |
|                                   | **Powder for oral liquid:** 125 mg (as trihydrate)+ 31.25 mg (as potassium salt)/5 mL;    |                                |   |
|                                   | 250 mg (as trihydrate) + 62.5 mg (as potassium salt)/5mL **\[c]**.                        |                                |   |
|                                   | **Tablet:** 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + |                                |   |
|                                   | 125 mg (as potassium salt).                                                               |                                |   |
|                                   |                                                                                           |                                |   |
|                                   | **FIRST CHOICE**                                                                          | **SECOND CHOICE**              |   |
| amoxicillin + clavulanic acid     | − _Bone and joint infections_                                                             |                                |   |
|                                   |                                                                                           |                                |   |
|                                   | − _Community acquired pneumonia_                                                          |                                |   |
|                                   | − _Community-acquired pneumonia (mild to_                                                 |                                |   |
|                                   | _(severe)_ **\[c]**                                                                       |                                |   |
|                                   | _moderate)_                                                                               |                                |   |
|                                   | − _Complicated intraabdominal_                                                            |                                |   |
|                                   | − _Community acquired pneumonia (severe)_                                                 |                                |   |
|                                   | _infections (mild to moderate)_                                                           |                                |   |
|                                   | − _Otitis media_                                                                          |                                |   |
|                                   | − _Exacerbations of COPD_                                                                 |                                |   |
|                                   | − _Surgical prophylaxis_                                                                  |                                |   |
|                                   | − _Hospital acquired pneumonia_                                                           |                                |   |
|                                   |                                                                                           |                                |   |
|                                   | − _Low-risk febrile neutropenia_                                                          |                                |   |
|                                   | − _Lower urinary tract infections_                                                        |                                |   |
|                                   | − _Sinusitis_                                                                             |                                |   |
|                                   | − _Skin and soft tissue infections_                                                       |                                |   |
|                                   |                                                                                           |                                |   |

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 8**

**WHO Model List of Essential Medicines – 22nd List (2021)**

|                                | **Powder for injection:** 500 mg; 1 g (as sodium) in vial.                                                        |                                         |   |
| ------------------------------ | ----------------------------------------------------------------------------------------------------------------- | --------------------------------------- | - |
|                                |                                                                                                                   |                                         |   |
|                                | **FIRST CHOICE**                                                                                                  | **SECOND CHOICE**                       |   |
|                                | − _Community acquired pneumonia_                                                                                  | − _Acute bacterial meningitis_          |   |
| ampicillin                     | _(severe)_ **\[c]**                                                                                               |                                         |   |
| − _Complicated intraabdominal_ |                                                                                                                   |                                         |   |
|                                |                                                                                                                   |                                         |   |
|                                | _infections_ **\[c]**                                                                                             |                                         |   |
|                                | − _Complicated severe acute_                                                                                      |                                         |   |
|                                | _malnutrition_ **\[c]**                                                                                           |                                         |   |
|                                | − _Sepsis in neonates and children_ **\[c]**                                                                      |                                         |   |
|                                |                                                                                                                   |                                         |   |
|                                | **Powder for injection:** 1.2 million IU (≈ **** 900 mg) in vial **\[c]**; 2.4 million IU (≈ **** 1.8 g) in vial. |                                         |   |
| benzathine benzylpenicillin    |                                                                                                                   |                                         |   |
|                                |                                                                                                                   |                                         |   |
|                                | **FIRST CHOICE**                                                                                                  | **SECOND CHOICE**                       |   |
|                                |                                                                                                                   |                                         |   |
|                                | − _Syphilis_                                                                                                      |                                         |   |
|                                |                                                                                                                   |                                         |   |
|                                | **Powder for injection:** 600 mg (= 1 million IU); 3 g (= 5 million IU) (sodium or potassium                      |                                         |   |
|                                | salt) in vial.                                                                                                    |                                         |   |
|                                |                                                                                                                   |                                         |   |
|                                | **FIRST CHOICE**                                                                                                  | **SECOND CHOICE**                       |   |
| benzylpenicillin               | − _Community acquired pneumonia_                                                                                  | − _Acute bacterial meningitis_ **\[c]** |   |
|                                |                                                                                                                   |                                         |   |
|                                | _(severe)_ **\[c]**                                                                                               |                                         |   |
|                                | − _Complicated severe acute_                                                                                      |                                         |   |
|                                | _malnutrition_ **\[c]**                                                                                           |                                         |   |
|                                | − _Sepsis in neonates and children_ **\[c]**                                                                      |                                         |   |
|                                | − _Syphilis_                                                                                                      |                                         |   |
|                                |                                                                                                                   |                                         |   |
|                                | **Powder for oral liquid:** 125 mg/5 mL; 250 mg/5 mL (anhydrous).                                                 |                                         |   |
|                                | **Solid oral dosage form:** 250 mg; 500 mg (as monohydrate).                                                      |                                         |   |
| cefalexin                      |                                                                                                                   |                                         |   |
| **FIRST CHOICE**               | **SECOND CHOICE**                                                                                                 |                                         |   |
|                                |                                                                                                                   |                                         |   |
|                                | − _Skin and soft tissue infections_                                                                               | − _Exacerbations of COPD_               |   |
|                                |                                                                                                                   | − _Pharyngitis_                         |   |
|                                |                                                                                                                   |                                         |   |
|                                | **Powder for injection:** 1 g (as sodium salt) in vial.                                                           |                                         |   |
|                                | **a** > 1 month.                                                                                                  |                                         |   |
| cefazolin **a**                |                                                                                                                   |                                         |   |
| **FIRST CHOICE**               | **SECOND CHOICE**                                                                                                 |                                         |   |
|                                |                                                                                                                   |                                         |   |
|                                | − _Surgical prophylaxis_                                                                                          | − _Bone and joint infections_           |   |
|                                |                                                                                                                   |                                         |   |
|                                | **Capsule:** 250 mg.                                                                                              |                                         |   |
|                                | **Oily suspension for injection\*:** 0.5 g/mL (as sodium succinate) in 2 mL ampoule.                              |                                         |   |
|                                | \*Only for the presumptive treatment of epidemic meningitis in children older than 2 years                        |                                         |   |
|                                | and in adults.                                                                                                    |                                         |   |
| chloramphenicol                | **Oral liquid:** 150 mg/5 mL (as palmitate).                                                                      |                                         |   |
|                                | **Powder for injection:** 1 g (sodium succinate) in vial.                                                         |                                         |   |
|                                |                                                                                                                   |                                         |   |
|                                | **FIRST CHOICE**                                                                                                  | **SECOND CHOICE**                       |   |
|                                |                                                                                                                   | − _Acute bacterial meningitis_          |   |
|                                |                                                                                                                   |                                         |   |

![](<../.gitbook/assets/10 (1)>) ![](<../.gitbook/assets/11 (1)>)

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 9**

**WHO Model List of Essential Medicines – 22nd List (2021)**

|                                   | **Capsule:** 150 mg (as hydrochloride).                                                         |                   |                                              |   |
| --------------------------------- | ----------------------------------------------------------------------------------------------- | ----------------- | -------------------------------------------- | - |
|                                   | **Injection:** 150 mg/mL (as phosphate); 600 mg/4 mL (as phosphate); 900 mg/6 mL (as            |                   |                                              |   |
|                                   | phosphate).                                                                                     |                   |                                              |   |
| clindamycin                       | **Oral liquid:** 75 mg/5 mL (as palmitate) **\[c]**.                                            |                   |                                              |   |
|                                   |                                                                                                 |                   |                                              |   |
|                                   |                                                                                                 |                   |                                              |   |
|                                   | **FIRST CHOICE**                                                                                |                   | **SECOND CHOICE**                            |   |
|                                   | − _Necrotizing fasciitis_                                                                       |                   | − _Bone and joint infections_                |   |
|                                   |                                                                                                 |                   |                                              |   |
|                                   | **Capsule:** 500 mg; 1 g (as sodium).                                                           |                   |                                              |   |
|                                   | **Powder for injection:** 500 mg (as sodium) in vial.                                           |                   |                                              |   |
|  cloxacillin\*                   | **Powder for oral liquid:** 125 mg/5 mL (as sodium).                                            |                   |                                              |   |
|                                   |                                                                                                 |                   |                                              |   |
| Therapeutic alternatives:         | \*cloxacillin, dicloxacillin and flucloxacillin are preferred for oral administration due to    |                   |                                              |   |
|                                   |                                                                                                 |                   |                                              |   |
| - 4th level ATC chemical subgroup | better bioavailability.                                                                         |                   |                                              |   |
| (J01CF Beta-lactamase resistant   |                                                                                                 |                   |                                              |   |
| penicillins)                      | **FIRST CHOICE**                                                                                |                   | **SECOND CHOICE**                            |   |
|                                   | − _Bone and joint infections_                                                                   |                   | − _Sepsis in neonates and children_ **\[c]** |   |
|                                   | − _Skin and soft tissue infections_                                                             |                   |                                              |   |
|                                   |                                                                                                 |                   |                                              |   |
|                                   | **Oral liquid:** 25 mg/5 mL **\[c]**; 50 mg/5 mL (anhydrous) **\[c]**.                          |                   |                                              |   |
|                                   | **Powder for injection**: 100 mg in vial.                                                       |                   |                                              |   |
|                                   | **Solid oral dosage form:** 50 mg **\[c]**; 100 mg (as hyclate).                                |                   |                                              |   |
|                                   | **a** Use in children <8 years only for life-threatening infections when no alternative exists. |                   |                                              |   |
| doxycycline **a**                 |                                                                                                 |                   |                                              |   |
| **FIRST CHOICE**                  |                                                                                                 | **SECOND CHOICE** |                                              |   |
|                                   |                                                                                                 |                   |                                              |   |
|                                   | − _Cholera_                                                                                     |                   | − _Cholera_ **\[c]**                         |   |
|                                   | − _Sexually transmitted infection due to_                                                       |                   | − _Community acquired pneumonia (mild to_    |   |
|                                   | _Chlamydia trachomatis_                                                                         |                   | _moderate)_                                  |   |
|                                   |                                                                                                 |                   | − _Exacerbations of COPD_                    |   |
|                                   |                                                                                                 |                   |                                              |   |
|                                   | **Injection:** 10 mg/mL (as sulfate); 40 mg/mL (as sulfate) in 2 mL vial.                       |                   |                                              |   |
|                                   |                                                                                                 |                   |                                              |   |
|                                   | **FIRST CHOICE**                                                                                |                   | **SECOND CHOICE**                            |   |
|                                   | − _Acute bacterial meningitis in neonates_                                                      |                   | − _Gonorrhoea_                               |   |
|                                   | **\[c]**                                                                                        |                   | − _Surgical prophylaxis_                     |   |
| gentamicin                        | − _Community acquired pneumonia_                                                                |                   |                                              |   |
| _(severe)_ **\[c]**               |                                                                                                 |                   |                                              |   |
|                                   |                                                                                                 |                   |                                              |   |
|                                   | − _Complicated intraabdominal_                                                                  |                   |                                              |   |
|                                   | _infections_ **\[c]**                                                                           |                   |                                              |   |
|                                   | − _Complicated severe acute_                                                                    |                   |                                              |   |
|                                   | _malnutrition_ **\[c]**                                                                         |                   |                                              |   |
|                                   | − _Sepsis in neonates and children_ **\[c]**                                                    |                   |                                              |   |
|                                   |                                                                                                 |                   |                                              |   |

![](<../.gitbook/assets/12 (1)>) ![](../.gitbook/assets/13)

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 10**

**WHO Model List of Essential Medicines – 22nd List (2021)**

|                                 | **Injection:** 500 mg in 100 mL vial.                                                      |                                           |   |
| ------------------------------- | ------------------------------------------------------------------------------------------ | ----------------------------------------- | - |
|                                 | **Oral liquid:** 200 mg/5 mL (as benzoate).                                                |                                           |   |
|                                 | **Suppository:** 500 mg; 1 g.                                                              |                                           |   |
|                                 | **Tablet:** 200 mg to 500 mg.                                                              |                                           |   |
|                                 |                                                                                            |                                           |   |
|                                 | **FIRST CHOICE**                                                                           | **SECOND CHOICE**                         |   |
| metronidazole                   | − _C. difficile infection_                                                                 | − _Complicated intraabdominal infections_ |   |
|                                 |                                                                                            |                                           |   |
|                                 | − _Complicated intraabdominal_                                                             | _(mild to moderate)_                      |   |
|                                 | _infections (mild to moderate)_                                                            |                                           |   |
|                                 | − _Complicated intrabdominal infections_                                                   |                                           |   |
|                                 | _(severe)_                                                                                 |                                           |   |
|                                 | − _Necrotizing fasciitis_                                                                  |                                           |   |
|                                 | − _Surgical prophylaxis_                                                                   |                                           |   |
|                                 | − _Trichomoniasis_                                                                         |                                           |   |
|                                 |                                                                                            |                                           |   |
|                                 | **Oral liquid:** 25 mg/5 mL **\[c]**.                                                      |                                           |   |
| nitrofurantoin                  | **Tablet:** 100 mg.                                                                        |                                           |   |
|                                 |                                                                                            |                                           |   |
|                                 | **FIRST CHOICE**                                                                           | **SECOND CHOICE**                         |   |
|                                 | − _Lower urinary tract infections_                                                         |                                           |   |
|                                 |                                                                                            |                                           |   |
|                                 | **Powder for oral liquid:** 250 mg/5 mL (as potassium).                                    |                                           |   |
|                                 | **Tablet:** 250 mg; 500 mg (as potassium).                                                 |                                           |   |
|                                 |                                                                                            |                                           |   |
| phenoxymethylpenicillin         | **FIRST CHOICE**                                                                           | **SECOND CHOICE**                         |   |
|                                 |                                                                                            |                                           |   |
|                                 |                                                                                            |                                           |   |
|                                 | − _Community acquired pneumonia (mild_                                                     |                                           |   |
|                                 | _to moderate)_                                                                             |                                           |   |
|                                 | − _Pharyngitis_                                                                            |                                           |   |
|                                 | − _Progressive apical dental abscess_                                                      |                                           |   |
|                                 |                                                                                            |                                           |   |
|                                 | **Powder for injection:** 1 g (=1 million IU); 3 g (=3 million IU) in vial.                |                                           |   |
|                                 | \*Procaine benzylpenicillin is not recommended as first-line treatment for neonatal sepsis |                                           |   |
|                                 | except in settings with high neonatal mortality, when given by trained health workers in   |                                           |   |
| procaine benzylpenicillin\*     | cases where hospital care is not achievable.                                               |                                           |   |
|                                 |                                                                                            |                                           |   |
|                                 | **FIRST CHOICE**                                                                           | **SECOND CHOICE**                         |   |
|                                 | − _Syphilis (congenital)_ **\[c]**                                                         | − _Syphilis_                              |   |
|                                 |                                                                                            |                                           |   |
|                                 | **Powder for injection:** 2 g (as hydrochloride) in vial.                                  |                                           |   |
|                                 |                                                                                            |                                           |   |
| spectinomycin                   | **FIRST CHOICE**                                                                           | **SECOND CHOICE**                         |   |
|                                 |                                                                                            | − _Gonorrhoea_                            |   |
|                                 |                                                                                            |                                           |   |
|                                 | **Injection:** 80 mg + 16 mg/mL in 5 mL ampoule; 80 mg + 16 mg/mL in 10 mL ampoule.        |                                           |   |
|                                 | **Oral liquid:** 200 mg + 40 mg/5 mL.                                                      |                                           |   |
|                                 | **Tablet:** 100 mg + 20 mg; 400 mg + 80 mg; 800 mg + 160 mg.                               |                                           |   |
| sulfamethoxazole + trimethoprim |                                                                                            |                                           |   |
| **FIRST CHOICE**                | **SECOND CHOICE**                                                                          |                                           |   |
|                                 |                                                                                            |                                           |   |
|                                 | − _Lower urinary tract infections_                                                         | − _Acute invasive diarrhoea / bacterial_  |   |
|                                 |                                                                                            | _dysentery_                               |   |
|                                 |                                                                                            |                                           |   |

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 11**

**WHO Model List of Essential Medicines – 22nd List (2021)**

|                                     | **Tablet:** 100 mg; 200 mg.                                                |                                              |   |
| ----------------------------------- | -------------------------------------------------------------------------- | -------------------------------------------- | - |
|                                     | **Oral liquid:** 50 mg/5 mL **\[c]**.                                      |                                              |   |
| trimethoprim                        |                                                                            |                                              |   |
| **FIRST CHOICE**                    | **SECOND CHOICE**                                                          |                                              |   |
|                                     |                                                                            |                                              |   |
|                                     | − _Lower urinary tract infections_                                         |                                              |   |
|                                     |                                                                            |                                              |   |
| _**6.2.2 Watch group antibiotics**_ |                                                                            |                                              |   |
|                                     |                                                                            |                                              |   |
|                                     | **Capsule:** 250 mg; 500 mg (anhydrous).                                   |                                              |   |
|                                     | **Oral liquid:** 200 mg/5 mL.                                              |                                              |   |
|                                     |                                                                            |                                              |   |
|                                     | **FIRST CHOICE**                                                           |                                              |   |
| azithromycin                        | − _Cholera_ **\[c]**                                                       | **SECOND CHOICE**                            |   |
|                                     |                                                                            |                                              |   |
|                                     | − _Enteric fever_                                                          |                                              |   |
|                                     |                                                                            |                                              |   |
|                                     | − _Gonorrhoea_                                                             | − _Acute invasive bacterial diarrhoea /_     |   |
|                                     | − _Sexually transmitted infection due to_                                  | _dysentery_                                  |   |
|                                     | _Chlamydia trachomatis_                                                    | − _Gonorrhoea_                               |   |
|                                     | − _Trachoma_                                                               |                                              |   |
|                                     | − _Yaws_                                                                   |                                              |   |
|                                     |                                                                            |                                              |   |
|                                     | **Powder for oral liquid:** 100 mg/5 mL **\[c]**.                          |                                              |   |
|                                     | **Solid oral dosage form:** 200 mg; 400 mg (as trihydrate).                |                                              |   |
| cefixime                            |                                                                            |                                              |   |
| **FIRST CHOICE**                    | **SECOND CHOICE**                                                          |                                              |   |
|                                     |                                                                            |                                              |   |
|                                     |                                                                            | − _Acute invasive bacterial diarrhoea /_     |   |
|                                     |                                                                            | _dysentery_                                  |   |
|                                     |                                                                            | − _Gonorrhoea_                               |   |
|                                     |                                                                            |                                              |   |
|                                     | **Powder for injection:** 250 mg (as sodium) in vial.                      |                                              |   |
|                                     | \*3rd generation cephalosporin of choice for use in hospitalized neonates. |                                              |   |
|                                     |                                                                            |                                              |   |
|                                     | **FIRST CHOICE**                                                           | **SECOND CHOICE**                            |   |
| cefotaxime\*                        | − _Acute bacterial meningitis_                                             | − _Bone and joint infections_                |   |
| − _Community acquired pneumonia_    | − _Pyelonephritis or prostatitis (mild to_                                 |                                              |   |
|                                     | _(severe)_                                                                 | _moderate)_                                  |   |
|                                     | − _Complicated intraabdominal_                                             | − _Sepsis in neonates and children_ **\[c]** |   |
|                                     | _infections (mild to moderate)_                                            |                                              |   |
|                                     | − _Complicated intraabdominal_                                             |                                              |   |
|                                     | _infections (severe)_                                                      |                                              |   |
|                                     | − _Hospital acquired pneumonia_                                            |                                              |   |
|                                     | − _Pyelonephritis or prostatitis (severe)_                                 |                                              |   |
|                                     |                                                                            |                                              |   |

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 12**

**WHO Model List of Essential Medicines – 22nd List (2021)**

|                                     | **Powder for injection:** 250 mg; 1 g; 2 g (as sodium) in vial.                               |                                              |   |
| ----------------------------------- | --------------------------------------------------------------------------------------------- | -------------------------------------------- | - |
|                                     | \*Do not administer with calcium and avoid in infants with hyperbilirubinaemia.               |                                              |   |
|                                     | **a** > 41 weeks corrected gestational age.                                                   |                                              |   |
|                                     |                                                                                               |                                              |   |
|                                     | _FIRST CHOICE_                                                                                | **SECOND CHOICE**                            |   |
|                                     | − _Acute bacterial meningitis_                                                                | − _Acute invasive bacterial diarrhoea /_     |   |
|                                     | − _Community acquired pneumonia_                                                              | _dysentery_                                  |   |
| ceftriaxone\* **a**                 | _(severe)_                                                                                    | − _Bone and joint infections_                |   |
| − _Complicated intraabdominal_      | − _Pyelonephritis or prostatitis (mild to_                                                    |                                              |   |
|                                     |                                                                                               |                                              |   |
|                                     | _infections (mild to moderate)_                                                               | _moderate)_                                  |   |
|                                     | − _Complicated intrabdominal infections_                                                      | − _Sepsis in neonates and children_ **\[c]** |   |
|                                     | _(severe)_                                                                                    |                                              |   |
|                                     | − _Endophthalmitis_                                                                           |                                              |   |
|                                     | − _Enteric fever_                                                                             |                                              |   |
|                                     | − _Gonorrhoea_                                                                                |                                              |   |
|                                     | − _Hospital acquired pneumonia_                                                               |                                              |   |
|                                     | − _Necrotizing fasciitis_                                                                     |                                              |   |
|                                     | − _Pyelonephritis or prostatitis (severe)_                                                    |                                              |   |
|                                     |                                                                                               |                                              |   |
|                                     | **Powder for injection:** 250 mg; 750 mg; 1.5 g (as sodium) in vial.                          |                                              |   |
|                                     |                                                                                               |                                              |   |
| cefuroxime                          | **FIRST CHOICE**                                                                              | **SECOND CHOICE**                            |   |
|                                     |                                                                                               | − _Surgical prophylaxis_                     |   |
|                                     |                                                                                               |                                              |   |
|                                     | **Oral liquid:** 250 mg/5 mL (anhydrous) **\[c]**.                                            |                                              |   |
|                                     | **Solution for IV infusion:** 2 mg/mL (as hyclate) **\[c]**.                                  |                                              |   |
|                                     | **Solid oral dosage form:** 250 mg; 500 mg (as hydrochloride).                                |                                              |   |
|                                     |                                                                                               |                                              |   |
| ciprofloxacin                       | **FIRST CHOICE**                                                                              | **SECOND CHOICE**                            |   |
|                                     |                                                                                               |                                              |   |
|                                     | − _Acute invasive bacterial diarrhoea /_                                                      | − _Cholera_                                  |   |
|                                     | _dysentery_                                                                                   | − _Complicated intraabdominal infections_    |   |
|                                     | − _Enteric fever_                                                                             | _(mild to moderate)_                         |   |
|                                     | − _Low-risk febrile neutropenia_                                                              |                                              |   |
|                                     | − _Pyelonephritis or prostatitis (mild to_                                                    |                                              |   |
|                                     | _moderate)_                                                                                   |                                              |   |
|                                     |                                                                                               |                                              |   |
|                                     | **Powder for oral liquid:** 125 mg/5 mL; 250                                                  | mg/5 mL.                                     |   |
|  clarithromycin†                   | **Powder for injection:** 500 mg in vial.                                                     |                                              |   |
| **Solid oral dosage form:** 500 mg. |                                                                                               |                                              |   |
| Therapeutic alternatives:           |                                                                                               |                                              |   |
|                                     |                                                                                               |                                              |   |
| - erythromycin\*                    | †clarithromycin is also listed for use in combination regimens for eradication of _H. pylori_ |                                              |   |
| in adults.                          |                                                                                               |                                              |   |
| \*as second choice treatment for    |                                                                                               |                                              |   |
|                                     |                                                                                               |                                              |   |
| pharyngitis in children (EMLc only) | **FIRST CHOICE**                                                                              | **SECOND CHOICE**                            |   |
|                                     | _Community acquired pneumonia_                                                                | − _Pharyngitis_                              |   |
|                                     | _(severe)_                                                                                    |                                              |   |
|                                     |                                                                                               |                                              |   |

![](<../.gitbook/assets/14 (1)>) ![](../.gitbook/assets/15)

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 13**

**WHO Model List of Essential Medicines – 22nd List (2021)**

|                                                              | **Powder for injection:** 2 g (as sodium) + 250 mg (as sodium); 4 g (as sodium) + 500 mg |                                                                              |                                                     |   |
| ------------------------------------------------------------ | ---------------------------------------------------------------------------------------- | ---------------------------------------------------------------------------- | --------------------------------------------------- | - |
|                                                              | (as sodium) in vial.                                                                     |                                                                              |                                                     |   |
|                                                              |                                                                                          |                                                                              |                                                     |   |
| piperacillin + tazobactam                                    | **FIRST CHOICE**                                                                         | **SECOND CHOICE**                                                            |                                                     |   |
| − _Complicated intraabdominal_                               |                                                                                          |                                                                              |                                                     |   |
|                                                              |                                                                                          |                                                                              |                                                     |   |
|                                                              | _infections (severe)_                                                                    |                                                                              |                                                     |   |
|                                                              | − _High-risk febrile neutropenia_                                                        |                                                                              |                                                     |   |
|                                                              | − _Hospital acquired pneumonia_                                                          |                                                                              |                                                     |   |
|                                                              | − _Necrotizing fasciitis_                                                                |                                                                              |                                                     |   |
|                                                              |                                                                                          |                                                                              |                                                     |   |
|                                                              | **Capsule:** 125 mg; 250 mg (as hydrochloride).                                          |                                                                              |                                                     |   |
| vancomycin                                                   |                                                                                          |                                                                              |                                                     |   |
| **FIRST CHOICE**                                             | **SECOND CHOICE**                                                                        |                                                                              |                                                     |   |
|                                                              |                                                                                          |                                                                              |                                                     |   |
|                                                              |                                                                                          |                                                                              | − _C. difficile infection_                          |   |
|                                                              |                                                                                          |                                                                              |                                                     |   |
| _**Complementary List**_                                     |                                                                                          |                                                                              |                                                     |   |
|                                                              |                                                                                          |                                                                              |                                                     |   |
|                                                              | _**Powder for injection:** 250 mg; 1 g (as pentahydrate) in vial._                       |                                                                              |                                                     |   |
| _ceftazidime_                                                |                                                                                          |                                                                              |                                                     |   |
| **FIRST CHOICE**                                             | **SECOND CHOICE**                                                                        |                                                                              |                                                     |   |
|                                                              |                                                                                          |                                                                              |                                                     |   |
|                                                              | − _Endophthalmitis_                                                                      |                                                                              |                                                     |   |
|                                                              |                                                                                          |                                                                              |                                                     |   |
|  _meropenem\*_ **a**                                        | _**Powder for injection:** 500 mg (as trihydrate); 1 g (as trihydrate) in vial._         |                                                                              |                                                     |   |
|                                                              | **a** > 3 months.                                                                        |                                                                              |                                                     |   |
| _Therapeutic alternatives\*:_                                |                                                                                          |                                                                              |                                                     |   |
| **FIRST CHOICE**                                             | **SECOND CHOICE**                                                                        |                                                                              |                                                     |   |
| _- imipenem + cilastatin_                                    |                                                                                          |                                                                              |                                                     |   |
|                                                              |                                                                                          |                                                                              |                                                     |   |
| _\*complicated intraabdominal_                               |                                                                                          |                                                                              | − _Acute bacterial meningitis in neonates **\[c]**_ |   |
| _infections and high-risk febrile_                           |                                                                                          |                                                                              | − _Complicated intraabdominal infections_           |   |
| _neutropenia only. Meropenem is the_                         |                                                                                          |                                                                              | _(severe)_                                          |   |
| _preferred choice for acute bacterial_                       |                                                                                          |                                                                              | − _High-risk febrile neutropenia_                   |   |
| _meningitis in neonates._                                    |                                                                                          |                                                                              |                                                     |   |
|                                                              |                                                                                          |                                                                              |                                                     |   |
|                                                              | _**Powder for injection:** 250 mg; 500 mg; 1 g (as hydrochloride) in vial._              |                                                                              |                                                     |   |
|                                                              |                                                                                          |                                                                              |                                                     |   |
| _vancomycin_                                                 | **FIRST CHOICE**                                                                         | **SECOND CHOICE**                                                            |                                                     |   |
| − _Endophthalmitis_                                          |                                                                                          |                                                                              |                                                     |   |
|                                                              | − _High-risk febrile neutropenia_                                                        |                                                                              |                                                     |   |
|                                                              | − _Necrotizing fasciitis_                                                                |                                                                              |                                                     |   |
|                                                              |                                                                                          |                                                                              |                                                     |   |
|                                                              |                                                                                          |                                                                              |                                                     |   |
| _**6.2.3 Reserve group antibiotics**_                        |                                                                                          |                                                                              |                                                     |   |
|                                                              |                                                                                          |                                                                              |                                                     |   |
| _**Complementary List**_                                     |                                                                                          |                                                                              |                                                     |   |
|                                                              |                                                                                          |                                                                              |                                                     |   |
| _cefiderocol_                                                |                                                                                          | _**Powder for injection:** 1 g (as sulfate toxylate) in vial._               |                                                     |   |
|                                                              |                                                                                          |                                                                              |                                                     |   |
| _ceftazidime + avibactam_                                    |                                                                                          | _**Powder for injection:** 2 g + 0.5 g in vial._                             |                                                     |   |
|                                                              |                                                                                          |                                                                              |                                                     |   |
| _colistin_                                                   |                                                                                          | _**Powder for injection:** 1 million IU (as colistemethate sodium) in vial._ |                                                     |   |
|                                                              |                                                                                          |                                                                              |                                                     |   |
| _fosfomycin_                                                 |                                                                                          | _**Powder for injection:** 2 g; 4 g (as sodium) in vial._                    |                                                     |   |
|                                                              |                                                                                          |                                                                              |                                                     |   |
|                                                              |                                                                                          | _**Injection for intravenous administration:** 2 mg/mL in 300 mL bag._       |                                                     |   |
| _linezolid_                                                  |                                                                                          | _**Powder for oral liquid**: 100 mg/5 mL._                                   |                                                     |   |
|                                                              |                                                                                          | _**Tablet:** 400 mg; 600 mg._                                                |                                                     |   |
|                                                              |                                                                                          |                                                                              |                                                     |   |
| _meropenem + vaborbactam_                                    |                                                                                          | _**Powder for injection:** 1 g (as trihydrate) + 1 g in vial._               |                                                     |   |
|                                                              |                                                                                          |                                                                              |                                                     |   |
| _plazomicin_                                                 |                                                                                          | _**Injection**: 500 mg/10 mL._                                               |                                                     |   |
|                                                              |                                                                                          |                                                                              |                                                     |   |
| _polymyxin B_                                                |                                                                                          | _**Powder for injection:** 500,000 IU in vial._                              |                                                     |   |
|                                                              |                                                                                          |                                                                              |                                                     |   |
| **WHO Model List of Essential Medicines – 22nd List (2021)** | **page 14**                                                                              |                                                                              |                                                     |   |

![](../.gitbook/assets/16) ![](../.gitbook/assets/17)

**WHO Model List of Essential Medicines – 22nd List (2021)**

_**6.2.4 Antileprosy medicines**_

Medicines used in the treatment of leprosy should never be used except in combination. Combination therapy is essential to prevent the emergence of drug resistance. Colour-coded blister packs (MDT blister packs) containing standard two-medicine (paucibacillary leprosy) or three-medicine (multibacillary leprosy) combinations for adult and childhood leprosy should be used. MDT blister packs can be supplied free of charge through WHO.

| clofazimine | **Capsule:** 50 mg; 100 mg.                 |
| ----------- | ------------------------------------------- |
|             |                                             |
| dapsone     | **Tablet:** 25 mg; 50 mg; 100 mg.           |
|             |                                             |
| rifampicin  | **Solid oral dosage form:** 150 mg; 300 mg. |
|             |                                             |

_**6.2.5 Antituberculosis medicines**_

WHO recommends and endorses the use of fixed-dose combinations and the development of appropriate new fixed-dose combinations, including modified dosage forms, non-refrigerated products and paediatric dosage forms of assured pharmaceutical quality.

|                                                                    | **Oral liquid:** 25 mg/mL **\[c]**.                        |   |
| ------------------------------------------------------------------ | ---------------------------------------------------------- | - |
| ethambutol                                                         | **Tablet:** 100 mg; 400 mg (hydrochloride).                |   |
|                                                                    | **Tablet (dispersible**): 100 mg **\[c]**                  |   |
|                                                                    |                                                            |   |
| ethambutol + isoniazid + pyrazinamide +                            | **Tablet:** 275 mg + 75 mg + 400 mg + 150 mg.              |   |
| rifampicin                                                         |                                                            |   |
|                                                                    |                                                            |   |
|                                                                    |                                                            |   |
| ethambutol + isoniazid + rifampicin                                | **Tablet:** 275 mg + 75 mg + 150 mg.                       |   |
|                                                                    |                                                            |   |
|                                                                    | **Oral liquid:** 50 mg/5 mL **\[c]**.                      |   |
| isoniazid                                                          | **Tablet:** 100 mg; 300 mg.                                |   |
|                                                                    | **Tablet (dispersible):** 100 mg **\[c]**.                 |   |
|                                                                    |                                                            |   |
| isoniazid + pyrazinamide + rifampicin                              | **Tablet (dispersible):** 50 mg + 150 mg + 75 mg **\[c]**. |   |
|                                                                    |                                                            |   |
| isoniazid + rifampicin                                             | **Tablet:** 75 mg + 150 mg; 150 mg + 300 mg.               |   |
| **Tablet (dispersible):** 50 mg + 75 mg **\[c].**                  |                                                            |   |
|                                                                    |                                                            |   |
|                                                                    |                                                            |   |
| isoniazid + rifapentine                                            | **Tablet (scored):** 300 mg + 300 mg.                      |   |
|                                                                    |                                                            |   |
| moxifloxacin                                                       | **Tablet:** 400 mg.                                        |   |
|                                                                    |                                                            |   |
|                                                                    | **Oral liquid:** 30 mg/mL **\[c]**.                        |   |
| pyrazinamide                                                       | **Tablet:** 400 mg; 500 mg                                 |   |
|                                                                    | **Tablet (dispersible):** 150 mg.                          |   |
|                                                                    |                                                            |   |
| rifabutin                                                          | **Solid oral dosage form:** 150 mg.\*                      |   |
| \*For use only in patients with HIV receiving protease inhibitors. |                                                            |   |
|                                                                    |                                                            |   |
|                                                                    |                                                            |   |
| rifampicin                                                         | **Oral liquid:** 20 mg/mL **\[c]**.                        |   |
| **Solid oral dosage form:** 150 mg; 300 mg.                        |                                                            |   |
|                                                                    |                                                            |   |
|                                                                    |                                                            |   |
| rifapentine                                                        | **Tablet:** 150 mg; 300 mg.                                |   |
|                                                                    |                                                            |   |

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 15**

**WHO Model List of Essential Medicines – 22nd List (2021)**

_**Complementary List**_

_Medicines for the treatment of multidrug-resistant tuberculosis (MDR-TB) should be used in specialized centres adhering to WHO standards for TB control._

| _amikacin_                                   | _**Injection:** 100 mg/2 mL (as sulfate) in 2 mL vial; 250 mg/mL (as sulfate) in_ |   |
| -------------------------------------------- | --------------------------------------------------------------------------------- | - |
| _2 mL vial._                                 |                                                                                   |   |
|                                              |                                                                                   |   |
|                                              |                                                                                   |   |
|                                              | _**Powder for oral liquid:** 250 mg (as trihydrate) + 62.5 mg (as potassium_      |   |
|                                              | _salt)/5mL **\[c]**._                                                             |   |
| _amoxicillin + clavulanic acid\*_            | _**Tablet:** 500 mg (as trihydrate) + 125 mg (as potassium salt)._                |   |
|                                              |                                                                                   |   |
|                                              | _\*For use only in combination with meropenem or imipenem+cilastatin._            |   |
|                                              |                                                                                   |   |
| _bedaquiline_ **a**                          | _**Tablet:** 20 mg **\[c]**; 100 mg._                                             |   |
| **a** ≥ **** 5 years                         |                                                                                   |   |
|                                              |                                                                                   |   |
|                                              |                                                                                   |   |
| _clofazimine_                                | _**Solid oral dosage form:** 50 mg; 100 mg._                                      |   |
|                                              |                                                                                   |   |
|  _cycloserine_                              |                                                                                   |   |
| _Therapeutic alternatives:_                  | _**Solid oral dosage form:** 125 mg **\[c]**; 250 mg._                            |   |
| _- terizidone_                               |                                                                                   |   |
|                                              |                                                                                   |   |
|                                              | _**Tablet (dispersible):** 25 mg **\[c]**._                                       |   |
| _delamanid_ **a**                            | **a** _≥_ **** _3_ **** years                                                     |   |
| _**Tablet:** 50 mg._                         |                                                                                   |   |
|                                              |                                                                                   |   |
|                                              | **a** _≥_ **** 6 years                                                            |   |
|                                              |                                                                                   |   |
|  _ethionamide_                              | _**Tablet:** 125 mg; 250 mg._                                                     |   |
| _Therapeutic alternatives:_                  |                                                                                   |   |
| _**Tablet (dispersible**): 125 mg **\[c]**._ |                                                                                   |   |
| _- protionamide_                             |                                                                                   |   |
|                                              |                                                                                   |   |
|                                              |                                                                                   |   |
| _levofloxacin_                               | _**Tablet:** 250mg; 500 mg; 750 mg._                                              |   |
| _**Tablet (dispersible**): 100 mg **\[c]**._ |                                                                                   |   |
|                                              |                                                                                   |   |
|                                              |                                                                                   |   |
|                                              | _**Powder for oral liquid**: 100 mg/5 mL._                                        |   |
| _linezolid_                                  | _**Tablet:** 600 mg._                                                             |   |
|                                              | _**Tablet (dispersible):** 150 mg **\[c]**._                                      |   |
|                                              |                                                                                   |   |
|  _meropenem_                                |                                                                                   |   |
| _Therapeutic alternatives:_                  | _**Powder for injection:** 500 mg (as trihydrate); 1 g (as trihydrate) in vial._  |   |
| _- imipenem + cilastatin_                    |                                                                                   |   |
|                                              |                                                                                   |   |
| _moxifloxacin_                               | _**Tablet:** 400 mg._                                                             |   |
| _**Tablet (dispersible):** 100 mg **\[c]**._ |                                                                                   |   |
|                                              |                                                                                   |   |
|                                              |                                                                                   |   |
| _p-aminosalicylic acid_                      | _**Granules:** 4 g in sachet._                                                    |   |
|                                              |                                                                                   |   |
| _streptomycin **\[c]**_                      | _**Powder for injection:** 1 g (as sulfate) in vial._                             |   |
|                                              |                                                                                   |   |

![](<../.gitbook/assets/18 (1)>) ![](<../.gitbook/assets/19 (1)>) ![](<../.gitbook/assets/20 (1)>)

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 16**

**WHO Model List of Essential Medicines – 22nd List (2021)**

**6.3 Antifungal medicines**

| amphotericin B                              | **Powder for injection:** 50 mg (as sodium deoxycholate or liposomal    |   |
| ------------------------------------------- | ----------------------------------------------------------------------- | - |
| complex) in vial.                           |                                                                         |   |
|                                             |                                                                         |   |
|                                             |                                                                         |   |
| clotrimazole                                | **Vaginal cream:** 1%; 10%.                                             |   |
| **Vaginal tablet:** 100 mg; 500 mg.         |                                                                         |   |
|                                             |                                                                         |   |
|                                             |                                                                         |   |
|                                             | **Capsule:** 50 mg.                                                     |   |
| fluconazole                                 | **Injection:** 2 mg/mL in vial.                                         |   |
|                                             | **Oral liquid:** 50 mg/5 mL.                                            |   |
|                                             |                                                                         |   |
| flucytosine                                 | **Capsule:** 250 mg.                                                    |   |
| **Infusion:** 2.5 g in 250 mL.              |                                                                         |   |
|                                             |                                                                         |   |
|                                             |                                                                         |   |
| griseofulvin                                | **Oral liquid:** 125 mg/5 mL **\[c]**.                                  |   |
| **Solid oral dosage form:** 125 mg; 250 mg. |                                                                         |   |
|                                             |                                                                         |   |
|                                             |                                                                         |   |
|                                             | **Capsule**: 100 mg.                                                    |   |
|                                             | **Oral liquid:** 10 mg/mL.                                              |   |
| itraconazole\*                              | \*For treatment of chronic pulmonary aspergillosis, histoplasmosis,     |   |
|                                             | sporotrichosis, paracoccidiodomycosis, mycoses caused by _T. marneffei_ |   |
|                                             | and chromoblastomycosis; and prophylaxis of histoplasmosis and          |   |
|                                             | infections caused by _T. marneffei_ in AIDS patients.                   |   |
|                                             |                                                                         |   |
|                                             | **Lozenge:** 100 000 IU.                                                |   |
| nystatin                                    | **Oral liquid:** 50 mg/5 mL **\[c]**; 100 000 IU/mL **\[c]**.           |   |
| **Pessary:** 100 000 IU.                    |                                                                         |   |
|                                             |                                                                         |   |
|                                             | **Tablet:** 100 000 IU; 500 000 IU.                                     |   |
|                                             |                                                                         |   |
|                                             | **Tablet:** 50 mg; 200 mg                                               |   |
|                                             | **Powder for injection:** 200 mg in vial                                |   |
| voriconazole\*                              | **Powder for oral liquid:** 40 mg/mL                                    |   |
|                                             |                                                                         |   |
|                                             | \*For treatment of chronic pulmonary aspergillosis and acute invasive   |   |
|                                             | aspergillosis.                                                          |   |
|                                             |                                                                         |   |

_**Complementary List**_

|  _micafungin_              |                                                                            |
| --------------------------- | -------------------------------------------------------------------------- |
| _Therapeutic alternatives:_ | _**Powder for injection:** 50 mg (as sodium); 100 mg (as sodium) in vial._ |
| _- anidulafungin_           |                                                                            |
| _- caspofungin_             |                                                                            |
|                             |                                                                            |
| _potassium iodide_          | _**Saturated solution.**_                                                  |
|                             |                                                                            |

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 17**

**WHO Model List of Essential Medicines – 22nd List (2021)**

**6.4 Antiviral medicines**

_**6.4.1 Antiherpes medicines**_

|  aciclovir               | **Oral liquid:** 200 mg/5 mL **\[c]**.                     |
| ------------------------- | ---------------------------------------------------------- |
| Therapeutic alternatives: | **Powder for injection:** 250 mg (as sodium salt) in vial. |
| - valaciclovir (oral)     | **Tablet:** 200 mg.                                        |
|                           |                                                            |

_**6.4.2 Antiretrovirals**_

Based on current evidence and experience of use, medicines in the following classes of antiretrovirals are included as essential medicines for treatment and prevention of HIV (prevention of mother-to-child transmission, pre-exposure prophylaxsis (where indicated) and post-exposure prophylaxis). WHO emphasizes the importance of using these products in accordance with global and national guidelines. WHO recommends and endorses the use of fixed-dose combinations and the development of appropriate new fixed-dose combinations, including modified dosage forms, non-refrigerated products and paediatric dosage forms of assured pharmaceutical quality.

Scored tablets can be used in children and therefore can be considered for inclusion in the listing of tablets, provided that adequate quality products are available.

_**6.4.2.1 Nucleoside/Nucleotide reverse transcriptase inhibitors**_

| abacavir                                                      | **Tablet:** 300 mg (as sulfate).                                                   |   |
| ------------------------------------------------------------- | ---------------------------------------------------------------------------------- | - |
|                                                               |                                                                                    |   |
| lamivudine                                                    | **Oral liquid:** 50 mg/5 mL **\[c]**.                                              |   |
| **Tablet:** 150 mg.                                           |                                                                                    |   |
|                                                               |                                                                                    |   |
|                                                               |                                                                                    |   |
|                                                               | **Tablet:** 300 mg (tenofovir disoproxil fumarate **** – **** equivalent to 245 mg |   |
| tenofovir disoproxil fumarate†                                | tenofovir disoproxil).                                                             |   |
|                                                               |                                                                                    |   |
|                                                               | †also indicated for pre-exposure prophylaxis.                                      |   |
|                                                               |                                                                                    |   |
|                                                               | **Capsule:** 250 mg.                                                               |   |
| zidovudine                                                    | **Oral liquid:** 50 mg/5 mL.                                                       |   |
| **Solution for IV infusion:** 10 mg/mL in 20 mL vial.         |                                                                                    |   |
|                                                               |                                                                                    |   |
|                                                               | **Tablet:** 300 mg.                                                                |   |
|                                                               |                                                                                    |   |
| _**6.4.2.2 Non-nucleoside reverse transcriptase inhibitors**_ |                                                                                    |   |
|                                                               |                                                                                    |   |
| efavirenz                                                     | **Tablet:** 600 mg.                                                                |   |
|                                                               |                                                                                    |   |
|                                                               | **Oral liquid:** 50 mg/5 mL.                                                       |   |
| nevirapine **a**                                              | **Tablet:** 50 mg (dispersible); 200 mg.                                           |   |
|                                                               | **a** > 6 weeks                                                                    |   |
|                                                               |                                                                                    |   |
| _**6.4.2.3 Protease inhibitors**_                             |                                                                                    |   |

Selection of protease inhibitor(s) from the Model List will need to be determined by each country after consideration of international and national treatment guidelines and experience. Ritonavir is recommended for use in combination as a pharmacological booster, and not as an antiretroviral in its own right. All other protease inhibitors should be used in boosted forms (e.g. with ritonavir).

| atazanavir + ritonavir                                    | **Tablet (heat stable):** 300 mg (as sulfate) + 100 mg. |   |
| --------------------------------------------------------- | ------------------------------------------------------- | - |
|                                                           |                                                         |   |
| darunavir**a**                                            | **Tablet:** 75 mg; 400 mg; 600 mg; 800 mg               |   |
| **a** > 3 years                                           |                                                         |   |
|                                                           |                                                         |   |
|                                                           |                                                         |   |
| lopinavir + ritonavir                                     | **Solid oral dosage form:** 40 mg + 10 mg **\[c]**.     |   |
| **Tablet (heat stable):** 100 mg + 25 mg; 200 mg + 50 mg. |                                                         |   |
|                                                           |                                                         |   |
|                                                           |                                                         |   |
| ritonavir                                                 | **Tablet (heat stable):** 25 mg; 100 mg.                |   |
|                                                           |                                                         |   |

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 18**

**WHO Model List of Essential Medicines – 22nd List (2021)**

_**6.4.2.4 Integrase inhibitors**_

|                                                                   | **Tablet (dispersible, scored):** 10 mg **\[c]**.          |   |
| ----------------------------------------------------------------- | ---------------------------------------------------------- | - |
| dolutegravir **a**                                                | **a** ≥ 4 weeks and ≥ **** 3 kg                            |   |
| **Tablet**: 50 mg                                                 |                                                            |   |
|                                                                   |                                                            |   |
|                                                                   | **a** ≥ **** 25 kg                                         |   |
|                                                                   |                                                            |   |
|                                                                   | **Granules for oral suspension**: 100 mg in sachet.        |   |
|                                                                   | **Tablet (chewable):** 25 mg.                              |   |
| raltegravir\*                                                     | **Tablet:** 400 mg.                                        |   |
|                                                                   |                                                            |   |
|                                                                   | \*For use in pregnant women and in second-line regimens in |   |
|                                                                   | accordance with WHO treatemnt guidelines.                  |   |
|                                                                   |                                                            |   |
| _**6.4.2.5 Fixed-dose combinations of antiretroviral medicines**_ |                                                            |   |

| abacavir + lamivudine                                                          | **Tablet (dispersible, scored):** 120 mg (as sulfate) + 60 mg.                    |   |
| ------------------------------------------------------------------------------ | --------------------------------------------------------------------------------- | - |
|                                                                                |                                                                                   |   |
| dolutegravir + lamivudine + tenofovir                                          | **Tablet:** 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate **** –         |   |
| equivalent to 245 mg tenofovir disoproxil)                                     |                                                                                   |   |
|                                                                                |                                                                                   |   |
|                                                                                |                                                                                   |   |
| efavirenz +  emtricitabine + tenofovir                                        |                                                                                   |   |
| Therapeutic alternatives:                                                      | **Tablet:** 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate **** –        |   |
| equivalent to 245 mg tenofovir disoproxil).                                    |                                                                                   |   |
|                                                                                |                                                                                   |   |
| - lamivudine (for emtricitabine)                                               |                                                                                   |   |
|                                                                                |                                                                                   |   |
| efavirenz + lamivudine + tenofovir                                             | **Tablet:** 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate **** –        |   |
| equivalent to 245 mg tenofovir disoproxil)                                     |                                                                                   |   |
|                                                                                |                                                                                   |   |
|                                                                                |                                                                                   |   |
|  emtricitabine + tenofovir†                                                   | **Tablet:** 200 mg + 300 mg (tenofovir disoproxil fumarate **** – **** equivalent |   |
| Therapeutic alternatives:                                                      | to 245 mg tenofovir disoproxil).                                                  |   |
|                                                                                |                                                                                   |   |
| - lamivudine (for emtricitabine)                                               | † combination also indicated for pre-exposure prophylaxis                         |   |
|                                                                                |                                                                                   |   |
| lamivudine + zidovudine                                                        | **Tablet:** 30 mg + 60 mg **\[c]**; 150 mg + 300 mg.                              |   |
|                                                                                |                                                                                   |   |
| _**6.4.2.6 Medicines for prevention of HIV-related opportunistic infections**_ |                                                                                   |   |
|                                                                                |                                                                                   |   |
| isoniazid + pyridoxine + sulfamethoxazole +                                    | **Tablet (scored):** 300 mg + 25 mg + 800 mg + 160 mg                             |   |
| trimethoprim                                                                   |                                                                                   |   |
|                                                                                |                                                                                   |   |
|                                                                                |                                                                                   |   |
| _**6.4.3 Other antivirals**_                                                   |                                                                                   |   |

ribavirin\*

valganciclovir\*

**Injection for intravenous administration:** 800 mg and 1 g in 10 mL **** phosphate buffer solution.

**Solid oral dosage form:** 200 mg; 400 mg; 600 mg.

\*For the treatment of viral haemorrhagic fevers

**Tablet:** 450 mg.

\*For the treatment of cytomegalovirus retinitis (CMVr).

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 19**

**WHO Model List of Essential Medicines – 22nd List (2021)**

_**Complementary list**_

|                                                                        | _**Capsule:** 30 mg; 45 mg; 75 mg (as phosphate)._                                 |   |
| ---------------------------------------------------------------------- | ---------------------------------------------------------------------------------- | - |
| _oseltamivir\*_                                                        | _\*Severe illness due to confirmed or suspected influenza virus_                   |   |
|                                                                        |                                                                                    |   |
|                                                                        | _infection in critically ill hospitalized patients_                                |   |
|                                                                        |                                                                                    |   |
|                                                                        | _**Powder for oral solution:** 50 mg/mL_                                           |   |
| _valganciclovir\***\[c]**_                                             | _**Tablet:** 450 mg._                                                              |   |
|                                                                        | _\*For the treatment of cytomegalovirus retinitis (CMVr)._                         |   |
|                                                                        |                                                                                    |   |
| _**6.4.4 Antihepatitis medicines**_                                    |                                                                                    |   |
|                                                                        |                                                                                    |   |
| _**6.4.4.1 Medicines for hepatitis B**_                                |                                                                                    |   |
|                                                                        |                                                                                    |   |
| _**6.4.4.1.1 Nucleoside/Nucleotide reverse transcriptase inhibitors**_ |                                                                                    |   |
|                                                                        |                                                                                    |   |
| entecavir                                                              | **Oral liquid:** 0.05 mg/mL                                                        |   |
| **Tablet:** 0.5 mg; 1 mg                                               |                                                                                    |   |
|                                                                        |                                                                                    |   |
|                                                                        |                                                                                    |   |
| tenofovir disoproxil fumarate                                          | **Tablet:** 300 mg (tenofovir disoproxil fumarate **** – **** equivalent to 245 mg |   |
| tenofovir disoproxil).                                                 |                                                                                    |   |
|                                                                        |                                                                                    |   |
|                                                                        |                                                                                    |   |

_**6.4.4.2 Medicines for hepatitis C**_

Pangenotypic direct-acting antivirals should be considered as therapeutic alternatives for the purposes of selection and procurement at national level.

_**6.4.4.2.1 □ Pangenotypic direct-acting antiviral combinations**_

| daclatasvir\*                                                         | **Tablet:** 30 mg; 60 mg (as hydrochloride).          |   |
| --------------------------------------------------------------------- | ----------------------------------------------------- | - |
| \*Pangenotypic when used in combination with sofosbuvir               |                                                       |   |
|                                                                       |                                                       |   |
|                                                                       |                                                       |   |
| daclatasvir + sofosbuvir                                              | **Tablet**: 60 mg + 400 mg**.**                       |   |
|                                                                       |                                                       |   |
| glecaprevir + pibrentasvir                                            | **Tablet:** 100 mg + 40 mg.                           |   |
| **Granules**: 50 mg + 20 mg in sachet **\[c]**.                       |                                                       |   |
|                                                                       |                                                       |   |
|                                                                       |                                                       |   |
| sofosbuvir\*                                                          | **Tablet:** 200 mg; 400 mg.                           |   |
| \*Pangenotypic when used in combination with daclatasvir              |                                                       |   |
|                                                                       |                                                       |   |
|                                                                       |                                                       |   |
| sofosbuvir + velpatasvir                                              | **Tablet:** 200 mg + 50 mg **\[c];** 400 mg + 100 mg. |   |
|                                                                       |                                                       |   |
| _**6.4.4.2.2 Non-pangenotypic direct-acting antiviral combinations**_ |                                                       |   |
|                                                                       |                                                       |   |
| dasabuvir                                                             | **Tablet:** 250 mg.                                   |   |
|                                                                       |                                                       |   |
| ledipasvir + sofosbuvir                                               | **Tablet:** 90 mg + 400 mg.                           |   |
|                                                                       |                                                       |   |
| ombitasvir + paritaprevir + ritonavir                                 | **Tablet:** 12.5 mg + 75 mg + 50 mg.                  |   |
|                                                                       |                                                       |   |

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 20**

**WHO Model List of Essential Medicines – 22nd List (2021)**

_**6.4.4.2.3 Other antivirals for hepatitis C**_

|                                                            | **Injection for intravenous administration:** 800 mg and 1 g in 10 mL |   |
| ---------------------------------------------------------- | --------------------------------------------------------------------- | - |
|                                                            | phosphate buffer solution.                                            |   |
| ribavirin\*                                                | **Solid oral dosage form:** 200 mg; 400 mg; 600 mg.                   |   |
|                                                            | \*For the treatment of hepatitis C, in combination with direct acting |   |
|                                                            | anti-viral medicines                                                  |   |
|                                                            |                                                                       |   |
| _**Complementary list**_                                   |                                                                       |   |
|                                                            |                                                                       |   |
|                                                            | _**Vial or pre-filled syringe:**_                                     |   |
| _pegylated interferon alfa (2a or 2b) \*_                  | _180 micrograms (peginterferon alfa-2a)._                             |   |
| _80 micrograms, 100 micrograms (peginterferon alfa-2b)._   |                                                                       |   |
|                                                            |                                                                       |   |
|                                                            | \*_To be used in combination with ribavirin._                         |   |
|                                                            |                                                                       |   |
| **6.5 Antiprotozoal medicines**                            |                                                                       |   |
|                                                            |                                                                       |   |
| _**6.5.1 Antiamoebic and antigiardiasis medicines**_       |                                                                       |   |
|                                                            |                                                                       |   |
| diloxanide **a**                                           | **Tablet:** 500 mg (furoate).                                         |   |
| **a** > 25 kg.                                             |                                                                       |   |
|                                                            |                                                                       |   |
|                                                            |                                                                       |   |
|  metronidazole                                            | **Injection:** 500 mg in 100 mL vial.                                 |   |
| Therapeutic alternatives:                                  | **Oral liquid:** 200 mg/5 mL (as benzoate).                           |   |
| - tinidazole                                               | **Tablet:** 200 mg to 500 mg.                                         |   |
|                                                            |                                                                       |   |
| _**6.5.2 Antileishmaniasis medicines**_                    |                                                                       |   |
|                                                            |                                                                       |   |
| amphotericin B                                             | **Powder for injection:** 50 mg in vial (as sodium deoxycholate or    |   |
| liposomal complex).                                        |                                                                       |   |
|                                                            |                                                                       |   |
|                                                            |                                                                       |   |
| miltefosine                                                | **Solid oral dosage form:** 10 mg; 50 mg.                             |   |
|                                                            |                                                                       |   |
| paromomycin                                                | **Solution for intramuscular injection:** 750 mg of paromomycin base  |   |
|                                                            | (as sulfate).                                                         |   |
| sodium stibogluconate **or** meglumine antimoniate         | **Injection:** 100 mg/mL, 1 vial = 30 mL **or** 30%, equivalent to    |   |
| approximately 8.1% antimony (pentavalent) in 5 mL ampoule. |                                                                       |   |
|                                                            |                                                                       |   |
|                                                            |                                                                       |   |
| _**6.5.3 Antimalarial medicines**_                         |                                                                       |   |
|                                                            |                                                                       |   |
| _**6.5.3.1 For curative treatment**_                       |                                                                       |   |

Medicines for the treatment of _P. falciparum_ malaria cases should be used in combination. The list currently recommends combinations according to treatment guidelines. WHO recognizes that not all of the fixed dose combinations (FDCs) in the WHO treatment guidelines exist, and encourages their development and rigorous testing. WHO also encourages development and testing of rectal dosage formulations.

**Tablet:** 153 mg or 200 mg (as hydrochloride).

amodiaquine\*

\*To be used in combination with artesunate 50 mg.

**Oily injection:** 80 mg/mL in 1 mL ampoule.

artemether\*

\*For use in the management of severe malaria.

**Tablet:** 20 mg + 120 mg.

artemether + lumefantrine\* **Tablet (dispersible):** 20 mg + 120 mg **\[c]**.

\*Not recommended in the first trimester of pregnancy or in children below 5 kg.

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 21**

**WHO Model List of Essential Medicines – 22nd List (2021)**

|                                                                       | **Injection:** ampoules, containing 60 mg anhydrous artesunic acid with       |   |
| --------------------------------------------------------------------- | ----------------------------------------------------------------------------- | - |
|                                                                       | a separate ampoule of 5% sodium bicarbonate solution.                         |   |
|                                                                       | For use in the management of severe malaria.                                  |   |
|                                                                       | **Rectal dosage form:** 50 mg **\[c]**; 100 mg **\[c]**; 200 mg capsules (for |   |
| artesunate\*                                                          | pre-referral treatment of severe malaria only; patients should be             |   |
| taken to an appropriate health facility for follow-up care) **\[c]**. |                                                                               |   |
|                                                                       |                                                                               |   |
|                                                                       | **Tablet:** 50 mg.                                                            |   |
|                                                                       | \*To be used in combination with either amodiaquine, mefloquine or            |   |
|                                                                       | sulfadoxine + pyrimethamine.                                                  |   |
|                                                                       |                                                                               |   |
|                                                                       | **Tablet:** 25 mg + 67.5 mg; 50 mg + 135 mg; 100 mg + 270 mg.                 |   |
| artesunate + amodiaquine\*                                            | \*Other combinations that deliver the target doses required such as           |   |
|                                                                       | 153 mg or 200 mg (as hydrochloride) with 50 mg artesunate can be              |   |
|                                                                       | alternatives.                                                                 |   |
| artesunate + mefloquine                                               | **Tablet:** 25 mg + 55 mg; 100 mg + 220 mg.                                   |   |
|                                                                       |                                                                               |   |
|                                                                       | **Granules**: 20 mg + 60 mg **\[c]**.                                         |   |
| artesunate + pyronaridine tetraphosphate **a**                        | **Tablet:** 60 mg + 180 mg.                                                   |   |
|                                                                       | **a** > 5 kg                                                                  |   |
|                                                                       |                                                                               |   |
|                                                                       | **Oral liquid:** 50 mg/5 mL (as phosphate or sulfate).                        |   |
| chloroquine\*                                                         | **Tablet:** 100 mg; 150 mg (as phosphate or sulfate).                         |   |
|                                                                       | \*For use only for the treatment of _Plasmodium vivax_ infection.             |   |
|                                                                       |                                                                               |   |
| dihydroartemisinin + piperaquine phosphate **a**                      | **Tablet:** 20 mg + 160 mg; 40 mg + 320 mg.                                   |   |
| **a** > 5 kg                                                          |                                                                               |   |
|                                                                       |                                                                               |   |
|                                                                       |                                                                               |   |
|                                                                       | **Capsule:** 100 mg (as hydrochloride or hyclate).                            |   |
| doxycycline\*                                                         | **Tablet (dispersible):** 100 mg (as monohydrate).                            |   |
|                                                                       | \*For use only in combination with quinine.                                   |   |
|                                                                       |                                                                               |   |
| mefloquine\*                                                          | **Tablet:** 250 mg (as hydrochloride).                                        |   |
| \*To be used in combination with artesunate 50 mg.                    |                                                                               |   |
|                                                                       |                                                                               |   |
|                                                                       |                                                                               |   |
|                                                                       | **Tablet:** 7.5 mg; 15 mg (as diphosphate).                                   |   |
| primaquine\*                                                          | \*Only for use to achieve radical cure of _Plasmodium vivax_ and              |   |
|                                                                       |                                                                               |   |
|                                                                       | _Plasmodium ovale_ infections, given for 14 days.                             |   |
|                                                                       |                                                                               |   |
|                                                                       | **Injection:** 300 mg/mL (hydrochloride) in 2 mL ampoule.                     |   |
| quinine\*                                                             | **Tablet:** 300 mg (sulfate) or 300 mg (bisulfate).                           |   |
|                                                                       |                                                                               |   |
|                                                                       | \*For use only in the management of severe malaria and should be              |   |
|                                                                       | used in combination with doxycycline.                                         |   |
|                                                                       |                                                                               |   |
| sulfadoxine + pyrimethamine\*                                         | **Tablet:** 500 mg + 25 mg.                                                   |   |
| \*Only in combination with artesunate 50 mg.                          |                                                                               |   |
|                                                                       |                                                                               |   |
|                                                                       |                                                                               |   |

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 22**

**WHO Model List of Essential Medicines – 22nd List (2021)**

_**6.5.3.2 For chemoprevention**_

|                                                                      | **Co-packaged dispersible tablets:**                                 |   |
| -------------------------------------------------------------------- | -------------------------------------------------------------------- | - |
|                                                                      | amodiaquine 76.5 mg (as hydrochloride) \[3] and sulfadoxine +        |   |
| amodiaquine – sulfadoxine + pyrimethamine **\[c]**                   | pyrimethamine 250 mg + 12.5 mg \[1];                                 |   |
|                                                                      | amodiaquine 153 mg (as hydrochloride) \[3] and sulfadoxine           |   |
|                                                                      | + pyrimethamine 500 mg + 25 mg \[1].                                 |   |
|                                                                      |                                                                      |   |
|                                                                      | **Oral liquid:** 50 mg/5 mL (as phosphate or sulfate).               |   |
| chloroquine\*                                                        | **Tablet:** 150 mg (as phosphate or sulfate).                        |   |
|                                                                      |                                                                      |   |
|                                                                      | \*For use only in central American regions, for _Plasmodium vivax_   |   |
|                                                                      | infections.                                                          |   |
|                                                                      |                                                                      |   |
| doxycycline **a**                                                    | **Solid oral dosage form:** 100 mg (as hydrochloride or hyclate).    |   |
| **a** > 8 years.                                                     |                                                                      |   |
|                                                                      |                                                                      |   |
|                                                                      |                                                                      |   |
| mefloquine **a**                                                     | **Tablet:** 250 mg (as hydrochloride).                               |   |
| **a** > 5 kg or > 3 months.                                          |                                                                      |   |
|                                                                      |                                                                      |   |
|                                                                      |                                                                      |   |
| proguanil\*                                                          | **Tablet:** 100 mg (as hydrochloride).                               |   |
| \*For use only in combination with chloroquine.                      |                                                                      |   |
|                                                                      |                                                                      |   |
|                                                                      |                                                                      |   |
| sulfadoxine + pyrimethamine                                          | **Tablet:** 250 mg + 12.5 mg **\[c]**; 500 mg + 25 mg.               |   |
|                                                                      |                                                                      |   |
| _**6.5.4 Antipneumocystosis and antitoxoplasmosis medicines**_       |                                                                      |   |
|                                                                      |                                                                      |   |
| pyrimethamine                                                        | **Tablet:** 25 mg.                                                   |   |
|                                                                      |                                                                      |   |
| sulfadiazine                                                         | **Tablet:** 500 mg.                                                  |   |
|                                                                      |                                                                      |   |
|                                                                      | **Injection:** 80 mg + 16 mg/mL in 5 mL ampoule; 80 mg + 16 mg/mL in |   |
|                                                                      | 10 mL ampoule.                                                       |   |
| sulfamethoxazole + trimethoprim                                      | **Oral liquid:** 200 mg + 40 mg/5 mL **\[c]**.                       |   |
|                                                                      |                                                                      |   |
|                                                                      | **Tablet:** 100 mg + 20 mg; 400 mg + 80 mg **\[c]**; 800 mg + 160 mg |   |
|                                                                      |                                                                      |   |
| _**Complementary List**_                                             |                                                                      |   |
|                                                                      |                                                                      |   |
| _pentamidine_                                                        | _**Tablet:** 200 mg; 300 mg (as isethionate)._                       |   |
|                                                                      |                                                                      |   |
| _**6.5.5 Antitrypanosomal medicines**_                               |                                                                      |   |
|                                                                      |                                                                      |   |
| _**6.5.5.1 African trypanosomiasis**_                                |                                                                      |   |
|                                                                      |                                                                      |   |
| fexinidazole\*                                                       | **Tablet:** 600 mg                                                   |   |
| \*For the treatment of 1st and 2nd stage of human African            |                                                                      |   |
|                                                                      | trypanosomiasis due to _Trypanosoma brucei gambiense_ infection.     |   |
| **Medicines for the treatment of 1st stage African trypanosomiasis** |                                                                      |   |
|                                                                      |                                                                      |   |
|                                                                      | **Powder for injection:** 200 mg (as isetionate) in vial.            |   |
| pentamidine\*                                                        | \*To be used for the treatment of _Trypanosoma brucei gambiense_     |   |
|                                                                      |                                                                      |   |
|                                                                      | infection.                                                           |   |
|                                                                      |                                                                      |   |
|                                                                      | **Powder for injection:** 1 g in vial.                               |   |
| suramin sodium\*                                                     | \*To be used for the treatment of the initial phase of_Trypanosoma_  |   |
|                                                                      | _brucei rhodesiense_ infection.                                      |   |
|                                                                      |                                                                      |   |

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 23**

**WHO Model List of Essential Medicines – 22nd List (2021)**

**Medicines for the treatment of 2nd stage African trypanosomiasis**

|                                                | **Injection:** 200 mg/mL (hydrochloride) in 100 mL bottle.               |   |
| ---------------------------------------------- | ------------------------------------------------------------------------ | - |
| eflornithine\*                                 | \*To be used for the treatment of _Trypanosoma brucei gambiense_         |   |
|                                                |                                                                          |   |
|                                                | infection.                                                               |   |
|                                                |                                                                          |   |
| melarsoprol                                    | **Injection:** 180 mg/5 mL in 5 mL ampoule (3.6% solution).              |   |
|                                                |                                                                          |   |
|                                                | **Tablet:** 120 mg.                                                      |   |
| nifurtimox \*                                  | \*Only to be used in combination with eflornithine, for the treatment of |   |
|                                                | _Trypanosoma brucei gambiense_ infection.                                |   |
|                                                |                                                                          |   |
| _**Complementary List**_                       |                                                                          |   |
|                                                |                                                                          |   |
| _melarsoprol **\[c]**_                         | _**Injection:** 180 mg/5 mL in 5 mL ampoule (3.6% solution)._            |   |
|                                                |                                                                          |   |
| _**6.5.5.2 American trypanosomiasis**_         |                                                                          |   |
|                                                |                                                                          |   |
| benznidazole                                   | **Tablet:** 12.5 mg **\[c]**;100 mg.                                     |   |
| **Tablet (scored):** 50 mg.                    |                                                                          |   |
|                                                |                                                                          |   |
|                                                |                                                                          |   |
| nifurtimox                                     | **Tablet:** 30 mg; 120 mg; 250 mg.                                       |   |
|                                                |                                                                          |   |
| **6.6 Medicines for ectoparasitic infections** |                                                                          |   |
|                                                |                                                                          |   |
| ivermectin                                     | **Tablet (scored):** 3 mg                                                |   |
|                                                |                                                                          |   |
| **7. ANTIMIGRAINE MEDICINES**                  |                                                                          |   |
|                                                |                                                                          |   |
| **7.1 For treatment of acute attack**          |                                                                          |   |
|                                                |                                                                          |   |
| acetylsalicylic acid                           | **Tablet:** 300 mg to 500 mg.                                            |   |
|                                                |                                                                          |   |
| ibuprofen **\[c]**                             | **Tablet:** 200 mg; 400 mg.                                              |   |
|                                                |                                                                          |   |
| paracetamol                                    | **Oral liquid:** 120 mg/5 mL **\[c]**; 125 mg/5 mL **\[c]**.             |   |
| **Tablet:** 300 mg to 500 mg.                  |                                                                          |   |
|                                                |                                                                          |   |
|                                                |                                                                          |   |
| sumatriptan                                    | **Tablet:** 50 mg                                                        |   |
|                                                |                                                                          |   |
| **7.2 For prophylaxis**                        |                                                                          |   |
|                                                |                                                                          |   |
|  propranolol                                  | **Tablet:** 20 mg; 40 mg (hydrochloride).                                |   |
| Therapeutic alternatives to be reviewed (2023) |                                                                          |   |
|                                                |                                                                          |   |
|                                                |                                                                          |   |

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 24**

**WHO Model List of Essential Medicines – 22nd List (2021)**

**8. IMMUNOMODULATORS AND ANTINEOPLASTICS**

**8.1 Immunomodulators for non-malignant disease**

_**Complementary List**_

|  _adalimumab\*_                                           |                                                                       |   |
| ---------------------------------------------------------- | --------------------------------------------------------------------- | - |
| _Therapeutic alternatives\*:_                              |                                                                       |   |
| _- certolizumab pegol_                                     | _**Injection:** 40 mg/0.8 mL; 40 mg/0.4 mL._                          |   |
| _- etanercept_                                             |                                                                       |   |
|                                                            |                                                                       |   |
| _- golimumab_                                              |                                                                       |   |
| _- infliximab_                                             |                                                                       |   |
| _\*including quality-assured biosimilars_                  |                                                                       |   |
|                                                            |                                                                       |   |
| _azathioprine_                                             | _**Powder for injection:** 100 mg (as sodium salt) in vial._          |   |
| _**Tablet (scored):** 50 mg._                              |                                                                       |   |
|                                                            |                                                                       |   |
|                                                            |                                                                       |   |
| _ciclosporin_                                              | _**Capsule:** 25 mg._                                                 |   |
| _**Concentrate for injection:** 50 mg/mL in 1 mL ampoule._ |                                                                       |   |
|                                                            |                                                                       |   |
|                                                            |                                                                       |   |
|                                                            | _**Capsule (immediate-release):** 0.5 mg; 0.75 mg; 1 mg; 2 mg; 5 mg._ |   |
| _tacrolimus_                                               | _**Granules for oral supsension:** 0.2 mg; 1 mg._                     |   |
|                                                            | _**Injection:** 5 mg/mL in 1 mL vial._                                |   |
|                                                            |                                                                       |   |
| **8.2 Antineoplastics and supportive medicines**           |                                                                       |   |

Medicines listed below should be used according to protocols for treatment of the diseases.

_**8.2.1 Cytotoxic medicines**_

_**Complementary List**_

| _arsenic trioxide_                        | _**Concentrate for solution for infusion:** 1 mg/mL_    |   |
| ----------------------------------------- | ------------------------------------------------------- | - |
| − _Acute promyelocytic leukaemia_         |                                                         |   |
|                                           |                                                         |   |
|                                           |                                                         |   |
| _asparaginase\*_                          | _**Powder for injection:** 10 000 IU in vial._          |   |
| _\*including quality-assured biosimilars_ | − _Acute lymphoblastic leukaemia._                      |   |
|                                           |                                                         |   |
|                                           | _**Injection:** 45 mg/0.5 mL; 180 mg/2 mL._             |   |
| _bendamustine_                            | − _Chronic lymphocytic leukaemia_                       |   |
|                                           |                                                         |   |
|                                           | − _Follicular lymphoma_                                 |   |
|                                           |                                                         |   |
|                                           | _**Powder for injection:** 15 mg (as sulfate) in vial._ |   |
| _bleomycin_                               | − _Hodgkin lymphoma_                                    |   |
| − _Kaposi sarcoma_                        |                                                         |   |
|                                           |                                                         |   |
|                                           | − _Ovarian germ cell tumour_                            |   |
|                                           | − _Testicular germ cell tumour_                         |   |
|                                           |                                                         |   |
|                                           | _**Injection:** 3 mg/mL in 10 mL ampoule._              |   |
|                                           | _**Tablet:** 5 mg; 15 mg; 25 mg._                       |   |
| _calcium folinate_                        | − _Burkitt lymphoma_                                    |   |
|                                           | − _Early stage colon cancer_                            |   |
|                                           | − _Early stage rectal cancer_                           |   |
|                                           | − _Gestational trophoblastic neoplasia_                 |   |
|                                           | − _Metastatic colorectal cancer_                        |   |
|                                           | − _Osteosarcoma_                                        |   |
|                                           |                                                         |   |

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 25**

**WHO Model List of Essential Medicines – 22nd List (2021)**

|                                                              | _**Tablet:** 150 mg; 500 mg._                            |   |
| ------------------------------------------------------------ | -------------------------------------------------------- | - |
| _capecitabine_                                               | − _Early stage colon cancer_                             |   |
| − _Early stage rectal cancer_                                |                                                          |   |
|                                                              |                                                          |   |
|                                                              | − _Metastatic breast cancer_                             |   |
|                                                              | − _Metastatic colorectal cancer_                         |   |
|                                                              |                                                          |   |
|                                                              | _**Injection:** 50 mg/5 mL; 150 mg/15 mL; 450 mg/45 mL;_ |   |
|                                                              | _600 mg/60 mL._                                          |   |
|                                                              | − _Cervical cancer_                                      |   |
|                                                              | − _Early stage breast cancer_                            |   |
|                                                              | − _Epithelial ovarian cancer_                            |   |
|                                                              | − _Head and neck cancer (as a radio-sensitizer)_         |   |
| _carboplatin_                                                | − _Low-grade glioma_                                     |   |
|                                                              | − _Nasopharyngeal cancer_                                |   |
|                                                              | − _Nephroblastoma (Wilms tumour)_                        |   |
|                                                              | − _Non-small cell lung cancer_                           |   |
|                                                              | − _Osteosarcoma_                                         |   |
|                                                              | − _Ovarian germ cell tumour_                             |   |
|                                                              | − _Retinoblastoma_                                       |   |
|                                                              | − _Testicular germ cell tumour_                          |   |
|                                                              |                                                          |   |
| _chlorambucil_                                               | _**Tablet:** 2 mg._                                      |   |
| − _Chronic lymphocytic leukaemia_                            |                                                          |   |
|                                                              |                                                          |   |
|                                                              |                                                          |   |
|                                                              | _**Injection:** 10 mg/10 mL; 20 mg/20 mL; 50 mg/50 mL;_  |   |
|                                                              | _100 mg/100 mL._                                         |   |
|                                                              | − _Cervical cancer_                                      |   |
|                                                              | − _Head and neck cancer (as a radio-sensitizer)_         |   |
| _cisplatin_                                                  | − _Low-grade glioma_                                     |   |
|                                                              | − _Nasopharyngeal cancer (as a radio-sensitizer)_        |   |
|                                                              | − _Non-small cell lung cancer_                           |   |
|                                                              | − _Osteosarcoma_                                         |   |
|                                                              | − _Ovarian germ cell tumour_                             |   |
|                                                              | − _Testicular germ cell tumour_                          |   |
|                                                              |                                                          |   |
|                                                              | _**Powder for injection:** 500 mg; 1 g; 2 g in vial._    |   |
|                                                              | _**Tablet:** 25 mg, 50 mg._                              |   |
|                                                              | − _Acute lymphoblastic leukaemia_                        |   |
|                                                              | − _Burkitt lymphoma_                                     |   |
|                                                              | − _Chronic lymphocytic leukaemia_                        |   |
|                                                              | − _Diffuse large B-cell lymphoma_                        |   |
| _cyclophosphamide_                                           | − _Early stage breast cancer_                            |   |
| − _Ewing sarcoma_                                            |                                                          |   |
|                                                              | − _Follicular lymphoma_                                  |   |
|                                                              | − _Gestational trophoblastic neoplasia_                  |   |
|                                                              | − _Hodgkin lymphoma_                                     |   |
|                                                              | − _Low-grade glioma_                                     |   |
|                                                              | − _Metastatic breast cancer_                             |   |
|                                                              | − _Multiple myeloma_                                     |   |
|                                                              | − _Nephroblastoma (Wilms tumour)_                        |   |
|                                                              | − _Rhabdomyosarcoma_                                     |   |
|                                                              |                                                          |   |
|                                                              | _**Powder for injection:** 100 mg in vial._              |   |
| _cytarabine_                                                 | − _Acute lymphoblastic leukaemia_                        |   |
| − _Acute myeloid leukaemia_                                  |                                                          |   |
|                                                              |                                                          |   |
|                                                              | − _Acute promyelocytic leukaemia_                        |   |
|                                                              | − _Burkitt lymphoma._                                    |   |
|                                                              |                                                          |   |
| **WHO Model List of Essential Medicines – 22nd List (2021)** | **page 26**                                              |   |

**WHO Model List of Essential Medicines – 22nd List (2021)**

| _dacarbazine_                           | _**Powder for injection:** 100 mg in vial._                       |   |
| --------------------------------------- | ----------------------------------------------------------------- | - |
| − _Hodgkin lymphoma_                    |                                                                   |   |
|                                         |                                                                   |   |
|                                         |                                                                   |   |
|                                         | _**Powder for injection:** 500 micrograms in vial._               |   |
| _dactinomycin_                          | − _Ewing sarcoma_                                                 |   |
|                                         | − _Gestational trophoblastic neoplasia_                           |   |
|                                         | − _Nephroblastoma (Wilms tumour)_                                 |   |
|                                         | − _Rhabdomyosarcoma_                                              |   |
|                                         |                                                                   |   |
|                                         | _**Powder for injection:** 50 mg (hydrochloride) in vial._        |   |
| _daunorubicin_                          | − _Acute lymphoblastic leukaemia_                                 |   |
|                                         | − _Acute myeloid leukaemia_                                       |   |
|                                         | − _Acute promyelocytic leukaemia_                                 |   |
|                                         |                                                                   |   |
|                                         | _**Injection:** 20 mg/mL; 40 mg/mL._                              |   |
| _docetaxel_                             | − _Early stage breast cancer_                                     |   |
|                                         | − _Metastatic breast cancer_                                      |   |
|                                         | − _Metastatic prostate cancer_                                    |   |
|                                         |                                                                   |   |
|                                         | _**Powder for injection:** 10 mg; 50 mg (hydrochloride) in vial._ |   |
|                                         | − _Acute lymphoblastic leukaemia_                                 |   |
|                                         | − _Burkitt lymphoma_                                              |   |
|                                         | − _Diffuse large B-cell lymphoma_                                 |   |
|                                         | − _Early stage breast cancer_                                     |   |
| _doxorubicin_                           | − _Ewing sarcoma_                                                 |   |
| − _Follicular lymphoma_                 |                                                                   |   |
|                                         |                                                                   |   |
|                                         | − _Hodgkin lymphoma_                                              |   |
|                                         | − _Kaposi sarcoma_                                                |   |
|                                         | − _Metastatic breast cancer_                                      |   |
|                                         | − _Multiple myeloma_                                              |   |
|                                         | − _Nephroblastoma (Wilms tumour)_                                 |   |
|                                         | − _Osteosarcoma_                                                  |   |
|                                         |                                                                   |   |
|                                         | _**Capsule:** 50 mg, 100 mg._                                     |   |
|                                         | _**Injection:** 20 mg/mL in 5 mL ampoule._                        |   |
|                                         | − _Acute lymphoblastic leukaemia_                                 |   |
|                                         | − _Acute myeloid leukaemia_                                       |   |
|                                         | − _Burkitt lymphoma_                                              |   |
| _etoposide_                             | − _Ewing sarcoma_                                                 |   |
| − _Gestational trophoblastic neoplasia_ |                                                                   |   |
|                                         | − _Hodgkin lymphoma_                                              |   |
|                                         | − _Nephroblastoma (Wilms tumour)_                                 |   |
|                                         | − _Non-small cell lung cancer_                                    |   |
|                                         | − _Osteosarcoma_                                                  |   |
|                                         | − _Ovarian germ cell tumour_                                      |   |
|                                         | − _Retinoblastoma_                                                |   |
|                                         | − _Testicular germ cell tumour_                                   |   |
|                                         |                                                                   |   |
|                                         | _**Powder for injection:** 50 mg (phosphate) in vial._            |   |
| _fludarabine_                           | _**Tablet:** 10 mg_                                               |   |
|                                         | − _Chronic lymphocytic leukaemia._                                |   |
|                                         |                                                                   |   |

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 27**

**WHO Model List of Essential Medicines – 22nd List (2021)**

|                                   | _**Injection:** 50 mg/mL in 5 mL ampoule._                              |   |
| --------------------------------- | ----------------------------------------------------------------------- | - |
|                                   | − _Early stage breast cancer_                                           |   |
| _fluorouracil_                    | − _Early stage colon cancer_                                            |   |
|                                   | − _Early stage rectal cancer_                                           |   |
|                                   | − _Metastatic colorectal cancer_                                        |   |
|                                   | − _Nasopharyngeal cancer_                                               |   |
|                                   |                                                                         |   |
|                                   | _**Powder for injection:** 200 mg; 1 g in vial._                        |   |
| _gemcitabine_                     | − _Epithelial ovarian cancer_                                           |   |
|                                   |                                                                         |   |
|                                   | − _Non-small cell lung cancer_                                          |   |
|                                   |                                                                         |   |
|                                   | _**Solid oral dosage form:** 200 mg; 250 mg; 300 mg; 400 mg; 500 mg;_   |   |
| _hydroxycarbamide_                | _1 g._                                                                  |   |
|                                   |                                                                         |   |
|                                   | − _Chronic myeloid leukaemia_                                           |   |
|                                   |                                                                         |   |
|                                   | _**Powder for injection:** 500 mg; 1 g; 2 g in vial._                   |   |
|                                   | − _Burkitt lymphoma_                                                    |   |
|                                   | − _Ewing sarcoma_                                                       |   |
| _ifosfamide_                      | − _Nephroblastoma (Wilms tumour)_                                       |   |
|                                   | − _Ovarian germ cell tumour_                                            |   |
|                                   | − _Osteosarcoma_                                                        |   |
|                                   | − _Rhabdomyosarcoma_                                                    |   |
|                                   | − _Testicular germ cell tumour_                                         |   |
|                                   |                                                                         |   |
|                                   | _**Injection:** 40 mg/2 mL in 2 mL vial; 100 mg/5 mL in 5 mL vial;_     |   |
|                                   | _500 mg/25 mL in 25 mL vial._                                           |   |
| _irinotecan_                      | − _Metastatic colorectal cancer_                                        |   |
|                                   |                                                                         |   |
|                                   | − _Nephroblastoma (Wilms tumour)_                                       |   |
|                                   | − _Rhabdomyosarcoma_                                                    |   |
|                                   |                                                                         |   |
|                                   | _**Tablet:** 2 mg_                                                      |   |
| _melphalan_                       | _**Powder for injection:** 50 mg in vial_                               |   |
|                                   | − _Multiple myeloma._                                                   |   |
|                                   |                                                                         |   |
|                                   | _**Tablet:** 50 mg._                                                    |   |
| _mercaptopurine_                  | − _Acute lymphoblastic leukaemia_                                       |   |
|                                   |                                                                         |   |
|                                   | − _Acute promyelocytic leukaemia._                                      |   |
|                                   |                                                                         |   |
|                                   | _**Powder for injection:** 50 mg (as sodium salt) in vial._             |   |
|                                   | _**Tablet:** 2.5 mg (as sodium salt)._                                  |   |
| _methotrexate_                    | − _Acute lymphoblastic leukaemia_                                       |   |
| − _Acute promyelocytic leukaemia_ |                                                                         |   |
|                                   | − _Burkitt lymphoma_                                                    |   |
|                                   | − _Early stage breast cancer_                                           |   |
|                                   | − _Gestational trophoblastic neoplasia_                                 |   |
|                                   | − _Osteosarcoma_                                                        |   |
|                                   |                                                                         |   |
|                                   | _**Injection:** 50 mg/10 mL in 10 mL vial; 100 mg/20 mL in 20 mL vial;_ |   |
|                                   | _200 mg/40 mL in 40 mL vial._                                           |   |
| _oxaliplatin_                     | _**Powder for injection:** 50 mg; 100 mg in vial._                      |   |
|                                   | − _Early stage colon cancer_                                            |   |
|                                   | − _Metastatic colorectal cancer_                                        |   |
|                                   |                                                                         |   |

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 28**

**WHO Model List of Essential Medicines – 22nd List (2021)**

|                                           | _**Injection:** 6 mg/mL in vial._                                    |   |
| ----------------------------------------- | -------------------------------------------------------------------- | - |
|                                           | − _Cervical cancer_                                                  |   |
|                                           | − _Epithelial ovarian cancer_                                        |   |
| _paclitaxel_                              | − _Early stage breast cancer_                                        |   |
| − _Metastatic breast cancer_              |                                                                      |   |
|                                           |                                                                      |   |
|                                           | − _Kaposi sarcoma_                                                   |   |
|                                           | − _Nasopharyngeal cancer_                                            |   |
|                                           | − _Non-small cell lung cancer_                                       |   |
|                                           | − _Ovarian germ cell tumour_                                         |   |
|                                           |                                                                      |   |
| _pegaspargase\*_                          | _**Injection:** 3,750 units/5 mL in vial._                           |   |
| _\*including quality-assured biosimilars_ | − _Acute lymphoblastic leukaemia_                                    |   |
|                                           |                                                                      |   |
| _procarbazine **\[c]**_                   | _**Capsule:** 50 mg (as hydrochloride)._                             |   |
| − _Hodgkin lymphoma_                      |                                                                      |   |
|                                           |                                                                      |   |
|                                           |                                                                      |   |
| _realgar-Indigo naturalis formulation_    | _**Tablet:** 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)._ |   |
| − _Acute promyelocytic leukaemia_         |                                                                      |   |
|                                           |                                                                      |   |
|                                           |                                                                      |   |
| _tioguanine **\[c]**_                     | _**Solid oral dosage form:** 40 mg._                                 |   |
| − _Acute lymphoblastic leukaemia_         |                                                                      |   |
|                                           |                                                                      |   |
|                                           |                                                                      |   |
|                                           | _**Injection:** 10 mg/10 mL (sulfate) in vial._                      |   |
|                                           | _**Powder for injection:** 10 mg (sulfate) in vial._                 |   |
| _vinblastine_                             | − _Hodgkin lymphoma_                                                 |   |
| − _Kaposi sarcoma_                        |                                                                      |   |
|                                           |                                                                      |   |
|                                           | − _Low-grade glioma_                                                 |   |
|                                           | − _Ovarian germ cell tumour_                                         |   |
|                                           | − _Testicular germ cell tumour_                                      |   |
|                                           |                                                                      |   |
|                                           | _**Injection**: 1 mg/mL (sulfate); 2 mg/2 mL (sulfate) in vial._     |   |
|                                           | _**Powder for injection:** 1 mg; 5 mg (sulfate) in vial._            |   |
|                                           | − _Acute lymphoblastic leukaemia_                                    |   |
|                                           | − _Burkitt lymphoma_                                                 |   |
|                                           | − _Diffuse large B-cell lymphoma_                                    |   |
| _vincristine_                             | − _Ewing sarcoma_                                                    |   |
| − _Follicular lymphoma_                   |                                                                      |   |
|                                           | − _Gestational trophoblastic neoplasia_                              |   |
|                                           | − _Hodgkin lymphoma_                                                 |   |
|                                           | − _Kaposi sarcoma_                                                   |   |
|                                           | − _Low-grade glioma_                                                 |   |
|                                           | − _Nephroblastoma (Wilms tumour)_                                    |   |
|                                           | − _Retinoblastoma_                                                   |   |
|                                           | − _Rhabdomyosarcoma_                                                 |   |
|                                           |                                                                      |   |
|                                           | _**Capsule:** 20 mg; 30 mg; 80 mg._                                  |   |
|                                           | _**Injection:** 10 mg/mL in 1 mL vial; 50 mg/5 mL in 5 mL vial._     |   |
| _vinorelbine_                             | − _Non-small cell lung cancer_                                       |   |
|                                           |                                                                      |   |
|                                           | − _Metastatic breast cancer_                                         |   |
|                                           | − _Rhabdomyosarcoma_                                                 |   |
|                                           |                                                                      |   |

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 29**

**WHO Model List of Essential Medicines – 22nd List (2021)**

_**8.2.2 Targeted therapies**_

_**Complementary List**_

| _all-trans retinoid acid (ATRA)_                      | _**Capsule:** 10 mg._                                                   |   |
| ----------------------------------------------------- | ----------------------------------------------------------------------- | - |
| − _Acute promyelocytic leukaemia._                    |                                                                         |   |
|                                                       |                                                                         |   |
|                                                       |                                                                         |   |
| _bortezomib_                                          | _**Powder for injection:** 3.5 mg in vial._                             |   |
| − _Multiple myeloma_                                  |                                                                         |   |
|                                                       |                                                                         |   |
|                                                       |                                                                         |   |
| _dasatinib_                                           | _**Tablet:** 20 mg; 50 mg; 70 mg; 80 mg; 100 mg; 140 mg._               |   |
| − _Imatinib-resistant chronic myeloid leukaemia_      |                                                                         |   |
|                                                       |                                                                         |   |
|                                                       |                                                                         |   |
|  _erlotinib_                                         |                                                                         |   |
| _Therapeutic alternatives:_                           | _**Tablet:** 100 mg, 150 mg._                                           |   |
|                                                       |                                                                         |   |
| _- afatinib_                                          | − _EGFR mutation-positive advanced non-small cell lung cancer_          |   |
| _- gefitinib_                                         |                                                                         |   |
|                                                       |                                                                         |   |
|                                                       | _**Tablet:** 2.5 mg; 5 mg; 7.5 mg; 10 mg._                              |   |
| _everolimus_                                          | _**Tablet (dispersible):** 2 mg; 3 mg; 5 mg._                           |   |
|                                                       | − _Subependymal giant cell astrocytoma_                                 |   |
|                                                       |                                                                         |   |
| _ibrutinib_                                           | _**Capsule:** 140 mg._                                                  |   |
| − _Relapsed/refractory chronic lymphocytic leukaemia_ |                                                                         |   |
|                                                       |                                                                         |   |
|                                                       |                                                                         |   |
|                                                       | _**Solid oral dosage form:** 100 mg; 400 mg._                           |   |
| _imatinib_                                            | − _Chronic myeloid leukaemia_                                           |   |
| − _Gastrointestinal stromal tumour_                   |                                                                         |   |
|                                                       |                                                                         |   |
|                                                       | − _Philadelphia chromosome positive acute lymphoblastic_                |   |
|                                                       | _leukaemia_                                                             |   |
|                                                       |                                                                         |   |
| _nilotinib_                                           | _**Capsule:** 150 mg; 200 mg._                                          |   |
| − _Imatinib-resistant chronic myeloid leukaemia_      |                                                                         |   |
|                                                       |                                                                         |   |
|                                                       |                                                                         |   |
|                                                       | _**Injection (intravenous):** 100 mg/10 mL in 10 mL vial; 500 mg/50 mL_ |   |
| _rituximab\*_                                         | _in 50 mL vial._                                                        |   |
| − _Diffuse large B-cell lymphoma_                     |                                                                         |   |
| _\*including quality-assured biosimilars_             |                                                                         |   |
| − _Chronic lymphocytic leukaemia_                     |                                                                         |   |
|                                                       |                                                                         |   |
|                                                       | − _Follicular lymphoma_                                                 |   |
|                                                       |                                                                         |   |
| _trastuzumab\*_                                       | _**Powder for injection:** 60 mg; 150 mg; 440 mg in vial._              |   |
|                                                       |                                                                         |   |
| _\*including quality-assured biosimilars_             | − _Early stage HER2 positive breast cancer_                             |   |
| − _Metastatic HER2 positive breast cancer_            |                                                                         |   |
|                                                       |                                                                         |   |
|                                                       |                                                                         |   |

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 30**

**WHO Model List of Essential Medicines – 22nd List (2021)**

_**8.2.3 Immunomodulators**_

_**Complementary List**_

|                                                                 | _**Injection:** 120 micrograms/0.2 mL; 300 micrograms/0.5 mL;_         |   |
| --------------------------------------------------------------- | ---------------------------------------------------------------------- | - |
|                                                                 | _480 micrograms/0.8 mL in pre-filled syringe._                         |   |
|                                                                 | _**Injection:** 300 micrograms/mL in 1 mL vial; 480 micrograms/1.6 mL_ |   |
| _filgrastim\*_                                                  | _in 1.6 mL vial._                                                      |   |
| − _Primary prophylaxis in patients at high risk for developing_ |                                                                        |   |
| _\*including quality-assured biosimilars_                       |                                                                        |   |
| _febrile neutropenia associated with myelotoxic chemotherapy._  |                                                                        |   |
|                                                                 |                                                                        |   |
|                                                                 | − _Secondary prophylaxis for patients who have experienced_            |   |
|                                                                 | _neutropenia following prior myelotoxic chemotherapy_                  |   |
|                                                                 | − _To facilitate administration of dose dense chemotherapy_            |   |
|                                                                 | _regimens_                                                             |   |
|                                                                 |                                                                        |   |
| _lenalidomide_                                                  | _**Capsule:** 25 mg._                                                  |   |
| − _Multiple myeloma_                                            |                                                                        |   |
|                                                                 |                                                                        |   |
|                                                                 |                                                                        |   |
|  _nivolumab\*_                                                 | _**Concentrate solution for infusion:** 10 mg/mL._                     |   |
| _Therapeutic alternatives\*:_                                   | − _Metastatic melanoma_                                                |   |
| _- pembrolizumab_                                               |                                                                        |   |
| _\*including quality-assured biosimilars_                       |                                                                        |   |
|                                                                 |                                                                        |   |
| _thalidomide_                                                   | _**Capsule:** 50 mg._                                                  |   |
| − _Multiple myeloma_                                            |                                                                        |   |
|                                                                 |                                                                        |   |
|                                                                 |                                                                        |   |
| _**8.2.4 Hormones and antihormones**_                           |                                                                        |   |
|                                                                 |                                                                        |   |
| _**Complementary List**_                                        |                                                                        |   |
|                                                                 |                                                                        |   |
|  _abiraterone_                                                 | _**Tablet:** 250 mg; 500 mg._                                          |   |
| _Therapeutic alternatives:_                                     | − _Metastatic castration-resistant prostate cancer_                    |   |
| _- enzalutamide_                                                |                                                                        |   |
|                                                                 |                                                                        |   |
|  _anastrozole_                                                 | _**Tablet:** 1 mg._                                                    |   |
| _Therapeutic alternatives:_                                     | − _Early stage breast cancer_                                          |   |
| _- 4th level ATC chemical subgroup (L02BG_                      | − _Metastatic breast cancer_                                           |   |
| _Aromatase inhibitors)_                                         |                                                                        |   |
|                                                                 |                                                                        |   |
|  _bicalutamide_                                                | _**Tablet:** 50 mg._                                                   |   |
|                                                                 |                                                                        |   |
| _Therapeutic alternatives:_                                     | − _Metastatic prostate cancer_                                         |   |
| _- flutamide_                                                   |                                                                        |   |
| _- nilutamide_                                                  |                                                                        |   |
|                                                                 |                                                                        |   |
|                                                                 | _**Injection:** 4 mg/mL (as disodium phosphate salt) in 1 mL ampoule._ |   |
|                                                                 | _**Oral liquid:** 2 mg/5 mL **\[c]**_.                                 |   |
| _dexamethasone_                                                 | _**Tablet:** 2 mg **\[c]**; 4 mg._                                     |   |
|                                                                 | − _Acute lymphoblastic leukaemia_                                      |   |
|                                                                 | − _Burkitt lymphoma_                                                   |   |
|                                                                 | − _Multiple myeloma_                                                   |   |
|                                                                 |                                                                        |   |
|                                                                 | _**Powder for injection:** 100 mg (as sodium succinate) in vial._      |   |
| _hydrocortisone_                                                | − _Acute lymphoblastic leukaemia_                                      |   |
|                                                                 |                                                                        |   |
|                                                                 | − _Burkitt lymphoma_                                                   |   |
|                                                                 |                                                                        |   |
| **WHO Model List of Essential Medicines – 22nd List (2021)**    | **page 31**                                                            |   |

**WHO Model List of Essential Medicines – 22nd List (2021)**

|  _leuprorelin_                   | _**Injection:** 7.5 mg; 22.5 mg in pre-filled syringe._                    |                                |   |
| --------------------------------- | -------------------------------------------------------------------------- | ------------------------------ | - |
|                                   |                                                                            |                                |   |
| _Therapeutic alternatives:_       | − _Early stage breast cancer_                                              |                                |   |
| − _Metastatic prostate cancer._   |                                                                            |                                |   |
| _- goserelin_                     |                                                                            |                                |   |
|                                   |                                                                            |                                |   |
| _- triptorelin_                   |                                                                            |                                |   |
|                                   |                                                                            |                                |   |
|                                   | _**Injection:** 40 mg/mL (as sodium succinate) in 1 mL single-dose vial_   |                                |   |
|                                   | _and 5 mL multi-dose vials; 80 mg/mL (as sodium succinate) in 1 mL_        |                                |   |
| _methylprednisolone **\[c]**_     | _single-dose vial._                                                        |                                |   |
|                                   |                                                                            |                                |   |
|                                   | −                                                                          | _Acute lymphoblastic leukamia_ |   |
|                                   | −                                                                          | _Burkitt lymphoma_             |   |
|                                   |                                                                            |                                |   |
|                                   | _**Oral liquid:** 5 mg/mL **\[c]**._                                       |                                |   |
|                                   | _**Tablet:** 5 mg; 25 mg._                                                 |                                |   |
|  _prednisolone_                  | − _Acute lymphoblastic leukaemia_                                          |                                |   |
| − _Burkitt lymphoma_              |                                                                            |                                |   |
|                                   |                                                                            |                                |   |
| _Therapeutic alternatives:_       | − _Chronic lymphocytic leukaemia_                                          |                                |   |
| _- prednisone_                    | − _Diffuse large B-cell lymphoma_                                          |                                |   |
| − _Follicular lymphoma_           |                                                                            |                                |   |
|                                   |                                                                            |                                |   |
|                                   | − _Hodgkin lymphoma_                                                       |                                |   |
|                                   | − _Metastatic castration-resitsant prostate cancer_                        |                                |   |
|                                   | − _Multiple myeloma_                                                       |                                |   |
|                                   |                                                                            |                                |   |
|                                   | _**Tablet:** 10 mg; 20 mg (as citrate)._                                   |                                |   |
| _tamoxifen_                       | − _Early stage breast cancer_                                              |                                |   |
|                                   |                                                                            |                                |   |
|                                   | − _Metastatic breast cancer._                                              |                                |   |
|                                   |                                                                            |                                |   |
| _**8.2.5 Supportive medicines**_  |                                                                            |                                |   |
|                                   |                                                                            |                                |   |
| _**Complementary List**_          |                                                                            |                                |   |
|                                   |                                                                            |                                |   |
| _allopurinol **\[c]**_            | _**Tablet:** 100 mg; 300 mg._                                              |                                |   |
| − _Tumour lysis syndrome_         |                                                                            |                                |   |
|                                   |                                                                            |                                |   |
|                                   |                                                                            |                                |   |
|                                   | _**Injection:** 100 mg/mL in 4 mL and 10 mL ampoules._                     |                                |   |
|                                   | _**Tablet:** 400 mg; 600 mg._                                              |                                |   |
|                                   | − _Burkitt lymphoma_                                                       |                                |   |
| _mesna_                           | − _Ewing sarcoma_                                                          |                                |   |
| − _Nephroblastoma (Wilms tumour)_ |                                                                            |                                |   |
|                                   |                                                                            |                                |   |
|                                   | − _Ovarian germ cell tumour_                                               |                                |   |
|                                   | − _Osteosarcoma_                                                           |                                |   |
|                                   | − _Rhabdomyosarcoma_                                                       |                                |   |
|                                   | − _Testicular germ cell tumour_                                            |                                |   |
|                                   |                                                                            |                                |   |
| _rasburicase_                     | _**Powder and solvent for solution for infusion:** 1.5 mg; 7.5 mg in vial_ |                                |   |
| − _Tumour lysis syndrome_         |                                                                            |                                |   |
|                                   |                                                                            |                                |   |
|                                   |                                                                            |                                |   |
|                                   | _**Concentrate solution for infusion:** 4 mg/5 mL in 5 mL vial._           |                                |   |
| _zoledronic acid_                 | _**Solution for infusion**: 4 mg/100 mL in 100 mL bottle._                 |                                |   |
|                                   | − _Malignancy-related bone disease_                                        |                                |   |
|                                   |                                                                            |                                |   |

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 32**

**WHO Model List of Essential Medicines – 22nd List (2021)**

| **9. ANTIPARKINSONISM MEDICINES**                            |                                                                        |   |
| ------------------------------------------------------------ | ---------------------------------------------------------------------- | - |
|                                                              |                                                                        |   |
|  biperiden                                                  | **Injection:** 5 mg (lactate) in 1 mL ampoule.                         |   |
| Therapeutic alternatives:                                    |                                                                        |   |
| **Tablet:** 2 mg (hydrochloride).                            |                                                                        |   |
| − trihexyphenidyl                                            |                                                                        |   |
|                                                              |                                                                        |   |
|                                                              |                                                                        |   |
| levodopa +  carbidopa                                       |                                                                        |   |
| Therapeutic alternatives:                                    | **Tablet:** 100 mg + 10 mg; 100 mg + 25 mg; 250 mg + 25 mg.            |   |
| − benserazide (for carbidopa)                                |                                                                        |   |
|                                                              |                                                                        |   |
| **10. MEDICINES AFFECTING THE BLOOD**                        |                                                                        |   |
|                                                              |                                                                        |   |
| **10.1 Antianaemia medicines**                               |                                                                        |   |
|                                                              |                                                                        |   |
| ferrous salt                                                 | **Oral liquid:** equivalent to 25 mg iron (as sulfate)/mL.             |   |
| **Tablet:** equivalent to 60 mg iron.                        |                                                                        |   |
|                                                              |                                                                        |   |
|                                                              |                                                                        |   |
| ferrous salt + folic acid                                    | **Tablet:** equivalent to 60 mg iron + 400 micrograms folic acid.      |   |
|                                                              |                                                                        |   |
|                                                              | \*nutritional supplement for use during pregnancy                      |   |
|                                                              |                                                                        |   |
|                                                              | **Tablet:** 400 micrograms\*; 1 mg; 5 mg.                              |   |
| folic acid                                                   | \*periconceptual use for prevention of first occurrence of neural tube |   |
|                                                              |                                                                        |   |
|                                                              | defects                                                                |   |
|                                                              |                                                                        |   |
| hydroxocobalamin                                             | **Injection:** 1 mg/mL (as acetate, as hydrochloride or as sulfate) in |   |
| 1 mL ampoule.                                                |                                                                        |   |
|                                                              |                                                                        |   |
|                                                              |                                                                        |   |
| _**Complementary List**_                                     |                                                                        |   |
|                                                              |                                                                        |   |
|  _erythropoiesis-stimulating agents\*_                      |                                                                        |   |
| _Therapeutic alternatives:_                                  | _**Injection: pre-filled syringe**_                                    |   |
| _- epoetin alfa, beta and theta_                             | _1000 IU/0.5 mL; 2000 IU/0.5 mL; 3000 IU/0.3 mL; 4000 IU/0.4 mL;_      |   |
| _- darbepoetin alfa_                                         | _5000 IU/0.5 mL; 6000 IU/0.6 mL; 8000 IU/0.8mL; 10 000 IU/1 mL;_       |   |
| _- methoxy polyethylene glycol-epoetin beta_                 |                                                                        |   |
| _20 000 IU/0.5 mL; 40 000 IU/1 mL._                          |                                                                        |   |
|                                                              |                                                                        |   |
| _\*including quality-assured biosimilars_                    |                                                                        |   |
|                                                              |                                                                        |   |
| **10.2 Medicines affecting coagulation**                     |                                                                        |   |
|                                                              |                                                                        |   |
|  dabigatran                                                 |                                                                        |   |
| Therapeutic alternatives:                                    |                                                                        |   |
| - apixaban                                                   | **Capsule:** 110 mg; 150 mg.                                           |   |
|                                                              |                                                                        |   |
| - edoxaban                                                   |                                                                        |   |
| - rivaroxaban                                                |                                                                        |   |
|                                                              |                                                                        |   |
|  enoxaparin\*                                               |                                                                        |   |
| Therapeutic alternatives\*:                                  | **Injection: ampoule or pre-filled syringe**                           |   |
|                                                              |                                                                        |   |
| - dalteparin                                                 | 20 mg/0.2 mL; 40 mg/0.4 mL; 60 mg/0.6 mL; 80 mg/0.8 mL;                |   |
| - nadroparin                                                 | 100 mg/1 mL; 120 mg/0.8 mL; 150 mg/1 mL.                               |   |
| _\*including quality-assured biosimilars_                    |                                                                        |   |
|                                                              |                                                                        |   |
| heparin sodium                                               | **Injection:** 1000 IU/mL; 5000 IU/mL; 20 000 IU/mL in 1 mL ampoule.   |   |
|                                                              |                                                                        |   |
| phytomenadione                                               | **Injection:** 1 mg/mL **\[c]**; 10 mg/mL in ampoule.                  |   |
| **Tablet:** 10 mg.                                           |                                                                        |   |
|                                                              |                                                                        |   |
|                                                              |                                                                        |   |
| protamine sulfate                                            | **Injection:** 10 mg/mL in 5 mL ampoule.                               |   |
|                                                              |                                                                        |   |
| **WHO Model List of Essential Medicines – 22nd List (2021)** | **page 33**                                                            |   |

**WHO Model List of Essential Medicines – 22nd List (2021)**

| tranexamic acid | **Injection:** 100 mg/mL in 10 mL ampoule. |
| --------------- | ------------------------------------------ |

* warfarin

Therapeutic alternatives to be reviewed (2023)

_**Complementary List**_

**Tablet:** 1 mg; 2 mg; 5 mg (sodium).

| _desmopressin**\[c]**_                                  | _**Injection**: 4 micrograms/mL (as acetate) in 1 mL ampoule._ |   |
| ------------------------------------------------------- | -------------------------------------------------------------- | - |
| _**Nasal spray:** 10 micrograms (as acetate) per dose._ |                                                                |   |
|                                                         |                                                                |   |
|                                                         |                                                                |   |
| _heparin sodium **\[c]**_                               | _**Injection:** 1000 IU/mL; 5000 IU/mL in 1 mL ampoule._       |   |
|                                                         |                                                                |   |
| _protamine sulfate **\[c]**_                            | _**Injection:** 10 mg/mL in 5 mL ampoule._                     |   |
|                                                         |                                                                |   |
|  _warfarin_ _**\[c]**_                                 | _**Tablet:** 0.5 mg; 1 mg; 2 mg; 5 mg (sodium)._               |   |
| _Therapeutic alternatives to be reviewed (2023)_        |                                                                |   |
|                                                         |                                                                |   |
|                                                         |                                                                |   |
| **10.3 Other medicines for haemoglobinopathies**        |                                                                |   |
|                                                         |                                                                |   |
| _**Complementary List**_                                |                                                                |   |
|                                                         |                                                                |   |
|  _deferoxamine_                                        | _**Powder for injection:** 500 mg (mesilate) in vial._         |   |
| _Therapeutic alternatives:_                             |                                                                |   |
| _- deferasirox (oral)_                                  |                                                                |   |
|                                                         |                                                                |   |
| _hydroxycarbamide_                                      | _**Solid oral dosage form:** 200 mg; 500 mg; 1 g._             |   |
|                                                         |                                                                |   |

**11. BLOOD PRODUCTS OF HUMAN ORIGIN AND PLASMA SUBSTITUTES**

**11.1 Blood and blood components**

In accordance with the World Health Assembly resolution WHA63.12, WHO recognizes that achieving self-sufficiency, unless special circumstances preclude it, in the supply of safe blood components based on voluntary, non-remunerated blood donation, and the security of that supply are important national goals to prevent blood shortages and meet the transfusion requirements of the patient population. All preparations should comply with the WHO requirements.

fresh-frozen plasma

platelets

red blood cells

whole blood

**11.2 Plasma-derived medicines**

All human plasma-derived medicines should comply with the WHO requirements.

**11.2.1 Human immunoglobulins**

| anti-D immunoglobulin       | **Injection:** 250 micrograms in single-dose vial. |                |
| --------------------------- | -------------------------------------------------- | -------------- |
|                             |                                                    |                |
| anti-rabies immunoglobulin  | **Injection:** 150                                 | IU/mL in vial. |
|                             |                                                    |                |
| anti-tetanus immunoglobulin | **Injection:** 500                                 | IU in vial.    |
|                             |                                                    |                |

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 34**

**WHO Model List of Essential Medicines – 22nd List (2021)**

| _**Complementary List**_                                     |                                                                         |   |
| ------------------------------------------------------------ | ----------------------------------------------------------------------- | - |
|                                                              |                                                                         |   |
|                                                              | _**Intramuscular administration:** 16% protein solution.\*_             |   |
|                                                              | _**Intravenous administration:** 5%; 10% protein solution.\*\*_         |   |
| _normal immunoglobulin_                                      | _**Subcutaneous administration:** 15%; 16% protein solution.\*_         |   |
|                                                              |                                                                         |   |
|                                                              | _\*Indicated for primary immune deficiency._                            |   |
|                                                              | _\*\*Indicated for primary immune deficiency and Kawasaki disease._     |   |
|                                                              |                                                                         |   |
| _**11.2.2 Blood coagulation factors**_                       |                                                                         |   |
|                                                              |                                                                         |   |
| _**Complementary List**_                                     |                                                                         |   |
|                                                              |                                                                         |   |
|  _coagulation factor VIII_                                  |                                                                         |   |
| _Therapeutic alternatives to be reviewed (2023)_             | _**Powder for injection:** 500 IU/vial._                                |   |
|                                                              |                                                                         |   |
|  _coagulation factor IX_                                    | _**Powder for injection:** 500 IU/vial, 1000 IU/vial._                  |   |
| _Therapeutic alternatives to be reviewed (2023)_             |                                                                         |   |
|                                                              |                                                                         |   |
|                                                              |                                                                         |   |
| **11.3 Plasma substitutes**                                  |                                                                         |   |
|                                                              |                                                                         |   |
|  dextran 70                                                 |                                                                         |   |
| Therapeutic alternatives:                                    | **Injectable solution:** 6%.                                            |   |
| - Polygeline injectable solution 3.5%                        |                                                                         |   |
|                                                              |                                                                         |   |
| **12. CARDIOVASCULAR MEDICINES**                             |                                                                         |   |
|                                                              |                                                                         |   |
| **12.1 Antianginal medicines**                               |                                                                         |   |
|                                                              |                                                                         |   |
|  bisoprolol                                                 |                                                                         |   |
| Therapeutic alternatives:                                    | **Tablet:** 1.25 mg; 5 mg.                                              |   |
|                                                              |                                                                         |   |
| - carvedilol                                                 |                                                                         |   |
| - metoprolol                                                 |                                                                         |   |
|                                                              |                                                                         |   |
| glyceryl trinitrate                                          | **Tablet (sublingual):** 500 micrograms.                                |   |
|                                                              |                                                                         |   |
| isosorbide dinitrate                                         | **Tablet (sublingual):** 5 mg.                                          |   |
|                                                              |                                                                         |   |
| verapamil                                                    | **Tablet:** 40 mg; 80 mg (hydrochloride).                               |   |
|                                                              |                                                                         |   |
| **12.2 Antiarrhythmic medicines**                            |                                                                         |   |
|                                                              |                                                                         |   |
|  bisoprolol                                                 |                                                                         |   |
| Therapeutic alternatives:                                    | **Tablet:** 1.25 mg; 5 mg.                                              |   |
|                                                              |                                                                         |   |
| - carvedilol                                                 |                                                                         |   |
| - metoprolol                                                 |                                                                         |   |
|                                                              |                                                                         |   |
|                                                              | **Injection:** 250 micrograms/mL in 2 mL ampoule.                       |   |
| digoxin                                                      | **Oral liquid:** 50 micrograms/mL.                                      |   |
|                                                              | **Tablet:** 62.5 micrograms; 250 micrograms.                            |   |
|                                                              |                                                                         |   |
| epinephrine (adrenaline)                                     | **Injection:** 100 micrograms/mL (as acid tartrate or hydrochloride) in |   |
| 10 mL ampoule.                                               |                                                                         |   |
|                                                              |                                                                         |   |
|                                                              |                                                                         |   |
| lidocaine                                                    | **Injection:** 20 mg/mL (hydrochloride) in 5 mL ampoule.                |   |
|                                                              |                                                                         |   |
| verapamil                                                    | **Injection:** 2.5 mg/mL (hydrochloride) in 2 mL ampoule.               |   |
| **Tablet:** 40 mg; 80 mg (hydrochloride).                    |                                                                         |   |
|                                                              |                                                                         |   |
|                                                              |                                                                         |   |
| **WHO Model List of Essential Medicines – 22nd List (2021)** | **page 35**                                                             |   |

**WHO Model List of Essential Medicines – 22nd List (2021)**

_**Complementary List**_

_**Injection:** 50 mg/mL (hydrochloride) in 3 mL ampoule._

_amiodarone_

_**Tablet:** 100 mg; 200 mg; 400 mg (hydrochloride)._

**12.3 Antihypertensive medicines**

|  amlodipine                                                 |                                                                        |   |
| ------------------------------------------------------------ | ---------------------------------------------------------------------- | - |
| Therapeutic alternatives:                                    | **Tablet:** 5 mg (as maleate, mesylate or besylate).                   |   |
| - 4th level ATC chemical subgroup (C08CA Dihydropyridine     |                                                                        |   |
| derivatives)                                                 |                                                                        |   |
|                                                              |                                                                        |   |
|  bisoprolol                                                 | **Tablet:** 1.25 mg; 5 mg.                                             |   |
| Therapeutic alternatives:                                    |                                                                        |   |
|                                                              |                                                                        |   |
| - atenolol\*                                                 | \*atenolol should not be used as a first-line agent in uncomplicated   |   |
| hypertension in patients > 60 years                          |                                                                        |   |
| - carvedilol                                                 |                                                                        |   |
|                                                              |                                                                        |   |
| - metoprolol                                                 |                                                                        |   |
|                                                              |                                                                        |   |
|  enalapril                                                  |                                                                        |   |
| Therapeutic alternatives:                                    | **Tablet:** 2.5 mg; 5 mg (as hydrogen maleate).                        |   |
|                                                              |                                                                        |   |
| - 4th level ATC chemical subgroup (C09AA ACE inhibitors,     |                                                                        |   |
| plain)                                                       |                                                                        |   |
|                                                              |                                                                        |   |
|                                                              | **Powder for injection:** 20 mg (hydrochloride) in ampoule.            |   |
|                                                              | **Tablet:** 25 mg; 50 mg (hydrochloride).                              |   |
| hydralazine\*                                                | \*Hydralazine is listed for use only in the acute management of severe |   |
|                                                              | pregnancy-induced hypertension. Its use in the treatment of essential  |   |
|                                                              | hypertension is not recommended in view of the evidence of greater     |   |
|                                                              | efficacy and safety of other medicines.                                |   |
|                                                              |                                                                        |   |
|  hydrochlorothiazide                                        |                                                                        |   |
| Therapeutic alternatives:                                    | **Oral liquid:** 50 mg/5 mL.                                           |   |
| - chlorothiazide                                             | **Solid oral dosage form:** 12.5 mg; 25 mg.                            |   |
| - chlorthalidone                                             |                                                                        |   |
|                                                              |                                                                        |   |
| - indapamide                                                 |                                                                        |   |
|                                                              |                                                                        |   |
|  lisinopril +  amlodipine                                  |                                                                        |   |
| Therapeutic alternatives:                                    |                                                                        |   |
| - 4th level ATC chemical subgroup (C09AA ACE inhibitors,     | **Tablet:** 10 mg + 5 mg; 20 mg + 5 mg; 20 mg + 10 mg.                 |   |
| plain) (for lisinopril)                                      |                                                                        |   |
| - 4th level ATC chemical subgroup (C08CA Dihydropyridine     |                                                                        |   |
| derivatives) (for amlodipine)                                |                                                                        |   |
|                                                              |                                                                        |   |
|  lisinopril +  hydrochlorothiazide                         |                                                                        |   |
| Therapeutic alternatives:                                    |                                                                        |   |
| - 4th level ATC chemical subgroup (C09AA ACE inhibitors,     | **Tablet:** 10 mg + 12.5 mg; 20 mg + 12.5 mg; 20 mg + 25 mg.           |   |
| plain) (for lisinopril)                                      |                                                                        |   |
|                                                              |                                                                        |   |
| - chlorthalidone, chlorothiazide, indapamide (for            |                                                                        |   |
| hydrochlorothiazide)                                         |                                                                        |   |
|                                                              |                                                                        |   |
|  losartan                                                   |                                                                        |   |
| Therapeutic alternatives:                                    | **Tablet:** 25 mg; 50 mg; 100 mg.                                      |   |
|                                                              |                                                                        |   |
| - 4th level ATC chemical subgroup (C09CA Angiotensin II      |                                                                        |   |
| receptor blockers (ARBs), plain)                             |                                                                        |   |
|                                                              |                                                                        |   |
| **WHO Model List of Essential Medicines – 22nd List (2021)** | **page 36**                                                            |   |

**WHO Model List of Essential Medicines – 22nd List (2021)**

|                                                             | **Tablet:** 250 mg.                                                 |   |
| ----------------------------------------------------------- | ------------------------------------------------------------------- | - |
| methyldopa\*                                                | \*Methyldopa is listed for use only in the management of pregnancy- |   |
| induced hypertension. Its use in the treatment of essential |                                                                     |   |
|                                                             |                                                                     |   |
|                                                             | hypertension is not recommended in view of the evidence of greater  |   |
|                                                             | efficacy and safety of other medicines.                             |   |
|                                                             |                                                                     |   |
|  telmisartan +  amlodipine                                |                                                                     |   |
| Therapeutic alternatives:                                   |                                                                     |   |
| - 4th level ATC chemical subgroup (C09CA Angiotensin II     | **Tablet:** 40 mg + 5 mg; 80 mg + 5 mg; 80 mg + 10 mg.              |   |
| receptor blockers (ARBs), plain) (for telmisartan)          |                                                                     |   |

* 4th level ATC chemical subgroup (C08CA Dihydropyridine derivatives) (for amlodipine)

|  telmisartan +  hydrochlorothiazide                   |                                                              |   |
| ------------------------------------------------------- | ------------------------------------------------------------ | - |
| Therapeutic alternatives:                               |                                                              |   |
| - 4th level ATC chemical subgroup (C09CA Angiotensin II | **Tablet:** 40 mg + 12.5 mg; 80 mg + 12.5 mg; 80 mg + 25 mg. |   |
| receptor blockers (ARBs), plain) (for telmisartan)      |                                                              |   |
|                                                         |                                                              |   |
| - chlorthalidone, chlorothiazide, indapamide (for       |                                                              |   |
| hydrochlorothiazide)                                    |                                                              |   |
|                                                         |                                                              |   |
| _**Complementary List**_                                |                                                              |   |

| _sodium nitroprusside_                   | _**Powder for infusion:** 50 mg in ampoule._      |   |
| ---------------------------------------- | ------------------------------------------------- | - |
|                                          |                                                   |   |
| **12.4 Medicines used in heart failure** |                                                   |   |
|                                          |                                                   |   |
|  bisoprolol                             |                                                   |   |
| Therapeutic alternatives:                | **Tablet:** 1.25 mg; 5 mg.                        |   |
| - carvedilol                             |                                                   |   |
| - metoprolol                             |                                                   |   |
|                                          |                                                   |   |
|                                          | **Injection:** 250 micrograms/mL in 2 mL ampoule. |   |
| digoxin                                  | **Oral liquid:** 50 micrograms/mL.                |   |
|                                          | **Tablet:** 62.5 micrograms; 250 micrograms.      |   |
|                                          |                                                   |   |
|  enalapril                              |                                                   |   |
| Therapeutic alternatives:                | **Tablet:** 2.5 mg; 5 mg (as hydrogen maleate).   |   |
|                                          |                                                   |   |

* 4th level ATC chemical subgroup (C09AA ACE inhibitors, plain)

|  furosemide              | **Injection:** 10 mg/mL in 2 mL ampoule. |   |
| ------------------------- | ---------------------------------------- | - |
|                           |                                          |   |
| Therapeutic alternatives: | **Oral liquid:** 20 mg/5 mL **\[c]**.    |   |
| - bumetanide              |                                          |   |
| **Tablet:** 40 mg.        |                                          |   |
| - torasemide              |                                          |   |
|                           |                                          |   |

|  hydrochlorothiazide     |                                    |   |
| ------------------------- | ---------------------------------- | - |
| Therapeutic alternatives: | **Oral liquid:** 50 mg/5 mL.       |   |
| - chlorothiazide          | **Solid oral dosage form:** 25 mg. |   |
| - chlorthalidone          |                                    |   |
| - indapamide              |                                    |   |
|                           |                                    |   |
|  losartan                |                                    |   |
| Therapeutic alternatives: | **Tablet:** 25 mg; 50 mg; 100 mg.  |   |
|                           |                                    |   |

* 4th level ATC chemical subgroup (C09CA Angiotensin II receptor blockers (ARBs), plain)

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 37**

**WHO Model List of Essential Medicines – 22nd List (2021)**

| spironolactone                       | **Tablet:** 25 mg.                                      |   |
| ------------------------------------ | ------------------------------------------------------- | - |
|                                      |                                                         |   |
| _**Complementary List**_             |                                                         |   |
|                                      |                                                         |   |
| _dopamine_                           | _**Injection:** 40 mg/mL (hydrochloride) in 5 mL vial._ |   |
|                                      |                                                         |   |
| **12.5 Antithrombotic medicines**    |                                                         |   |
|                                      |                                                         |   |
| _**12.5.1 Anti-platelet medicines**_ |                                                         |   |
|                                      |                                                         |   |
| acetylsalicylic acid                 | **Tablet:** 100 mg.                                     |   |
|                                      |                                                         |   |
| clopidogrel                          | **Tablet:** 75 mg; 300 mg                               |   |
|                                      |                                                         |   |
| _**12.5.2 Thrombolytic medicines**_  |                                                         |   |
|                                      |                                                         |   |
| _**Complementary List**_             |                                                         |   |
|                                      |                                                         |   |
| _alteplase_                          | _**Powder for injection:** 10 mg; 20 mg; 50 mg in vial_ |   |
|                                      |                                                         |   |
| _streptokinase_                      | _**Powder for injection:** 1.5 million IU in vial._     |   |
|                                      |                                                         |   |
| **12.6 Lipid-lowering agents**       |                                                         |   |
|                                      |                                                         |   |
|  simvastatin\*                      |                                                         |   |
| Therapeutic alternatives:            | **Tablet:** 5 mg; 10 mg; 20 mg; 40 mg.                  |   |
| - atorvastatin                       |                                                         |   |
| \*For use in high-risk patients.     |                                                         |   |
| - fluvastatin                        |                                                         |   |
| - lovastatin                         |                                                         |   |
| - pravastatin                        |                                                         |   |
|                                      |                                                         |   |

| **13. DERMATOLOGICAL MEDICINES (topical)**             |                                            |   |
| ------------------------------------------------------ | ------------------------------------------ | - |
|                                                        |                                            |   |
| **13.1 Antifungal medicines**                          |                                            |   |
|                                                        |                                            |   |
|  miconazole                                           |                                            |   |
| Therapeutic alternatives:                              | **Cream or ointment:** 2% (nitrate).       |   |
| - 4th level ATC chemical subgroup (D01AC Imidazole and |                                            |   |
|                                                        |                                            |   |
| triazole derivatives) excluding combinations           |                                            |   |
|                                                        |                                            |   |
| selenium sulfide                                       | **Detergent-based suspension:** 2%.        |   |
|                                                        |                                            |   |
| sodium thiosulfate                                     | **Solution:** 15%.                         |   |
|                                                        |                                            |   |
| terbinafine                                            | **Cream or ointment:** 1% (hydrochloride). |   |
|                                                        |                                            |   |

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 38**

**WHO Model List of Essential Medicines – 22nd List (2021)**

**13.2 Anti-infective medicines**

| mupirocin                                                           | **Cream:** 2% (as calcium).                       |   |
| ------------------------------------------------------------------- | ------------------------------------------------- | - |
| **Ointment:** 2%.                                                   |                                                   |   |
|                                                                     |                                                   |   |
|                                                                     |                                                   |   |
| potassium permanganate                                              | **Aqueous solution:** 1:10 000.                   |   |
|                                                                     |                                                   |   |
| silver sulfadiazine **a**                                           | **Cream:** 1%.                                    |   |
| **a** > 2 months.                                                   |                                                   |   |
|                                                                     |                                                   |   |
|                                                                     |                                                   |   |
| **13.3 Anti-inflammatory and antipruritic medicines**               |                                                   |   |
|                                                                     |                                                   |   |
|  betamethasone **a**                                               |                                                   |   |
| Therapeutic alternatives:                                           | **Cream or ointment:** 0.1% (as valerate).        |   |
|                                                                     |                                                   |   |
| - 4th level ATC chemical subgroup (D07AC Corticosteroids,           | **a** Hydrocortisone preferred in neonates.       |   |
| potent (group III))                                                 |                                                   |   |
|                                                                     |                                                   |   |
| calamine                                                            | **Lotion.**                                       |   |
|                                                                     |                                                   |   |
|  hydrocortisone                                                    |                                                   |   |
| Therapeutic alternatives:                                           | **Cream or ointment:** 1% (acetate).              |   |
|                                                                     |                                                   |   |
| - 4th level ATC chemical subgroup (D07AA Corticosteroids,           |                                                   |   |
| weak (group I))                                                     |                                                   |   |
|                                                                     |                                                   |   |
| **13.4 Medicines affecting skin differentiation and proliferation** |                                                   |   |
|                                                                     |                                                   |   |
| benzoyl peroxide                                                    | **Cream or lotion:** 5%.                          |   |
|                                                                     |                                                   |   |
|  calcipotriol                                                      | **Cream or ointment:** 50 micrograms/mL (0.005%). |   |
| Therapeutic alternatives:                                           |                                                   |   |
| **Lotion:** 50 micrograms/mL (0.005%).                              |                                                   |   |
| - calcitriol                                                        |                                                   |   |
|                                                                     |                                                   |   |
| - tacalcitol                                                        |                                                   |   |
|                                                                     |                                                   |   |
| coal tar                                                            | **Solution:** 5%.                                 |   |
|                                                                     |                                                   |   |
| fluorouracil                                                        | **Ointment:** 5%.                                 |   |
|                                                                     |                                                   |   |
|  podophyllum resin                                                 |                                                   |   |
| Therapeutic alternatives:                                           | **Solution:** 10% to 25%.                         |   |
| - podophyllotoxin                                                   |                                                   |   |
|                                                                     |                                                   |   |
| salicylic acid                                                      | **Solution:** 5%.                                 |   |
|                                                                     |                                                   |   |
| urea                                                                | **Cream or ointment:** 5%; 10%.                   |   |
|                                                                     |                                                   |   |
| **13.5 Scabicides and pediculicides**                               |                                                   |   |
|                                                                     |                                                   |   |
|  benzyl benzoate **a**                                             | **Lotion:** 25%.                                  |   |
| Therapeutic alternatives:                                           |                                                   |   |
| **a** > 2 years.                                                    |                                                   |   |
| - precipitated sulfur topical ointment                              |                                                   |   |
|                                                                     |                                                   |   |
|                                                                     |                                                   |   |
| permethrin                                                          | **Cream:** 5%.                                    |   |
| **Lotion:** 1%.                                                     |                                                   |   |
|                                                                     |                                                   |   |
|                                                                     |                                                   |   |

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 39**

**WHO Model List of Essential Medicines – 22nd List (2021)**

**14. DIAGNOSTIC AGENTS**

**14.1 Ophthalmic medicines**

| fluorescein                                                   | **Eye drops:** 1% (sodium salt).                                  |   |
| ------------------------------------------------------------- | ----------------------------------------------------------------- | - |
|                                                               |                                                                   |   |
|  tropicamide                                                 |                                                                   |   |
| Therapeutic alternatives:                                     | **Eye drops:** 0.5%.                                              |   |
| - atropine                                                    |                                                                   |   |
|                                                               |                                                                   |   |
| - cyclopentolate                                              |                                                                   |   |
|                                                               |                                                                   |   |
| **14.2 Radiocontrast media**                                  |                                                                   |   |
|                                                               |                                                                   |   |
|  amidotrizoate                                               | **Injection:** 140 mg to 420 mg iodine/mL (as sodium or meglumine |   |
| Therapeutic alternatives to be reviewed (2023)                | salt) in 20 mL ampoule.                                           |   |
|                                                               |                                                                   |   |
|                                                               |                                                                   |   |
| barium sulfate                                                | **Aqueous suspension.**                                           |   |
|                                                               |                                                                   |   |
|  iohexol                                                     | **Injection:** 140 mg to 350 mg iodine/mL in 5 mL; 10 mL; 20 mL   |   |
| Therapeutic alternatives to be reviewed (2023)                | ampoules.                                                         |   |
|                                                               |                                                                   |   |
|                                                               |                                                                   |   |
| _**Complementary List**_                                      |                                                                   |   |
|                                                               |                                                                   |   |
| _barium sulfate **\[c]**_                                     | _**Aqueous suspension.**_                                         |   |
|                                                               |                                                                   |   |
|  _meglumine iotroxate_                                       | _**Solution:** 5 g to 8 g iodine in 100 mL to 250 mL._            |   |
| _Therapeutic alternatives to be reviewed (2023)_              |                                                                   |   |
|                                                               |                                                                   |   |
|                                                               |                                                                   |   |
| **15. ANTISEPTICS AND DISINFECTANTS**                         |                                                                   |   |
|                                                               |                                                                   |   |
| **15.1 Antiseptics**                                          |                                                                   |   |
|                                                               |                                                                   |   |
|  chlorhexidine                                               | **Solution:** 5% (digluconate).                                   |   |
|                                                               |                                                                   |   |
| Therapeutic alternatives to be reviewed (2023)                |                                                                   |   |
|                                                               |                                                                   |   |
|  ethanol                                                     |                                                                   |   |
| Therapeutic alternatives:                                     | **Solution:** 70% (denatured).                                    |   |
| - propanol                                                    |                                                                   |   |
|                                                               |                                                                   |   |
|  povidone iodine                                             |                                                                   |   |
| Therapeutic alternatives:                                     | **Solution:** 10% (equivalent to 1% available iodine).            |   |
| - iodine                                                      |                                                                   |   |
|                                                               |                                                                   |   |
| **15.2 Disinfectants**                                        |                                                                   |   |
|                                                               |                                                                   |   |
| alcohol based hand rub                                        | **Solution:** containing ethanol 80% volume/volume.               |   |
| **Solution:** containing isopropyl alcohol 75% volume/volume. |                                                                   |   |
|                                                               |                                                                   |   |
|                                                               |                                                                   |   |
|                                                               | **Liquid:** (0.1% available chlorine) for solution.               |   |
| chlorine base compound                                        | **Powder:** (0.1% available chlorine) for solution.               |   |
|                                                               | **Solid:** (0.1% available chlorine) for solution.                |   |
|                                                               |                                                                   |   |

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 40**

**WHO Model List of Essential Medicines – 22nd List (2021)**

|  chloroxylenol           |                     |   |
| ------------------------- | ------------------- | - |
| Therapeutic alternatives: | **Solution:** 4.8%. |   |
|                           |                     |   |

* 4th level ATC chemical subgroup (D08AE Phenol and derivatives)

| glutaral                                             | **Solution:** 2%.                                                   |   |
| ---------------------------------------------------- | ------------------------------------------------------------------- | - |
|                                                      |                                                                     |   |
| **16. DIURETICS**                                    |                                                                     |   |
|                                                      |                                                                     |   |
| amiloride                                            | **Tablet:** 5 mg (hydrochloride).                                   |   |
|                                                      |                                                                     |   |
|  furosemide                                         | **Injection:** 10 mg/mL in 2 mL ampoule.                            |   |
| Therapeutic alternatives:                            | **Oral liquid:** 20 mg/5 mL **\[c]**.                               |   |
| - bumetanide                                         | **Tablet:** 10 mg **\[c]**; 20 mg **\[c]**; 40 mg.                  |   |
| - torasemide                                         |                                                                     |   |
|  hydrochlorothiazide                                |                                                                     |   |
| Therapeutic alternatives:                            |                                                                     |   |
| - chlorothiazide                                     | **Solid oral dosage form:** 25 mg.                                  |   |
|                                                      |                                                                     |   |
| - chlortalidone                                      |                                                                     |   |
| - indapamide                                         |                                                                     |   |
|                                                      |                                                                     |   |
| mannitol                                             | **Injectable solution:** 10%; 20%.                                  |   |
|                                                      |                                                                     |   |
| spironolactone                                       | **Tablet:** 25 mg.                                                  |   |
|                                                      |                                                                     |   |
| _**Complementary List**_                             |                                                                     |   |
|                                                      |                                                                     |   |
|  _hydrochlorothiazide**\[c]**_                      |                                                                     |   |
| _Therapeutic alternatives:_                          | _**Tablet (scored):** 25 mg._                                       |   |
| _- chlorothiazide_                                   |                                                                     |   |
| _- chlortalidone_                                    |                                                                     |   |
|                                                      |                                                                     |   |
| _mannitol **\[c]**_                                  | _**Injectable solution:** 10%; 20%._                                |   |
|                                                      |                                                                     |   |
| _spironolactone**\[c]**_                             | _**Oral liquid:** 5 mg/5 mL; 10 mg/5 mL; 25 mg/5 mL._               |   |
| _**Tablet:** 25 mg._                                 |                                                                     |   |
|                                                      |                                                                     |   |
|                                                      |                                                                     |   |
| **17. GASTROINTESTINAL MEDICINES**                   |                                                                     |   |
|                                                      |                                                                     |   |
| _**Complementary List**_                             |                                                                     |   |
|                                                      |                                                                     |   |
| _pancreatic enzymes**\[c]**_                         | _Age-appropriate formulations and doses including lipase, protease_ |   |
| _and amylase._                                       |                                                                     |   |
|                                                      |                                                                     |   |
|                                                      |                                                                     |   |
| **17.1 Antiulcer medicines**                         |                                                                     |   |
|                                                      |                                                                     |   |
|  omeprazole                                         | **Powder for injection:** 40 mg in vial                             |   |
|                                                      |                                                                     |   |
| Therapeutic alternatives:                            | **Powder for oral liquid:** 20 mg; 40 mg sachets.                   |   |
|                                                      |                                                                     |   |
| - 4th level ATC chemical subgroup (A02BC Proton pump | **Solid oral dosage form:** 10 mg; 20 mg; 40 mg.                    |   |
| inhibitors) excluding combinations                   |                                                                     |   |
|                                                      |                                                                     |   |
|                                                      |                                                                     |   |
|  ranitidine                                         | **Injection:** 25 mg/mL (as hydrochloride) in 2 mL ampoule.         |   |
|                                                      |                                                                     |   |
| Therapeutic alternatives:                            | **Oral liquid:** 75 mg/5 mL (as hydrochloride).                     |   |
|                                                      |                                                                     |   |
| - 4th level ATC chemical subgroup (A02BA H2-receptor | **Tablet:** 150 mg (as hydrochloride).                              |   |
| antagonists) excluding combinations                  |                                                                     |   |
|                                                      |                                                                     |   |
|                                                      |                                                                     |   |

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 41**

**WHO Model List of Essential Medicines – 22nd List (2021)**

**17.2 Antiemetic medicines**

|                                                     | **Injection:** 4 mg/mL (as disodium phosphate salt) in 1 mL ampoule.                     |   |
| --------------------------------------------------- | ---------------------------------------------------------------------------------------- | - |
| dexamethasone                                       | **Oral liquid:** 0.5 mg/5 mL; 2 mg/5 mL.                                                 |   |
|                                                     | **Solid oral dosage form:** 0.5 mg; 0.75 mg; 1.5 mg; 4 mg.                               |   |
|                                                     |                                                                                          |   |
|                                                     | **Injection:** 5 mg/mL (hydrochloride) in 2 mL ampoule.                                  |   |
| metoclopramide **a**                                | **Oral liquid:** 5 mg/5 mL **\[c]**.                                                     |   |
| **Tablet:** 10 mg (hydrochloride).                  |                                                                                          |   |
|                                                     |                                                                                          |   |
|                                                     | **a** Not in neonates.                                                                   |   |
|                                                     |                                                                                          |   |
|  ondansetron **a**                                 | **Injection:** 2 mg base/mL in 2 mL ampoule (as hydrochloride).                          |   |
| Therapeutic alternatives:                           | **Oral liquid:** 4 mg base/5 mL.                                                         |   |
| - dolasetron                                        | **Solid oral dosage form:** Eq 4 mg base; Eq 8 mg base; Eq 24 mg                         |   |
| - granisetron                                       | base.                                                                                    |   |
| - palonosetron                                      | **a** > 1 month.                                                                         |   |
| - tropisetron                                       |                                                                                          |   |
|                                                     |                                                                                          |   |
| _**Complementary list**_                            |                                                                                          |   |
|                                                     |                                                                                          |   |
| _aprepitant_                                        | _**Capsule:** 80 mg; 125 mg; 165 mg_                                                     |   |
| _**Powder for oral susupension:** 125 mg in sachet_ |                                                                                          |   |
|                                                     |                                                                                          |   |
|                                                     |                                                                                          |   |
| **17.3 Anti-inflammatory medicines**                |                                                                                          |   |
|                                                     |                                                                                          |   |
|  sulfasalazine                                     | **Retention enema.**                                                                     |   |
|                                                     |                                                                                          |   |
| Therapeutic alternatives:                           | **Suppository:** 500 mg.                                                                 |   |
|                                                     |                                                                                          |   |
| - mesalazine                                        | **Tablet:** 500 mg.                                                                      |   |
|                                                     |                                                                                          |   |
| _**Complementary List**_                            |                                                                                          |   |
|                                                     |                                                                                          |   |
| _hydrocortisone_                                    | _**Retention enema:** 100 mg/60 mL._                                                     |   |
| _**Suppository:** 25 mg (acetate)._                 |                                                                                          |   |
|                                                     |                                                                                          |   |
|                                                     |                                                                                          |   |
| _prednisolone_                                      | _**Retention enema:** 20 mg/100 mL (as sodium phosphate)**.**_                           |   |
|                                                     |                                                                                          |   |
| **17.4 Laxatives**                                  |                                                                                          |   |
|                                                     |                                                                                          |   |
|  senna                                             |                                                                                          |   |
| Therapeutic alternatives:                           | **Tablet:** 7.5 mg (sennosides) (or traditional dosage forms).                           |   |
| - bisacodyl                                         |                                                                                          |   |
|                                                     |                                                                                          |   |
| **17.5 Medicines used in diarrhoea**                |                                                                                          |   |
|                                                     |                                                                                          |   |
|                                                     | **Co-package containing:**                                                               |   |
| oral rehydration salts – zinc sulfate **\[c]**      | **ORS powder for dilution** (see Section 17.5.1) **** – **** zinc sulfate **solid oral** |   |
|                                                     |                                                                                          |   |
|                                                     | **dosage form** 20 mg (see Section 17.5.2)                                               |   |
|                                                     |                                                                                          |   |

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 42**

**WHO Model List of Essential Medicines – 22nd List (2021)**

_**17.5.1 Oral rehydration**_

|                                                     | **Powder for dilution** in 200 mL; 500 mL; 1 L.                        |                  |   |
| --------------------------------------------------- | ---------------------------------------------------------------------- | ---------------- | - |
|                                                     | glucose:                                                               | 75 mEq           |   |
|                                                     | sodium:                                                                | 75 mEq or mmol/L |   |
|                                                     | chloride:                                                              | 65 mEq or mmol/L |   |
|                                                     | potassium:                                                             | 20 mEq or mmol/L |   |
|                                                     | citrate:                                                               | 10 mmol/L        |   |
| oral rehydration salts                              | osmolarity:                                                            | 245 mOsm/L       |   |
| glucose:                                            | 13.5 g/L                                                               |                  |   |
|                                                     | sodium chloride:                                                       | 2.6 g/L          |   |
|                                                     | potassium chloride:                                                    | 1.5 g/L          |   |
|                                                     | trisodium citrate dihydrate\*:                                         | 2.9 g/L          |   |
|                                                     | \*trisodium citrate dihydrate may be replaced by sodium hydrogen       |                  |   |
|                                                     | carbonate (sodium bicarbonate) 2.5 g/L. However, as the stability of   |                  |   |
|                                                     | this latter formulation is very poor under tropical conditions, it is  |                  |   |
|                                                     | recommended only when manufactured for immediate use.                  |                  |   |
|                                                     |                                                                        |                  |   |
| _**17.5.2 Medicines for diarrhoea**_                |                                                                        |                  |   |
|                                                     |                                                                        |                  |   |
|                                                     | **Solid oral dosage form:** 20 mg.                                     |                  |   |
| zinc sulfate\*                                      | \*In acute diarrhoea zinc sulfate should be used as an adjunct to oral |                  |   |
|                                                     |                                                                        |                  |   |
|                                                     | rehydration salts.                                                     |                  |   |
|                                                     |                                                                        |                  |   |
| **18. MEDICINES FOR ENDOCRINE DISORDERS**           |                                                                        |                  |   |
|                                                     |                                                                        |                  |   |
| **18.1 Adrenal hormones and synthetic substitutes** |                                                                        |                  |   |
|                                                     |                                                                        |                  |   |
| fludrocortisone                                     | **Tablet:** 100 micrograms (acetate).                                  |                  |   |
|                                                     |                                                                        |                  |   |
| hydrocortisone                                      | **Tablet:** 5 mg; 10 mg; 20 mg.                                        |                  |   |
|                                                     |                                                                        |                  |   |
| **18.2 Androgens**                                  |                                                                        |                  |   |
|                                                     |                                                                        |                  |   |
| _**Complementary List**_                            |                                                                        |                  |   |
|                                                     |                                                                        |                  |   |
| _testosterone_                                      | _**Injection:** 200 mg (enanthate) in 1 mL ampoule._                   |                  |   |
|                                                     |                                                                        |                  |   |
| **18.3 Estrogens**                                  |                                                                        |                  |   |
|                                                     |                                                                        |                  |   |
| **18.4 Progestogens**                               |                                                                        |                  |   |
|                                                     |                                                                        |                  |   |
|  medroxyprogesterone acetate                       |                                                                        |                  |   |
| Therapeutic alternatives:                           | **Tablet:** 5 mg.                                                      |                  |   |
|                                                     |                                                                        |                  |   |
| - norethisterone                                    |                                                                        |                  |   |
|                                                     |                                                                        |                  |   |

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 43**

**WHO Model List of Essential Medicines – 22nd List (2021)**

| **18.5 Medicines for diabetes**                              |                                                                           |   |
| ------------------------------------------------------------ | ------------------------------------------------------------------------- | - |
|                                                              |                                                                           |   |
| _**18.5.1 Insulins**_                                        |                                                                           |   |
|                                                              |                                                                           |   |
| insulin injection (soluble)\*                                | **Injection:** 40 IU/mL in 10 mL vial; 100 IU/mL in 10 mL vial.           |   |
| _\*including quality-assured biosimilars_                    |                                                                           |   |
|                                                              |                                                                           |   |
|                                                              |                                                                           |   |
| intermediate-acting insulin\*                                | **Injection:** 40 IU/mL in 10 mL vial; 100 IU/mL in 10 mL vial (as        |   |
|                                                              |                                                                           |   |
| _\*including quality-assured biosimilars_                    | compound insulin zinc suspension or isophane insulin).                    |   |
|                                                              |                                                                           |   |
|                                                              |                                                                           |   |
|  long-acting insulin analogues\*                            |                                                                           |   |
| Therapeutic alternatives:                                    |                                                                           |   |
| - insulin degludec                                           | **Injection:** 100 IU/mL in 3 mL cartridge or pre-filled pen.             |   |
| - insulin detemir                                            |                                                                           |   |
| - insulin glargine                                           |                                                                           |   |
| _\*including quality-assured biosimilars_                    |                                                                           |   |
|                                                              |                                                                           |   |
| _**18.5.2 Oral hypoglycaemic agents**_                       |                                                                           |   |
|                                                              |                                                                           |   |
|  empagliflozin                                              |                                                                           |   |
| Therapeutic alternatives:                                    | **Tablet:** 10 mg; 25 mg.                                                 |   |
|                                                              |                                                                           |   |
| - canagliflozin                                              |                                                                           |   |
| - dapagliflozin                                              |                                                                           |   |
|                                                              |                                                                           |   |
|  gliclazide\*                                               | **Solid oral dosage form:** (controlled-release tablets) 30 mg; 60 mg;    |   |
| Therapeutic alternatives:                                    | 80 mg.                                                                    |   |
|                                                              |                                                                           |   |
| - 4th level ATC chemical subgroup (A10BB Sulfonylureas)      | \*glibenclamide not suitable above 60 years.                              |   |
|                                                              |                                                                           |   |
|                                                              |                                                                           |   |
| metformin                                                    | **Tablet:** 500 mg (hydrochloride).                                       |   |
|                                                              |                                                                           |   |
| _**Complementary List**_                                     |                                                                           |   |
|                                                              |                                                                           |   |
| _metformin **\[c]**_                                         | _**Tablet:** 500 mg (hydrochloride)._                                     |   |
|                                                              |                                                                           |   |
| **18.6 Medicines for hypoglycaemia**                         |                                                                           |   |
|                                                              |                                                                           |   |
| glucagon                                                     | **Injection:** 1 mg/mL.                                                   |   |
|                                                              |                                                                           |   |
| _**Complementary List**_                                     |                                                                           |   |
|                                                              |                                                                           |   |
| _diazoxide **\[c]**_                                         | _**Oral liquid:** 50 mg/mL._                                              |   |
| _**Tablet:** 50 mg._                                         |                                                                           |   |
|                                                              |                                                                           |   |
|                                                              |                                                                           |   |
| **18.7 Thyroid hormones and antithyroid medicines**          |                                                                           |   |
|                                                              |                                                                           |   |
| levothyroxine                                                | **Tablet:** 25 micrograms **\[c]**; 50 micrograms; 100 micrograms (sodium |   |
| salt).                                                       |                                                                           |   |
|                                                              |                                                                           |   |
|                                                              |                                                                           |   |
| potassium iodide                                             | **Tablet:** 60 mg.                                                        |   |
|                                                              |                                                                           |   |
|  methimazole                                                |                                                                           |   |
| Therapeutic alternatives:                                    | **Tablet:** 5mg, 10mg, 20mg.                                              |   |
|                                                              |                                                                           |   |
| - carbimazole (depending on local availability)              |                                                                           |   |
|                                                              |                                                                           |   |
|                                                              | **Tablet:** 50 mg.                                                        |   |
| propylthiouracil\*                                           | \*For use when alternative first-line treatment is not appropriate or     |   |
|                                                              |                                                                           |   |
|                                                              | available; and in patients during the first trimester of pregnancy.       |   |
|                                                              |                                                                           |   |
| **WHO Model List of Essential Medicines – 22nd List (2021)** | **page 44**                                                               |   |

**WHO Model List of Essential Medicines – 22nd List (2021)**

_**Complementary List**_

| _Lugol's solution **\[c]**_                       | _**Oral liquid:** about 130 mg total iodine/mL._                        |   |
| ------------------------------------------------- | ----------------------------------------------------------------------- | - |
|                                                   |                                                                         |   |
|  _methimazole_ _**\[c]**_                        |                                                                         |   |
| _Therapeutic alternatives:_                       | _Tablet: 5mg, 10mg, 20mg._                                              |   |
| _- carbimazole (depending on local availability)_ |                                                                         |   |
|                                                   |                                                                         |   |
| _potassium iodide **\[c]**_                       | _**Tablet:** 60 mg._                                                    |   |
|                                                   |                                                                         |   |
|                                                   | _**Tablet:** 50 mg._                                                    |   |
| _propylthiouracil\* **\[c]**_                     | _\*For use when alternative first-line treatment is not appropriate or_ |   |
|                                                   |                                                                         |   |
|                                                   | _available_                                                             |   |
|                                                   |                                                                         |   |
| **19. IMMUNOLOGICALS**                            |                                                                         |   |

**19.1 Diagnostic agents**

All tuberculins should comply with the WHO requirements for tuberculins.

| tuberculin, purified protein derivative (PPD) | **Injection.** |
| --------------------------------------------- | -------------- |
|                                               |                |

**19.2 Sera, immunoglobulins and monoclonal antibodies**

All plasma fractions should comply with the WHO requirements.

|                                           | **Injection:** 40 IU/mL in 1.25 mL, 2.5 mL vial; 100 IU/mL in 2.5 mL vial |   |
| ----------------------------------------- | ------------------------------------------------------------------------- | - |
| anti-rabies virus monoclonal antibodies\* | (human).                                                                  |   |
| _\*including quality-assured biosimilars_ | **Injection:** 300 IU/mL in 10 mL vial; 600 IU/mL in 1 mL, 2.5 mL and     |   |
|                                           | 5 mL vial (murine).                                                       |   |
|                                           |                                                                           |   |
| antivenom immunoglobulin\*                | **Injection.**                                                            |   |
| \*Exact type to be defined locally.       |                                                                           |   |
|                                           |                                                                           |   |
|                                           |                                                                           |   |
| diphtheria antitoxin                      | **Injection:** 10 000 IU; 20 000 IU in vial.                              |   |
|                                           |                                                                           |   |
| equine rabies immunoglobulin              | **Injection:** 150 IU/mL; 200 IU/mL; 300 IU/mL; 400 IU/mL in vial.        |   |
|                                           |                                                                           |   |

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 45**

**WHO Model List of Essential Medicines – 22nd List (2021)**

**19.3 Vaccines**

WHO immunization policy recommendations are published in vaccine position papers based on recommendations made by the Strategic Advisory Group of Experts on Immunization (SAGE).

WHO vaccine position papers are updated three to four times per year. The list below details the vaccines for which there is a recommendation from SAGE and a corresponding WHO position paper as at September 2020. The most recent versions of the WHO position papers, reflecting the current evidence related to a specific vaccine and the related recommendations, can be accessed at any time on the WHO website at:

[https://www.who.int/teams/immunization-vaccines-and-biologicals/policies/position-papers](https://www.who.int/teams/immunization-vaccines-and-biologicals/policies/position-papers)

Vaccine recommendations may be universal or conditional (e.g., in certain regions, in some high-risk populations or as part of immunization programmes with certain characteristics). Details are available in the relevant position papers, and in the Summary Tables of WHO Routine Immunization Recommendations available on the WHO website at:

[https://www.who.int/teams/immunization-vaccines-and-biologicals/policies/who-recommendations-for-routine-immunization---summary-tables](https://www.who.int/teams/immunization-vaccines-and-biologicals/policies/who-recommendations-for-routine-immunization---summary-tables)

Selection of vaccines from the Model List will need to be determined by each country after consideration of international recommendations, epidemiology and national priorities.

All vaccines should comply with the WHO requirements for biological substances.

WHO noted the need for vaccines used in children to be polyvalent.

_**Recommendations for all**_

BCG vaccine

diphtheria vaccine

Haemophilus influenzae type b vaccine

hepatitis B vaccine

human papilloma virus (HPV) vaccine

measles vaccine

pertussis vaccine

pneumococcal vaccine

poliomyelitis vaccine

rotavirus vaccine

rubella vaccine

tetanus vaccine

_**Recommendations for certain regions**_

Japanese encephalitis vaccine

tick-borne encephalitis vaccine

yellow fever vaccine

_**Recommendations for some high-risk populations**_

cholera vaccine

dengue vaccine

hepatitis A vaccine

meningococcal meningitis vaccine

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 46**

**WHO Model List of Essential Medicines – 22nd List (2021)**

rabies vaccine

typhoid vaccine

_**Recommendations for immunization programmes with certain characteristics**_

influenza vaccine (seasonal)

mumps vaccine

varicella vaccine

**20. MUSCLE RELAXANTS (PERIPHERALLY-ACTING) AND CHOLINESTERASE INHIBITORS**

|  atracurium                                     | **Injection:** 10 mg/mL (besylate).                               |   |
| ------------------------------------------------ | ----------------------------------------------------------------- | - |
|                                                  |                                                                   |   |
| Therapeutic alternatives to be reviewed (2023)   |                                                                   |   |
|                                                  |                                                                   |   |
|                                                  | **Injection:** 500 micrograms/mL (methylsulfate) in 1 mL ampoule; |   |
| neostigmine                                      | 2.5 mg/mL (methylsulfate) in 1 mL ampoule.                        |   |
|                                                  |                                                                   |   |
|                                                  | **Tablet:** 15 mg (bromide).                                      |   |
|                                                  |                                                                   |   |
| suxamethonium                                    | **Injection:** 50 mg/mL (chloride) in 2 mL ampoule.               |   |
| **Powder for injection:** (chloride), in vial.   |                                                                   |   |
|                                                  |                                                                   |   |
|                                                  |                                                                   |   |
|  vecuronium **\[c]**                            | **Powder for injection:** 10 mg (bromide) in vial.                |   |
|                                                  |                                                                   |   |
| Therapeutic alternatives to be reviewed (2023)   |                                                                   |   |
|                                                  |                                                                   |   |
| _**Complementary List**_                         |                                                                   |   |
|                                                  |                                                                   |   |
| _pyridostigmine_                                 | _**Injection:** 1 mg in 1 mL ampoule._                            |   |
| _**Tablet:** 60 mg (bromide)._                   |                                                                   |   |
|                                                  |                                                                   |   |
|                                                  |                                                                   |   |
|  _vecuronium_                                   | _**Powder for injection:** 10 mg (bromide) in vial._              |   |
| _Therapeutic alternatives to be reviewed (2023)_ |                                                                   |   |
|                                                  |                                                                   |   |
|                                                  |                                                                   |   |
| **21. OPHTHALMOLOGICAL PREPARATIONS**            |                                                                   |   |
|                                                  |                                                                   |   |
| **21.1 Anti-infective agents**                   |                                                                   |   |

| aciclovir                 | **Ointment:** 3% W/W.                                    |   |
| ------------------------- | -------------------------------------------------------- | - |
|                           |                                                          |   |
| azithromycin              | **Solution (eye drops):** 1.5%.                          |   |
| − _Trachoma_              |                                                          |   |
|                           |                                                          |   |
|                           |                                                          |   |
|                           | **Ointment:** 0.5% **\[c]**                              |   |
| erythromycin              | − _Infections due to Chlamydia trachomatis or Neisseria_ |   |
|                           |                                                          |   |
|                           | _gonorrhoea._                                            |   |
|                           |                                                          |   |
|  gentamicin              |                                                          |   |
| Therapeutic alternatives: | **Solution (eye drops):** 0.3% (sulfate).                |   |
| - amikacin                | − _Bacterial blepharitis_                                |   |
| - kanamycin               | − _Bacterial conjunctivitis_                             |   |
| - netilmicin              |                                                          |   |
| - tobramycin              |                                                          |   |
|                           |                                                          |   |

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 47**

**WHO Model List of Essential Medicines – 22nd List (2021)**

| natamycin                                              |       | **Suspension (eye drops):** 5%                               |                          |   |   |   |   |   |
| ------------------------------------------------------ | ----- | ------------------------------------------------------------ | ------------------------ | - | - | - | - | - |
|                                                        |       | − _Fungal keratitis_                                         |                          |   |   |   |   |   |
|                                                        |       |                                                              |                          |   |   |   |   |   |
|                                                        |       |                                                              |                          |   |   |   |   |   |
|  ofloxacin                                            |       | **Solution (eye drops):** 0.3%.                              |                          |   |   |   |   |   |
| Therapeutic alternatives:                              |       |                                                              |                          |   |   |   |   |   |
|                                                        |       | − _Bacterial conjunctivitis_                                 |                          |   |   |   |   |   |
| - 4th level ATC chemical subgroup (S01AE               |       |                                                              |                          |   |   |   |   |   |
|                                                        |       | − _Bacterial keratitis_                                      |                          |   |   |   |   |   |
| Fluoroquinolones)                                      |       |                                                              |                          |   |   |   |   |   |
|                                                        |       |                                                              |                          |   |   |   |   |   |
|  tetracycline                                         |       | **Eye ointment:** 1% (hydrochloride).                        |                          |   |   |   |   |   |
|                                                        |       | − _Bacterial blepharitis_                                    |                          |   |   |   |   |   |
| Therapeutic alternatives:                              |       |                                                              |                          |   |   |   |   |   |
|                                                        |       | − _Bacterial conjunctivitis_                                 |                          |   |   |   |   |   |
|                                                        |       |                                                              |                          |   |   |   |   |   |
| - chlortetracycline                                    |       |                                                              | − _Bacterial keratitis_  |   |   |   |   |   |
| - oxytetracycline                                      |       |                                                              | − _Trachoma_             |   |   |   |   |   |
|                                                        |       |                                                              |                          |   |   |   |   |   |
| **21.2 Anti-inflammatory agents**                      |       |                                                              |                          |   |   |   |   |   |
|                                                        |       |                                                              |                          |   |   |   |   |   |
|  prednisolone                                         |       | **Solution (eye drops):** 0.5% (sodium phosphate).           |                          |   |   |   |   |   |
| Therapeutic alternatives to be reviewed (2023)         |       |                                                              |                          |   |   |   |   |   |
|                                                        |       |                                                              |                          |   |   |   |   |   |
|                                                        |       |                                                              |                          |   |   |   |   |   |
| **21.3 Local anaesthetics**                            |       |                                                              |                          |   |   |   |   |   |
|                                                        |       |                                                              |                          |   |   |   |   |   |
|  tetracaine                                           | **a** |                                                              |                          |   |   |   |   |   |
| Therapeutic alternatives:                              |       | **Solution (eye drops):** 0.5% (hydrochloride).              |                          |   |   |   |   |   |
|                                                        |       |                                                              |                          |   |   |   |   |   |
|                                                        |       |                                                              |                          |   |   |   |   |   |
| - 4th level ATC chemical subgroup (S01HA Local         |       | **a**                                                        | Not in preterm neonates. |   |   |   |   |   |
|                                                        |       |                                                              |                          |   |   |   |   |   |
| anaesthetics) excluding cocaine and combinations       |       |                                                              |                          |   |   |   |   |   |
|                                                        |       |                                                              |                          |   |   |   |   |   |
| **21.4 Miotics and antiglaucoma medicines**            |       |                                                              |                          |   |   |   |   |   |
|                                                        |       |                                                              |                          |   |   |   |   |   |
| acetazolamide                                          |       | **Tablet:** 250 mg.                                          |                          |   |   |   |   |   |
|                                                        |       |                                                              |                          |   |   |   |   |   |
| latanoprost                                            |       | **Solution (eye drops):** 50 micrograms/mL                   |                          |   |   |   |   |   |
|                                                        |       |                                                              |                          |   |   |   |   |   |
|  pilocarpine                                          |       |                                                              |                          |   |   |   |   |   |
| Therapeutic alternatives:                              |       | **Solution (eye drops):** 2%; 4% (hydrochloride or nitrate). |                          |   |   |   |   |   |
| - carbachol                                            |       |                                                              |                          |   |   |   |   |   |
|                                                        |       |                                                              |                          |   |   |   |   |   |
|  timolol                                              |       |                                                              |                          |   |   |   |   |   |
| Therapeutic alternatives:                              |       | **Solution (eye drops):** 0.25%; 0.5% (as hydrogen maleate). |                          |   |   |   |   |   |
|                                                        |       |                                                              |                          |   |   |   |   |   |
| - 4th level ATC chemical subgroup (S01ED Beta blocking |       |                                                              |                          |   |   |   |   |   |
| agents) excluding combinations                         |       |                                                              |                          |   |   |   |   |   |
|                                                        |       |                                                              |                          |   |   |   |   |   |
| **21.5 Mydriatics**                                    |       |                                                              |                          |   |   |   |   |   |
|                                                        |       |                                                              |                          |   |   |   |   |   |
|  atropine                                             | **a** |                                                              |                          |   |   |   |   |   |
| Therapeutic alternatives\*:                            |       | **Solution (eye drops):** 0.1%; 0.5%; 1% (sulfate).          |                          |   |   |   |   |   |
| - cyclopentolate hydrochloride                         |       |                                                              |                          |   |   |   |   |   |
|                                                        | **a** | > 3 months.                                                  |                          |   |   |   |   |   |
| - homatropine hydrobromide                             |       |                                                              |                          |   |   |   |   |   |
|                                                        |       |                                                              |                          |   |   |   |   |   |
| \*_EMLc only_                                          |       |                                                              |                          |   |   |   |   |   |
|                                                        |       |                                                              |                          |   |   |   |   |   |
| _**Complementary List**_                               |       |                                                              |                          |   |   |   |   |   |
|                                                        |       |                                                              |                          |   |   |   |   |   |
| _epinephrine (adrenaline)_                             |       | _**Solution (eye drops):** 2% (as hydrochloride)._           |                          |   |   |   |   |   |
|                                                        |       |                                                              |                          |   |   |   |   |   |

**21.6 Anti-vascular endothelial growth factor (VEGF) preparations**

_**Complementary List**_

_bevacizumab\*_

_**Injection:** 25 mg/mL._

_\*including quality-assured biosimilars_

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 48**

**WHO Model List of Essential Medicines – 22nd List (2021)**

| **22. MEDICINES FOR REPRODUCTIVE HEALTH AND PERINATAL CARE** |                                                                           |   |
| ------------------------------------------------------------ | ------------------------------------------------------------------------- | - |
|                                                              |                                                                           |   |
| **22.1 Contraceptives**                                      |                                                                           |   |
|                                                              |                                                                           |   |
| _**22.1.1 Oral hormonal contraceptives**_                    |                                                                           |   |
|                                                              |                                                                           |   |
|  ethinylestradiol +  levonorgestrel                        | **Tablet:** 30 micrograms + 150 micrograms.                               |   |
|                                                              |                                                                           |   |
| Therapeutic alternatives to be reviewed (2023)               |                                                                           |   |
|                                                              |                                                                           |   |
|  ethinylestradiol +  norethisterone                        | **Tablet:** 35 micrograms + 1 mg.                                         |   |
|                                                              |                                                                           |   |
| Therapeutic alternatives to be reviewed (2023)               |                                                                           |   |
|                                                              |                                                                           |   |
| levonorgestrel                                               | **Tablet:** 30 micrograms; 750 micrograms (pack of two); 1.5 mg.          |   |
|                                                              |                                                                           |   |
| ulipristal                                                   | **Tablet:** 30 mg (as acetate)                                            |   |
|                                                              |                                                                           |   |
| _**22.1.2 Injectable hormonal contraceptives**_              |                                                                           |   |
|                                                              |                                                                           |   |
| estradiol cypionate + medroxyprogesterone acetate            | **Injection:** 5 mg + 25 mg.                                              |   |
|                                                              |                                                                           |   |
|                                                              | **Injection (intramuscular):** 150 mg mL in 1 mL vial.                    |   |
| medroxyprogesterone acetate                                  | **Injection (subcutaneous):** 104 mg/0.65 mL in pre-filled syringe or     |   |
|                                                              |                                                                           |   |
|                                                              | single-dose injection delivery system.                                    |   |
|                                                              |                                                                           |   |
| norethisterone enantate                                      | **Oily solution:** 200 mg/mL in 1 mL ampoule.                             |   |
|                                                              |                                                                           |   |
| _**22.1.3 Intrauterine devices**_                            |                                                                           |   |
|                                                              |                                                                           |   |
| copper-containing device                                     |                                                                           |   |
|                                                              |                                                                           |   |
| levonorgestrel-releasing intrauterine system                 | **Intrauterine system**: with reservoir containing 52 mg of levonorestrel |   |
|                                                              |                                                                           |   |
| _**22.1.4 Barrier methods**_                                 |                                                                           |   |
|                                                              |                                                                           |   |
| condoms                                                      |                                                                           |   |
|                                                              |                                                                           |   |
| diaphragms                                                   |                                                                           |   |
|                                                              |                                                                           |   |
| _**22.1.5 Implantable contraceptives**_                      |                                                                           |   |
|                                                              |                                                                           |   |
| etonogestrel-releasing implant                               | **Single-rod etonogestrel-releasing implant:** containing 68 mg of        |   |
| etonogestrel.                                                |                                                                           |   |
|                                                              |                                                                           |   |
|                                                              |                                                                           |   |
| levonorgestrel-releasing implant                             | **Two-rod levonorgestrel-releasing implant:** each rod containing 75 mg   |   |
| of levonorgestrel (150 mg total).                            |                                                                           |   |
|                                                              |                                                                           |   |
|                                                              |                                                                           |   |
| _**22.1.6 Intravaginal contraceptives**_                     |                                                                           |   |
|                                                              |                                                                           |   |
| ethinylestradiol + etonogestrel                              | **Vaginal ring:** containing 2.7 mg + 11.7 mg                             |   |
|                                                              |                                                                           |   |
|                                                              | **Progesterone-releasing vaginal ring:** containing 2.074 g of            |   |
| progesterone vaginal ring\*                                  | micronized progesterone.                                                  |   |
|                                                              |                                                                           |   |
|                                                              | \*For use in women actively breastfeeding at least 4 times per day        |   |
|                                                              |                                                                           |   |
| **22.2 Ovulation inducers**                                  |                                                                           |   |
|                                                              |                                                                           |   |
| _**Complementary List**_                                     |                                                                           |   |
|                                                              |                                                                           |   |
| _clomifene_                                                  | _**Tablet:** 50 mg (citrate)._                                            |   |
|                                                              |                                                                           |   |

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 49**

**WHO Model List of Essential Medicines – 22nd List (2021)**

**22.3 Uterotonics**

| carbetocin                                                        | **Injection (heat stable):** 100 micrograms/mL                           |                                          |                                                                         |                                   |   |
| ----------------------------------------------------------------- | ------------------------------------------------------------------------ | ---------------------------------------- | ----------------------------------------------------------------------- | --------------------------------- | - |
|                                                                   |                                                                          |                                          |                                                                         |                                   |   |
|  ergometrine                                                     |                                                                          |                                          |                                                                         |                                   |   |
| Therapeutic alternatives:                                         | **Injection:** 200 micrograms (hydrogen maleate) in 1 mL ampoule.        |                                          |                                                                         |                                   |   |
| - methylergometrine                                               |                                                                          |                                          |                                                                         |                                   |   |
|                                                                   |                                                                          |                                          |                                                                         |                                   |   |
| mifepristone – misoprostol                                        | **Tablet** 200 mg **** – **tablet** 200 micrograms.                      |                                          |                                                                         |                                   |   |
|                                                                   |                                                                          |                                          | **Co-package containing:**                                              |                                   |   |
|                                                                   | Where permitted under national law and                                   |                                          |                                                                         |                                   |   |
|                                                                   |                                                                          |                                          |                                                                         |                                   |   |
|                                                                   | where culturally acceptable.                                             |                                          | mifepristone 200 mg tablet \[1] and misoprostol 200 micrograms          |                                   |   |
|                                                                   |                                                                          |                                          |                                                                         |                                   |   |
|                                                                   |                                                                          |                                          | tablet \[4]                                                             |                                   |   |
|                                                                   |                                                                          |                                          |                                                                         |                                   |   |
|                                                                   |                                                                          |                                          | **Tablet:** 200 micrograms.                                             |                                   |   |
|                                                                   |                                                                          |                                          | − Management of incomplete abortion and miscarriage;                    |                                   |   |
|                                                                   |                                                                          |                                          | − Prevention and treatment of postpartum haemorrhage where              |                                   |   |
| misoprostol                                                       | oxytocin is not available or cannot be safely used                       |                                          |                                                                         |                                   |   |
|                                                                   |                                                                          |                                          |                                                                         |                                   |   |
|                                                                   |                                                                          |                                          | **Vaginal tablet:** 25 micrograms.\*                                    |                                   |   |
|                                                                   |                                                                          |                                          | \*Only for use for induction of labour where appropriate facilities are |                                   |   |
|                                                                   |                                                                          |                                          | available.                                                              |                                   |   |
|                                                                   |                                                                          |                                          |                                                                         |                                   |   |
| oxytocin                                                          | **Injection:** 10 IU in 1 mL.                                            |                                          |                                                                         |                                   |   |
|                                                                   |                                                                          |                                          |                                                                         |                                   |   |
| **22.4 Antioxytocics (tocolytics)**                               |                                                                          |                                          |                                                                         |                                   |   |
|                                                                   |                                                                          |                                          |                                                                         |                                   |   |
| nifedipine                                                        | **Immediate-release capsule:** 10 mg.                                    |                                          |                                                                         |                                   |   |
|                                                                   |                                                                          |                                          |                                                                         |                                   |   |
| **22.5 Other medicines administered to the mother**               |                                                                          |                                          |                                                                         |                                   |   |
|                                                                   |                                                                          |                                          |                                                                         |                                   |   |
| dexamethasone                                                     | **Injection:** 4 mg/mL (as disodium phosphate salt) in 1 mL ampoule.     |                                          |                                                                         |                                   |   |
|                                                                   |                                                                          |                                          |                                                                         |                                   |   |
|                                                                   |                                                                          |                                          | **Tablet containing:**                                                  |                                   |   |
|                                                                   |                                                                          |                                          | Vitamin A (retinol acetate)                                             | 800 micrograms retinol activity   |   |
|                                                                   |                                                                          |                                          |                                                                         | equivalent                        |   |
|                                                                   |                                                                          |                                          | Vitamin C (ascorbic acid)                                               | 70 mg                             |   |
|                                                                   |                                                                          |                                          | Vitamin D (cholecalciferol)                                             | 5 micrograms (200 IU)             |   |
|                                                                   |                                                                          |                                          | Vitamin E (alpha tocopherol succinate)                                  | 10 mg alpha tocopherol equivalent |   |
|                                                                   |                                                                          |                                          | Vitamin B1 (thiamine mononitrate)                                       | 1.4 mg                            |   |
|                                                                   |                                                                          |                                          | Vitamin B2 (riboflavin)                                                 | 1.4 mg                            |   |
|                                                                   |                                                                          |                                          | Vitamin B3 (niacinamide)                                                | 18 mg niacin equivalent           |   |
|                                                                   |                                                                          |                                          | Vitamin B6 (pyridoxine hydrochloride)                                   | 1.9 mg                            |   |
| multiple micronutrient supplement\*                               | Folic acid (folic acid)                                                  | 680 micrograms dietary folate equivalent |                                                                         |                                   |   |
|                                                                   |                                                                          |                                          |                                                                         | (400 micrograms)                  |   |
|                                                                   |                                                                          |                                          | Vitamin B12 (cyanocobalamin)                                            | 2.6 micrograms                    |   |
|                                                                   |                                                                          |                                          | Iron (ferrous fumarate)                                                 | 30 mg                             |   |
|                                                                   |                                                                          |                                          | Iodine (potassium iodide)                                               | 150 micrograms                    |   |
|                                                                   |                                                                          |                                          | Zinc (zinc oxide)                                                       | 15 mg                             |   |
|                                                                   |                                                                          |                                          | Selenium (sodium selenite)                                              | 65 micrograms                     |   |
|                                                                   |                                                                          |                                          | Copper (cupric oxide)                                                   | 2 mg                              |   |
|                                                                   |                                                                          |                                          | \*For use in specific contexts. Refer to current WHO                    |                                   |   |
|                                                                   |                                                                          |                                          | recommendations.                                                        |                                   |   |
|                                                                   |                                                                          |                                          |                                                                         |                                   |   |
| tranexamic acid                                                   | **Injection:** 100 mg/mL in 10 mL ampoule                                |                                          |                                                                         |                                   |   |
|                                                                   |                                                                          |                                          |                                                                         |                                   |   |
| **22.6 Medicines administered to the neonate \[c]**               |                                                                          |                                          |                                                                         |                                   |   |
|                                                                   |                                                                          |                                          |                                                                         |                                   |   |
| caffeine citrate **\[c]**                                         | **Injection:** 20 mg/mL (equivalent to 10 mg caffeine base/mL).          |                                          |                                                                         |                                   |   |
| **Oral liquid:** 20 mg/mL (equivalent to 10 mg caffeine base/mL). |                                                                          |                                          |                                                                         |                                   |   |
|                                                                   |                                                                          |                                          |                                                                         |                                   |   |
|                                                                   |                                                                          |                                          |                                                                         |                                   |   |
| chlorhexidine **\[c]**                                            | **Solution or gel:** 7.1% (digluconate) delivering 4% chlorhexidine (for |                                          |                                                                         |                                   |   |
| umbilical cord care).                                             |                                                                          |                                          |                                                                         |                                   |   |
|                                                                   |                                                                          |                                          |                                                                         |                                   |   |
|                                                                   |                                                                          |                                          |                                                                         |                                   |   |

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 50**

**WHO Model List of Essential Medicines – 22nd List (2021)**

| _**Complementary List**_                               |                                                                        |   |
| ------------------------------------------------------ | ---------------------------------------------------------------------- | - |
|                                                        |                                                                        |   |
|  _ibuprofen_ _**\[c]**_                               |                                                                        |   |
| _Therapeutic alternatives:_                            | _**Solution for injection**_: 5 mg/mL.                                 |   |
| _- indometacin_                                        |                                                                        |   |
|                                                        |                                                                        |   |
|  _prostaglandin E1_ _**\[c]**_                        |                                                                        |   |
| _Therapeutic alternatives:_                            | _**Solution for injection:**_ 0.5 mg/mL in alcohol.                    |   |
| _- prostaglandin E2_                                   |                                                                        |   |
|                                                        |                                                                        |   |
| _surfactant **\[c]**_                                  | _**Suspension for intratracheal instillation:** 25 mg/mL or 80 mg/mL._ |   |
|                                                        |                                                                        |   |
| **23. PERITONEAL DIALYSIS SOLUTION**                   |                                                                        |   |
|                                                        |                                                                        |   |
| _**Complementary List**_                               |                                                                        |   |
|                                                        |                                                                        |   |
| _intraperitoneal dialysis solution_                    | _**Parenteral solution.**_                                             |   |
| _(of appropriate composition)_                         |                                                                        |   |
|                                                        |                                                                        |   |
|                                                        |                                                                        |   |
| **24. MEDICINES FOR MENTAL AND BEHAVIOURAL DISORDERS** |                                                                        |   |
|                                                        |                                                                        |   |
| **24.1 Medicines used in psychotic disorders**         |                                                                        |   |
|                                                        |                                                                        |   |
|  chlorpromazine                                       | **Injection:** 25 mg/mL (hydrochloride) in 2 mL ampoule.               |   |
| **Oral liquid:** 25 mg/5 mL (hydrochloride).           |                                                                        |   |
|                                                        |                                                                        |   |
| Therapeutic alternatives to be reviewed (2023)         | **Tablet:** 100 mg (hydrochloride).                                    |   |
|                                                        |                                                                        |   |
|                                                        |                                                                        |   |
|  fluphenazine                                         | **Injection:** 25 mg (decanoate or enantate) in 1 mL ampoule.          |   |
|                                                        |                                                                        |   |
| Therapeutic alternatives to be reviewed (2023)         |                                                                        |   |
|                                                        |                                                                        |   |
|  haloperidol                                          | **Injection:** 5 mg in 1 mL ampoule.                                   |   |
|                                                        |                                                                        |   |
| Therapeutic alternatives to be reviewed (2023)         | **Tablet:** 2 mg; 5 mg.                                                |   |
|                                                        |                                                                        |   |
|                                                        |                                                                        |   |
|  paliperidone                                         |                                                                        |   |
| Therapeutic alternatives:                              | **Injection (prolonged-release):** 25 mg; 50 mg; 75 mg; 100 mg;        |   |
| 150 mg (as palmitate) in pre-filled syringe            |                                                                        |   |
|                                                        |                                                                        |   |
| - risperidone injection                                |                                                                        |   |
|                                                        |                                                                        |   |
| risperidone                                            | **Solid oral dosage form:** 0.25 mg to 6.0 mg.                         |   |
|                                                        |                                                                        |   |
| _**Complementary List**_                               |                                                                        |   |
|                                                        |                                                                        |   |
|                                                        | _**Injection:** 25 mg/mL (hydrochloride) in 2 mL ampoule._             |   |
| _chlorpromazine_ **\[c]**                              | _**Oral liquid:** 25 mg/5 mL (hydrochloride)._                         |   |
|                                                        | _**Tablet:** 10 mg; 25 mg; 50 mg; 100 mg (hydrochloride)._             |   |
|                                                        |                                                                        |   |
| _clozapine_                                            | _**Solid oral dosage form:** 25 to 200 mg._                            |   |
|                                                        |                                                                        |   |
|                                                        | _**Injection:** 5 mg in 1 mL ampoule._                                 |   |
| _haloperidol_ **\[c]**                                 | _**Oral liquid:** 2 mg/mL._                                            |   |
|                                                        | _**Solid oral dosage form:** 0.5 mg; 2 mg; 5 mg._                      |   |
|                                                        |                                                                        |   |

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 51**

**WHO Model List of Essential Medicines – 22nd List (2021)**

| **24.2 Medicines used in mood disorders**           |                                                         |   |
| --------------------------------------------------- | ------------------------------------------------------- | - |
|                                                     |                                                         |   |
| _**24.2.1 Medicines used in depressive disorders**_ |                                                         |   |
|                                                     |                                                         |   |
|  amitriptyline                                     | **Tablet:** 25 mg; 75mg. (hydrochloride).               |   |
|                                                     |                                                         |   |
| Therapeutic alternatives to be reviewed (2023)      |                                                         |   |
|                                                     |                                                         |   |
|  fluoxetine                                        |                                                         |   |
| Therapeutic alternatives:                           |                                                         |   |
| - citalopram                                        | **Solid oral dosage form:** 20 mg (as hydrochloride).   |   |
| - escitalopram                                      |                                                         |   |
|                                                     |                                                         |   |
| - fluvoxamine                                       |                                                         |   |
| - paroxetine                                        |                                                         |   |
| - sertraline                                        |                                                         |   |
|                                                     |                                                         |   |
| _**Complementary List**_                            |                                                         |   |
|                                                     |                                                         |   |
| _fluoxetine_ **a** _ **\[c]**_                      | _**Solid oral dosage form:** 20 mg (as hydrochloride)._ |   |
| **a** > 8 years.                                    |                                                         |   |
|                                                     |                                                         |   |
|                                                     |                                                         |   |
| _**24.2.2 Medicines used in bipolar disorders**_    |                                                         |   |

| carbamazepine                                                      | **Tablet (scored):** 100 mg; 200 mg.                                  |   |
| ------------------------------------------------------------------ | --------------------------------------------------------------------- | - |
|                                                                    |                                                                       |   |
| lithium carbonate                                                  | **Solid oral dosage form:** 300 mg.                                   |   |
|                                                                    |                                                                       |   |
| valproic acid (sodium valproate)\*                                 |                                                                       |   |
| _\*avoid use in pregnancy and in women and girls of child-_        |                                                                       |   |
| _bearing potential, unless alternative treatments are_             | **Tablet (enteric-coated):** 200 mg; 500 mg.                          |   |
| _ineffective or not tolerated because of the high risk of birth_   |                                                                       |   |
| _defects and developmental disorders in children exposed to_       |                                                                       |   |
| _valproate in the womb._                                           |                                                                       |   |
|                                                                    |                                                                       |   |
| **24.3 Medicines for anxiety disorders**                           |                                                                       |   |
|                                                                    |                                                                       |   |
|  diazepam                                                         | **Tablet (scored):** 2 mg; 5 mg.                                      |   |
|                                                                    |                                                                       |   |
| Therapeutic alternatives to be reviewed (2023)                     |                                                                       |   |
|                                                                    |                                                                       |   |
| **24.4 Medicines used for obsessive compulsive disorders**         |                                                                       |   |
|                                                                    |                                                                       |   |
| clomipramine                                                       | **Capsule:** 10 mg; 25 mg (hydrochloride).                            |   |
|                                                                    |                                                                       |   |
| **24.5 Medicines for disorders due to psychoactive substance use** |                                                                       |   |
|                                                                    |                                                                       |   |
| bupropion                                                          | **Tablet (sustained-release):** 150 mg (hydrochloride)                |   |
|                                                                    |                                                                       |   |
| nicotine replacement therapy (NRT)                                 | **Chewing gum:** 2 mg; 4 mg (as polacrilex).                          |   |
| **Transdermal patch:** 5 mg to 30 mg/16 hrs; 7 mg to 21 mg/24 hrs. |                                                                       |   |
|                                                                    |                                                                       |   |
|                                                                    |                                                                       |   |
| varenicline                                                        | **Tablet:** 0.5 mg, 1 mg                                              |   |
|                                                                    |                                                                       |   |
| _**Complementary List**_                                           |                                                                       |   |
|                                                                    |                                                                       |   |
|  _methadone_\*                                                    | _**Concentrate for oral liquid:** 5 mg/mL; 10 mg/mL (hydrochloride)._ |   |
|                                                                    |                                                                       |   |
| _Therapeutic alternatives:_                                        | _**Oral liquid:** 5 mg/5 mL; 10 mg/5 mL (hydrochloride)._             |   |
|                                                                    |                                                                       |   |
| _- buprenorphine_                                                  | _\*The medicines should only be used within an established support_   |   |
| _programme._                                                       |                                                                       |   |
|                                                                    |                                                                       |   |
|                                                                    |                                                                       |   |

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 52**

**WHO Model List of Essential Medicines – 22nd List (2021)**

**25. MEDICINES ACTING ON THE RESPIRATORY TRACT**

**25.1 Antiasthmatic medicines and medicines for chronic obstructive pulmonary disease**

|  budesonide                                                               |                                                                          |   |
| -------------------------------------------------------------------------- | ------------------------------------------------------------------------ | - |
| Therapeutic alternatives:                                                  |                                                                          |   |
| - beclometasone                                                            | **Inhalation (aerosol):** 100 micrograms per dose; 200 micrograms per    |   |
| - ciclesonide                                                              | dose.                                                                    |   |
| - flunisolide                                                              |                                                                          |   |
|                                                                            |                                                                          |   |
| - fluticasone                                                              |                                                                          |   |
| - mometasone                                                               |                                                                          |   |
|                                                                            |                                                                          |   |
|  budesonide +  formoterol                                                |                                                                          |   |
| Therapeutic alternatives:                                                  |                                                                          |   |
| - beclometasone + formoterol                                               | **Dry powder inhaler:** 100 micrograms + 6 micrograms per dose;          |   |
| - budesonide + salmeterol                                                  | 200 micrograms + 6 micrograms per dose                                   |   |
| - fluticasone + formoterol                                                 |                                                                          |   |
| - fluticasone furoate + vilanterol                                         |                                                                          |   |
| - mometasone + formoterol                                                  |                                                                          |   |
|                                                                            |                                                                          |   |
| epinephrine (adrenaline)                                                   | **Injection:** 1 mg/mL (as hydrochloride or hydrogen tartrate) in 1 mL   |   |
| ampoule.                                                                   |                                                                          |   |
|                                                                            |                                                                          |   |
|                                                                            |                                                                          |   |
| ipratropium bromide                                                        | **Inhalation (aerosol):** 20 micrograms/metered dose.                    |   |
|                                                                            |                                                                          |   |
|  salbutamol                                                               | **Inhalation (aerosol):** 100 micrograms (as sulfate) per dose.          |   |
| **Injection:** 50 micrograms/mL (as sulfate) in 5 mL ampoule.              |                                                                          |   |
| Therapeutic alternatives:                                                  |                                                                          |   |
| **Metered dose inhaler (aerosol):** 100 micrograms (as sulfate) per        |                                                                          |   |
| - terbutaline                                                              |                                                                          |   |
| dose.                                                                      |                                                                          |   |
|                                                                            | **Respirator solution for use in nebulizers:** 5 mg/mL (as sulfate).     |   |
|                                                                            |                                                                          |   |
|  tiotropium                                                               |                                                                          |   |
| Therapeutic alternatives:                                                  | **Powder for inhalaton, capsule:** 18 micrograms                         |   |
|                                                                            |                                                                          |   |
| - aclidinium                                                               | **Inhalation solution:** 1.25 micrograms; 2.5 micrograms per actuation   |   |
| - glycopyrronium                                                           |                                                                          |   |
|                                                                            |                                                                          |   |
| - umeclidinium                                                             |                                                                          |   |
|                                                                            |                                                                          |   |
| **26. SOLUTIONS CORRECTING WATER, ELECTROLYTE AND ACID–BASE DISTURBANCES** |                                                                          |   |
|                                                                            |                                                                          |   |
| **26.1 Oral**                                                              |                                                                          |   |
|                                                                            |                                                                          |   |
| oral rehydration salts                                                     | See section 17.5.1.                                                      |   |
|                                                                            |                                                                          |   |
| potassium chloride                                                         | **Powder for solution.**                                                 |   |
|                                                                            |                                                                          |   |
| **26.2 Parenteral**                                                        |                                                                          |   |
|                                                                            |                                                                          |   |
| glucose                                                                    | **Injectable solution:** 5% (isotonic); 10% (hypertonic);                |   |
| 50% (hypertonic).                                                          |                                                                          |   |
|                                                                            |                                                                          |   |
|                                                                            |                                                                          |   |
|                                                                            | **Injectable solution:** 4% glucose, 0.18% sodium chloride               |   |
|                                                                            | (equivalent to Na+ 30 mmol/L, Cl- 30 mmol/L).                            |   |
| glucose with sodium chloride                                               | **Injectable solution:** 5% glucose, 0.9% sodium chloride (equivalent to |   |
|                                                                            |                                                                          |   |
|                                                                            | Na+ 150 mmol/L and Cl- 150 mmol/L); 5% glucose, 0.45% sodium             |   |
|                                                                            | chloride (equivalent to Na+ 75 mmol/L and Cl- 75 mmol/L) **\[c]**.       |   |
|                                                                            |                                                                          |   |

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 53**

**WHO Model List of Essential Medicines – 22nd List (2021)**

|                                                                     | **Solution:** 11.2% in 20 mL ampoule                                      |   |
| ------------------------------------------------------------------- | ------------------------------------------------------------------------- | - |
|                                                                     | (equivalent to K+ 1.5 mmol/mL, Cl- 1.5 mmol/mL).                          |   |
| potassium chloride                                                  | **Solution for dilution:** 7.5% (equivalent to K 1 mmol/mL and Cl         |   |
|                                                                     |                                                                           |   |
|                                                                     | 1 mmol/mL) **\[c]**; 15% (equivalent to K 2 mmol/mL and Cl 2 mmol/mL)     |   |
|                                                                     | **\[c]**.                                                                 |   |
|                                                                     |                                                                           |   |
| sodium chloride                                                     | **Injectable solution:** 0.9% isotonic (equivalent to Na+ 154 mmol/L, Cl- |   |
| 154 mmol/L).                                                        |                                                                           |   |
|                                                                     |                                                                           |   |
|                                                                     |                                                                           |   |
|                                                                     | **Injectable solution:** 1.4% isotonic (equivalent to Na+ 167 mmol/L,     |   |
| sodium hydrogen carbonate                                           | HCO3- 167 mmol/L).                                                        |   |
| **Solution:** 8.4% in 10 mL ampoule (equivalent to Na+ 1000 mmol/L, |                                                                           |   |
|                                                                     |                                                                           |   |
|                                                                     | HCO3-1000 mmol/L).                                                        |   |
|                                                                     |                                                                           |   |
| sodium lactate, compound solution                                   | **Injectable solution.**                                                  |   |
|                                                                     |                                                                           |   |
| **26.3 Miscellaneous**                                              |                                                                           |   |
|                                                                     |                                                                           |   |
| water for injection                                                 | 2 mL; 5 mL; 10 mL ampoules.                                               |   |
|                                                                     |                                                                           |   |
| **27. VITAMINS AND MINERALS**                                       |                                                                           |   |
|                                                                     |                                                                           |   |
| ascorbic acid                                                       | **Tablet:** 50 mg.                                                        |   |
|                                                                     |                                                                           |   |
| calcium                                                             | **Tablet:** 500 mg (elemental).                                           |   |
|                                                                     |                                                                           |   |
|  colecalciferol **\[c]**                                           | **Oral liquid:** 400 IU/mL.                                               |   |
|                                                                     |                                                                           |   |
| Therapeutic alternatives:                                           | **Solid oral dosage form:** 400 IU; 1000 IU.                              |   |
|                                                                     |                                                                           |   |
| - ergocalciferol                                                    |                                                                           |   |
|  ergocalciferol                                                    | **Oral liquid:** 250 micrograms/mL (10 000 IU/mL).                        |   |
| Therapeutic alternatives:                                           |                                                                           |   |
|                                                                     |                                                                           |   |
| - colecalciferol                                                    | **Solid oral dosage form:** 1.25 mg (50 000 IU).                          |   |
|                                                                     |                                                                           |   |
|                                                                     |                                                                           |   |
|                                                                     | **Capsule:** 190 mg.                                                      |   |
| iodine                                                              | **Iodized oil:** 1 mL (480 mg iodine); 0.5 mL (240 mg iodine) in ampoule  |   |
|                                                                     | (oral or injectable); 0.57 mL (308 mg iodine) in dispenser bottle.        |   |
|                                                                     |                                                                           |   |
|                                                                     | **Sachets containing:**                                                   |   |
|                                                                     | - iron (elemental) 12.5 mg (as coated ferrous fumarate)                   |   |
| multiple micronutrient powder **\[c]**                              | - zinc (elemental) 5 mg                                                   |   |
|                                                                     | - vitamin A 300 micrograms                                                |   |
|                                                                     | - with or without other micronutrients at recommended daily values        |   |
|                                                                     |                                                                           |   |
| nicotinamide                                                        | **Tablet:** 50 mg.                                                        |   |
|                                                                     |                                                                           |   |
| pyridoxine                                                          | **Tablet:** 25 mg (hydrochloride).                                        |   |
|                                                                     |                                                                           |   |
|                                                                     | **Capsule:** 50 000 IU; 100 000 IU; 200 000 IU (as palmitate).            |   |
|                                                                     | **Oral oily solution:** 100 000 IU/mL (as palmitate) in multidose         |   |
| retinol                                                             | dispenser.                                                                |   |
| **Tablet (sugar-coated):** 10 000 IU (as palmitate).                |                                                                           |   |
|                                                                     |                                                                           |   |
|                                                                     | **Water-miscible injection:** 100 000 IU (as palmitate) in                |   |
|                                                                     | 2 mL ampoule.                                                             |   |
|                                                                     |                                                                           |   |
| riboflavin                                                          | **Tablet:** 5 mg.                                                         |   |
|                                                                     |                                                                           |   |
| thiamine                                                            | **Tablet:** 50 mg (hydrochloride).                                        |   |
|                                                                     |                                                                           |   |

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 54**

**WHO Model List of Essential Medicines – 22nd List (2021)**

_**Complementary List**_

| _calcium gluconate_ | _**Injection:** 100 mg/mL in 10 mL ampoule._ |
| ------------------- | -------------------------------------------- |
|                     |                                              |

**28. EAR, NOSE AND THROAT MEDICINES**

| acetic acid **\[c]**                                         | **Topical:** 2%, in alcohol.                                             |   |
| ------------------------------------------------------------ | ------------------------------------------------------------------------ | - |
|                                                              |                                                                          |   |
|  budesonide **\[c]**                                        | **Nasal spray:** 100 micrograms per dose.                                |   |
|                                                              |                                                                          |   |
| Therapeutic alternatives to be reviewed (2023)               |                                                                          |   |
|                                                              |                                                                          |   |
|  ciprofloxacin **\[c]**                                     |                                                                          |   |
| Therapeutic alternatives:                                    | **Solution (ear drops):** 0.3% (as hydrochloride).                       |   |
| - ofloxacin                                                  |                                                                          |   |
|                                                              |                                                                          |   |
|  xylometazoline **a \[c]**                                  | **Nasal spray:** 0.05%.                                                  |   |
| Therapeutic alternatives to be reviewed (2023)               | **a** Not in children less than 3 months.                                |   |
|                                                              |                                                                          |   |
|                                                              |                                                                          |   |
| **29. MEDICINES FOR DISEASES OF JOINTS**                     |                                                                          |   |
|                                                              |                                                                          |   |
| **29.1 Medicines used to treat gout**                        |                                                                          |   |
|                                                              |                                                                          |   |
| allopurinol                                                  | **Tablet:** 100 mg.                                                      |   |
|                                                              |                                                                          |   |
| **29.2 Disease-modifying anti-rheumatic drugs (DMARDs)**     |                                                                          |   |
|                                                              |                                                                          |   |
| chloroquine                                                  | **Tablet:** 100 mg; 150 mg (as phosphate or sulfate).                    |   |
|                                                              |                                                                          |   |
| _**Complementary List**_                                     |                                                                          |   |
|                                                              |                                                                          |   |
| _azathioprine_                                               | _**Tablet:** 50 mg._                                                     |   |
|                                                              |                                                                          |   |
| _hydroxychloroquine_                                         | _**Solid oral dosage form:** 200 mg (as sulfate)_.                       |   |
|                                                              |                                                                          |   |
| _methotrexate_                                               | _**Tablet:** 2.5 mg (as sodium salt)._                                   |   |
|                                                              |                                                                          |   |
| _penicillamine_                                              | _**Solid oral dosage form:** 250 mg._                                    |   |
|                                                              |                                                                          |   |
| _sulfasalazine_                                              | _**Tablet:** 500 mg._                                                    |   |
|                                                              |                                                                          |   |
| **29.3 Juvenile joint diseases**                             |                                                                          |   |
|                                                              |                                                                          |   |
| _**Complementary List**_                                     |                                                                          |   |
|                                                              |                                                                          |   |
|                                                              | _**Suppository:** 50 mg to 150 mg._                                      |   |
| _acetylsalicylic acid\* (acute or chronic use)_              | _**Tablet:** 100 mg to 500 mg._                                          |   |
|                                                              | _\*For use for rheumatic fever, juvenile arthritis, Kawasaki disease._   |   |
|                                                              |                                                                          |   |
| **30. DENTAL PREPARATIONS**                                  |                                                                          |   |
|                                                              |                                                                          |   |
|                                                              | **Paste, cream or gel:** containing between 1000 and 1500 ppm            |   |
| fluoride                                                     | fluoride (any type).                                                     |   |
|                                                              |                                                                          |   |
|                                                              | **In other appropriate topical formulations.**                           |   |
|                                                              |                                                                          |   |
|                                                              | **Single-use capsules:** 0.4 g powder + 0.09 mL liquid.                  |   |
|                                                              | **Multi-use bottle:** powder + liquid.                                   |   |
| glass ionomer cement                                         | Powder (fluoro-alumino-silicate glass) contains: 25-50% silicate, 20-40% |   |
|                                                              | aluminium oxide, 1-20% fluoride, 15-40% metal oxide, 0-15% phosphate,    |   |
|                                                              | remainder are polyacrylic acid powder and metals in minimal quantities.  |   |
|                                                              | Liquid (aqueous) contains: 7-25% polybasic carboxylic acid, 45-60%       |   |
|                                                              | polyacrylic acid.                                                        |   |
|                                                              |                                                                          |   |
| silver diamine fluoride                                      | **Solution:** 38% w/v.                                                   |   |
|                                                              |                                                                          |   |
| **WHO Model List of Essential Medicines – 22nd List (2021)** | **page 55**                                                              |   |

**WHO Model List of Essential Medicines – 22nd List (2021)**

**Table 1.1: Medicines with age or weight restrictions**

| artesunate + pyronaridine tetraphosphate   | > 5 kg                                                   |
| ------------------------------------------ | -------------------------------------------------------- |
| atropine                                   | > 3 months                                               |
| bedaquiline                                | ≥ 5 years                                                |
| benzyl benzoate                            | >2 years                                                 |
| betamethasone topical preparations         | hydrocortisone preferred in neonates                     |
| cefazolin                                  | > 1 month                                                |
| ceftriaxone                                | > 41 weeks corrected gestational age                     |
| darunavir                                  | > 3 years                                                |
| delamanid                                  | ≥ 3 years (25 mg dispersible tablet)                     |
|                                            | ≥ 6 years (50 mg tablet)                                 |
| dihydroartemisinin + piperaquine phosphate | > 5 kg                                                   |
| diloxanide                                 | >25 kg                                                   |
| dolutegravir                               | ≥ 4 weeks and ≥ 3 kg (10 mg dispersible tablet)          |
|                                            | ≥ 25 kg (50 mg tablet)                                   |
| doxycycline                                | > 8 years (except for serious infections e.g. cholera)   |
| fluoxetine                                 | > 8 years                                                |
| ibuprofen                                  | > 3 months (except IV form for patent ductus arteriosus) |
| mefloquine                                 | > 5 kg or > 3 months                                     |
| metoclopramide                             | Not in neonates                                          |
| nevirapine                                 | > 6 weeks                                                |
| ondansetron                                | > 1 month                                                |
| silver sulfadiazine                        | > 2 months                                               |
| tetracaine                                 | Not in preterm neonates                                  |
| xylometazoline                             | > 3 months                                               |

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 56**

**WHO Model List of Essential Medicines – 22nd List (2021)**

**Table 1.2: Explanation of dosage forms**

**A. Principal dosage forms used in EML – oral administration**

| **Term**                                                                 | **Definition**                                                                   |   |
| ------------------------------------------------------------------------ | -------------------------------------------------------------------------------- | - |
|                                                                          |                                                                                  |   |
|                                                                          | Refers to tablets or capsules or other solid dosage forms such as 'melts'        |   |
|                                                                          | that are immediate-release preparations. It implies that there is no             |   |
|                                                                          | difference in clinical efficacy or safety between the available dosage forms,    |   |
|                                                                          | and countries should therefore choose the form(s) to be listed depending         |   |
| **Solid oral dosage form**                                               | on quality and availability.                                                     |   |
|                                                                          | The term 'solid oral dosage form' is _never_ intended to allow any type of       |   |
|                                                                          | modified-release tablet.                                                         |   |
|                                                                          |                                                                                  |   |
|                                                                          | Refers to:                                                                       |   |
|                                                                          | • uncoated or coated (film-coated or sugar-coated) tablets that are              |   |
|                                                                          | intended to be swallowed whole;                                                  |   |
|                                                                          | • unscored and scored\*;                                                         |   |
| **Tablets**                                                              | • tablets that are intended to be chewed before being swallowed;                 |   |
| • tablets that are intended to be dispersed or dissolved in water or     |                                                                                  |   |
|                                                                          | another suitable liquid before being swallowed;                                  |   |
|                                                                          | • tablets that are intended to be crushed before being swallowed.                |   |
|                                                                          | The term 'tablet' without qualification is _never_ intended to allow any type of |   |
|                                                                          | modified-release tablet.                                                         |   |
|                                                                          |                                                                                  |   |
|                                                                          | Refers to a specific type of tablet:                                             |   |
|                                                                          | **chewable** - tablets that are intended to be chewed before being swallowed;    |   |
|                                                                          | **dispersible** - tablets that are intended to be dispersed in water or another  |   |
|                                                                          | suitable liquid before being swallowed;                                          |   |
|                                                                          | **soluble** - tablets that are intended to be dissolved in water or another      |   |
|                                                                          | suitable liquid before being swallowed;                                          |   |
|                                                                          | **crushable** - tablets that are intended to be crushed before being             |   |
| **Tablets (qualified)**                                                  | swallowed;                                                                       |   |
| **scored** - tablets bearing a break mark or marks where sub-division is |                                                                                  |   |
|                                                                          |                                                                                  |   |
|                                                                          | intended in order to provide doses of less than one tablet;                      |   |
|                                                                          | **sublingual** - tablets that are intended to be placed beneath the tongue.      |   |
|                                                                          | The term 'tablet' is _always_ qualified with an additional term (in parentheses) |   |
|                                                                          | in entries where one of the following types of tablet is intended: **gastro-**   |   |
|                                                                          | **resistant** (such tablets may sometimes be described as enteric-coated or      |   |
|                                                                          | as delayed-release), **prolonged-release** or another modified-release form.     |   |

* Scored tablets may be divided for ease of swallowing, provided that dose is a whole number of tablets.

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 57**

**WHO Model List of Essential Medicines – 22nd List (2021)**

|                                                                              | Refers to hard or soft capsules.                                               |   |
| ---------------------------------------------------------------------------- | ------------------------------------------------------------------------------ | - |
| **Capsules**                                                                 | The term 'capsule' without qualification is _never_ intended to allow any type |   |
|                                                                              | of modified-release capsule.                                                   |   |
|                                                                              |                                                                                |   |
|                                                                              | The term 'capsule' with qualification refers to **gastro-resistant** (such     |   |
| **Capsules (qualified)**                                                     | capsules may sometimes be described as enteric-coated or as delayed-           |   |
| release), **prolonged-release** or another modified-release form.            |                                                                                |   |
|                                                                              |                                                                                |   |
|                                                                              |                                                                                |   |
|                                                                              | Preparations that are issued to patient as granules to be swallowed without    |   |
|                                                                              | further preparation, to be chewed, or to be taken in or with water or          |   |
|                                                                              | another suitable liquid.                                                       |   |
| **Granules**                                                                 |                                                                                |   |
|                                                                              | The term 'granules' without further qualification is _never_ intended to allow |   |
|                                                                              | any type of modified-release granules.                                         |   |
|                                                                              |                                                                                |   |
|                                                                              | Preparations that are issued to patient as powder (usually as single-dose)     |   |
| **Oral powder**                                                              | to be taken in or with water or another suitable liquid.                       |   |
|                                                                              |                                                                                |   |
|                                                                              | Liquid preparations intended to be _swallowed_ i.e. oral solutions,            |   |
|                                                                              | suspensions, emulsions and oral drops, including those constituted from        |   |
|                                                                              | powders or granules, but _not_ those preparations intended for _oromucosal_    |   |
|                                                                              | _administration_ e.g. gargles and mouthwashes.                                 |   |
| **Oral liquid**                                                              | Oral liquids presented as powders or granules may offer benefits in the        |   |
| form of better stability and lower transport costs. If more than one type of |                                                                                |   |
|                                                                              |                                                                                |   |
|                                                                              | oral liquid is available on the same market (e.g. solution, suspension,        |   |
|                                                                              | granules for reconstitution), they may be interchanged and in such cases       |   |
|                                                                              | should be bioequivalent. It is preferable that oral liquids do not contain     |   |
|                                                                              | sugar and that solutions for children do not contain alcohol.                  |   |
|                                                                              |                                                                                |   |

**B. Principal dosage forms used in EML – parenteral administration**

| **Term**                  | **Definition**                                                             |
| ------------------------- | -------------------------------------------------------------------------- |
| **Injection**             | Refers to solutions, suspensions and emulsions including those constituted |
|                           | from powders or concentrated solutions.                                    |
| **Injection (qualified)** | Route of administration is indicated in parentheses where relevant.        |
| **Injection (oily)**      | The term \`injection’ is qualified by \`(oily)’ in relevant entries.       |
| **Intravenous infusion**  | Refers to solutions and emulsions including those constituted from powders |
|                           | or concentrated solutions.                                                 |
|                           | **C. Other dosage forms**                                                  |

| **Mode of administration** | **Term to be used**                                       |
| -------------------------- | --------------------------------------------------------- |
| **To the eye**             | Eye drops, eye ointments.                                 |
| **Topical**                | For liquids: lotions, paints.                             |
|                            | For semi-solids: cream, ointment.                         |
| **Rectal**                 | Suppositories, gel or solution.                           |
| **Vaginal**                | Pessaries or vaginal tablets.                             |
| **Inhalation**             | Powder for inhalation, pressurized inhalation, nebulizer. |

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 58**

**WHO Model List of Essential Medicines – 22nd List (2021)**

**Index**

| abacavir                                                     | 18            | _bleomycin_               | 25         |
| ------------------------------------------------------------ | ------------- | ------------------------- | ---------- |
| abacavir + lamivudine                                        | 19            | _bortezomib_              | 30         |
| _abiraterone_                                                | 31            | budesonide                | 53, 55     |
| acetazolamide                                                | 48            | budesonide + formoterol   | 53         |
| acetic acid                                                  | 55            | bupivacaine               | 1          |
| acetylcysteine                                               | 4             | bupropion                 | 52         |
| acetylsalicylic acid                                         | 2, 24, 38, 55 | caffeine citrate          | 50         |
| aciclovir                                                    | 18, 47        | calamine                  | 39         |
| _adalimumab_                                                 | 25            | calcipotriol              | 39         |
| albendazole                                                  | 6             | calcium                   | 54         |
| alcohol based hand rub                                       | 40            | _calcium folinate_        | 25         |
| _allopurinol_                                                | 32, 55        | calcium gluconate         | 4, 55      |
| _all-trans retinoid acid (ATRA)_                             | 30            | _capecitabine_            | 26         |
| _alteplase_                                                  | 38            | carbamazepine             | 5, 52      |
| amidotrizoate                                                | 40            | carbetocin                | 50         |
| amikacin                                                     | 8, 16         | _carboplatin_             | 26         |
| amiloride                                                    | 41            | cefalexin                 | 9          |
| _amiodarone_                                                 | 36            | cefazolin                 | 9          |
| amitriptyline                                                | 3, 52         | _cefiderocol_             | 14         |
| amlodipine                                                   | 36            | cefixime                  | 12         |
| amodiaquine                                                  | 21            | cefotaxime                | 12         |
| amodiaquine – sulfadoxine + pyrimethamine                    | 23            | _ceftazidime_             | 14         |
| amoxicillin                                                  | 8             | _ceftazidime + avibactam_ | 14         |
| amoxicillin + clavulanic acid                                | 8, 16         | ceftriaxone               | 13         |
| amphotericin B                                               | 17, 21        | cefuroxime                | 13         |
| ampicillin                                                   | 9             | charcoal, activated       | 4          |
| _anastrozole_                                                | 31            | _chlorambucil_            | 26         |
| anti-D immunoglobulin                                        | 34            | chloramphenicol           | 9          |
| anti-rabies immunoglobulin                                   | 34            | chlorhexidine             | 40, 50     |
| anti-rabies virus monoclonal antibodies                      | 45            | chlorine base compound    | 40         |
| anti-tetanus immunoglobulin                                  | 34            | chloroquine               | 22, 23, 55 |
| antivenom immunoglobulin                                     | 45            | chloroxylenol             | 41         |
| _aprepitant_                                                 | 42            | chlorpromazine            | 51         |
| _arsenic trioxide_                                           | 25            | cholera vaccine           | 46         |
| artemether                                                   | 21            | _ciclosporin_             | 25         |
| artemether + lumefantrine                                    | 21            | ciprofloxacin             | 13, 55     |
| artesunate                                                   | 22            | _cisplatin_               | 26         |
| artesunate + amodiaquine                                     | 22            | clarithromycin            | 13         |
| artesunate + mefloquine                                      | 22            | clindamycin               | 10         |
| artesunate + pyronaridine tetraphosphate                     | 22            | clofazimine               | 15, 16     |
| ascorbic acid                                                | 54            | _clomifene_               | 49         |
| _asparaginase_                                               | 25            | clomipramine              | 52         |
| atazanavir + ritonavir                                       | 18            | clopidogrel               | 38         |
| atracurium                                                   | 47            | clotrimazole              | 17         |
| atropine                                                     | 1, 4, 48      | cloxacillin               | 10         |
| _azathioprine_                                               | 25, 55        | _clozapine_               | 51         |
| azithromycin                                                 | 12, 47        | _coagulation factor IX_   | 35         |
| barium sulfate                                               | 40            | _coagulation factor VIII_ | 35         |
| BCG vaccine                                                  | 46            | coal tar                  | 39         |
| _bedaquiline_                                                | 16            | codeine                   | 2          |
| _bendamustine_                                               | 25            | colecalciferol            | 54         |
| benzathine benzylpenicillin                                  | 9             | _colistin_                | 14         |
| benznidazole                                                 | 24            | condoms                   | 49         |
| benzoyl peroxide                                             | 39            | copper-containing device  | 49         |
| benzyl benzoate                                              | 39            | cyclizine                 | 3          |
| benzylpenicillin                                             | 9             | _cyclophosphamide_        | 26         |
| betamethasone                                                | 39            | _cycloserine_             | 16         |
| _bevacizumab_                                                | 48            | _cytarabine_              | 26         |
| _bicalutamide_                                               | 31            | dabigatran                | 33         |
| biperiden                                                    | 33            | _dacarbazine_             | 27         |
| bisoprolol                                                   | 35, 36, 37    | daclatasvir               | 20         |
| **WHO Model List of Essential Medicines – 22nd List (2021)** |               | **page 59**               |            |

**WHO Model List of Essential Medicines – 22nd List (2021)**

| daclatasvir + sofosbuvir                                     |                  | 20                                                  | fluconazole                                              | 17                |
| ------------------------------------------------------------ | ---------------- | --------------------------------------------------- | -------------------------------------------------------- | ----------------- |
| _dactinomycin_                                               |                  | 27                                                  | flucytosine                                              | 17                |
| dapsone                                                      |                  | 15                                                  | _fludarabine_                                            | 27                |
| darunavir                                                    |                  | 18                                                  | fludrocortisone                                          | 43                |
| dasabuvir                                                    |                  | 20                                                  | fluorescein                                              | 40                |
| _dasatinib_                                                  |                  | 30                                                  | fluoride                                                 | 55                |
| _daunorubicin_                                               |                  | 27                                                  | _fluorouracil_                                           | 28, 39            |
| _deferoxamine_                                               |                  | 4, 34                                               | fluoxetine                                               | 3, 52             |
| _delamanid_                                                  |                  | 16                                                  | fluphenazine                                             | 51                |
| dengue vaccine                                               |                  | 46                                                  | folic acid                                               | 33                |
| desmopressin                                                 |                  | 34                                                  | _fomepizole_                                             | 4                 |
| dexamethasone                                                | 3, 4, 31, 42, 50 | _fosfomycin_                                        | 14                                                       |                   |
| dextran 70                                                   |                  | 35                                                  | fresh-frozen plasma                                      | 34                |
| diaphragms                                                   |                  | 49                                                  | furosemide                                               | 37, 41            |
| diazepam                                                     | 3, 5, 52         | _gemcitabine_                                       | 28                                                       |                   |
| _diazoxide_                                                  |                  | 44                                                  | gentamicin                                               | 10, 47            |
| diethylcarbamazine                                           |                  | 6                                                   | glass ionomer cement                                     | 55                |
| digoxin                                                      | 35, 37           | glecaprevir + pibrentasvir                          | 20                                                       |                   |
| dihydroartemisinin + piperaquine phosphate                   | 22               | gliclazide                                          | 44                                                       |                   |
| diloxanide                                                   |                  | 21                                                  | glucagon                                                 | 44                |
| _dimercaprol_                                                |                  | 4                                                   | glucose                                                  | 53                |
| diphtheria antitoxin                                         |                  | 45                                                  | glucose with sodium chloride                             | 53                |
| diphtheria vaccine                                           |                  | 46                                                  | glutaral                                                 | 41                |
| _docetaxel_                                                  |                  | 27                                                  | glyceryl trinitrate                                      | 35                |
| docusate sodium                                              |                  | 3                                                   | griseofulvin                                             | 17                |
| dolutegravir                                                 |                  | 19                                                  | Haemophilus influenzae type b vaccine                    | 46                |
| dolutegravir + lamivudine + tenofovir                        |                  | 19                                                  | haloperidol                                              | 3, 51             |
| _dopamine_                                                   |                  | 38                                                  | halothane                                                | 1                 |
| _doxorubicin_                                                |                  | 27                                                  | heparin sodium                                           | 33, 34            |
| doxycycline                                                  | 10, 22, 23       | hepatitis A vaccine                                 | 46                                                       |                   |
| efavirenz                                                    |                  | 18                                                  | hepatitis B vaccine                                      | 46                |
| efavirenz + emtricitabine + tenofovir                        |                  | 19                                                  | human papilloma virus (HPV) vaccine                      | 46                |
| efavirenz + lamivudine + tenofovir                           |                  | 19                                                  | hydralazine                                              | 36                |
| eflornithine                                                 |                  | 24                                                  | hydrochlorothiazide                                      | 36, 37, 41        |
| empagliflozin                                                |                  | 44                                                  | hydrocortisone                                           | 4, 31, 39, 42, 43 |
| emtricitabine + tenofovir                                    |                  | 19                                                  | hydroxocobalamin                                         | 33                |
| enalapril                                                    | 36, 37           | _hydroxycarbamide_                                  | 28, 34                                                   |                   |
| enoxaparin                                                   |                  | 33                                                  | _hydroxychloroquine_                                     | 55                |
| entecavir                                                    |                  | 20                                                  | hyoscine butylbromide                                    | 3                 |
| _ephedrine_                                                  |                  | 1                                                   | hyoscine hydrobromide                                    | 3                 |
| epinephrine (adrenaline)                                     | 4, 35, 48, 53    | _ibrutinib_                                         | 30                                                       |                   |
| equine rabies immunoglobulin                                 |                  | 45                                                  | ibuprofen                                                | 2, 24, 51         |
| ergocalciferol                                               |                  | 54                                                  | _ifosfamide_                                             | 28                |
| ergometrine                                                  |                  | 50                                                  | _imatinib_                                               | 30                |
| _erlotinib_                                                  |                  | 30                                                  | influenza vaccine                                        | 47                |
| erythromycin                                                 |                  | 47                                                  | insulin injection (soluble)                              | 44                |
| _erythropoiesis-stimulating agents_                          |                  | 33                                                  | intermediate-acting insulin                              | 44                |
| estradiol cypionate + medroxyprogesterone acetate            | 49               | _intraperitoneal dialysis solution (of appropriate_ |                                                          |                   |
| ethambutol                                                   |                  | 15                                                  | _composition)_                                           | 51                |
| ethambutol + isoniazid + pyrazinamide + rifampicin           | 15               | iodine                                              | 54                                                       |                   |
| ethambutol + isoniazid + rifampicin                          |                  | 15                                                  | iohexol                                                  | 40                |
| ethanol                                                      |                  | 40                                                  | ipratropium bromide                                      | 53                |
| ethinylestradiol + etonogestrel                              |                  | 49                                                  | _irinotecan_                                             | 28                |
| ethinylestradiol + levonorgestrel                            |                  | 49                                                  | isoflurane                                               | 1                 |
| ethinylestradiol + norethisterone                            |                  | 49                                                  | isoniazid                                                | 15                |
| _ethionamide_                                                |                  | 16                                                  | isoniazid + pyrazinamide + rifampicin                    | 15                |
| _ethosuximide_                                               |                  | 6                                                   | isoniazid + pyridoxine + sulfamethoxazole + trimethoprim |                   |
| etonogestrel-releasing implant                               |                  | 49                                                  |                                                          | 19                |
| _etoposide_                                                  |                  | 27                                                  | isoniazid + rifampicin                                   | 15                |
| _everolimus_                                                 |                  | 30                                                  | isoniazid + rifapentine                                  | 15                |
| fentanyl                                                     |                  | 2                                                   | isosorbide dinitrate                                     | 35                |
| ferrous salt                                                 |                  | 33                                                  | itraconazole                                             | 17                |
| ferrous salt + folic acid                                    |                  | 33                                                  | ivermectin                                               | 6, 24             |
| fexinidazole                                                 |                  | 23                                                  | Japanese encephalitis vaccine                            | 46                |
| _filgrastim_                                                 |                  | 31                                                  | ketamine                                                 | 1                 |
| **WHO Model List of Essential Medicines – 22nd List (2021)** |                  |                                                     | **page 60**                                              |                   |

**WHO Model List of Essential Medicines – 22nd List (2021)**

| lactulose                                                    | 3       | natamycin                                              | 48            |
| ------------------------------------------------------------ | ------- | ------------------------------------------------------ | ------------- |
| lamivudine                                                   | 18      | neostigmine                                            | 47            |
| lamivudine + zidovudine                                      | 19      | nevirapine                                             | 18            |
| lamotrigine                                                  | 5       | niclosamide                                            | 6             |
| latanoprost                                                  | 48      | nicotinamide                                           | 54            |
| ledipasvir + sofosbuvir                                      | 20      | nicotine replacement therapy (NRT)                     | 52            |
| _lenalidomide_                                               | 31      | nifedipine                                             | 50            |
| _leuprorelin_                                                | 32      | nifurtimox                                             | 24            |
| levamisole                                                   | 6       | _nilotinib_                                            | 30            |
| levodopa + carbidopa                                         | 33      | nitrofurantoin                                         | 11            |
| _levofloxacin_                                               | 16      | nitrous oxide                                          | 1             |
| levonorgestrel                                               | 49      | _nivolumab_                                            | 31            |
| levonorgestrel-releasing implant                             | 49      | norethisterone enantate                                | 49            |
| levonorgestrel-releasing intrauterine system                 | 49      | _normal immunoglobulin_                                | 35            |
| levothyroxine                                                | 44      | nystatin                                               | 17            |
| lidocaine                                                    | 1, 35   | ofloxacin                                              | 48            |
| lidocaine + epinephrine (adrenaline)                         | 1       | ombitasvir + paritaprevir + ritonavir                  | 20            |
| _linezolid_                                                  | 14, 16  | omeprazole                                             | 41            |
| lisinopril + amlodipine                                      | 36      | ondansetron                                            | 3, 42         |
| lisinopril + hydrochlorothiazide                             | 36      | oral rehydration salts                                 | 43, 53        |
| lithium carbonate                                            | 52      | oral rehydration salts – zinc sulfate                  | 42            |
| long-acting insulin analogues                                | 44      | _oseltamivir_                                          | 20            |
| loperamide                                                   | 3       | _oxaliplatin_                                          | 28            |
| lopinavir + ritonavir                                        | 18      | _oxamniquine_                                          | 6             |
| loratadine                                                   | 4       | oxygen                                                 | 1, 2          |
| lorazepam                                                    | 5       | oxytocin                                               | 50            |
| losartan                                                     | 36, 37  | _paclitaxel_                                           | 29            |
| _Lugol's solution_                                           | 45      | paliperidone                                           | 51            |
| magnesium sulfate                                            | 5       | _p-aminosalicylic acid_                                | 16            |
| mannitol                                                     | 41      | _pancreatic enzymes_                                   | 41            |
| measles vaccine                                              | 46      | paracetamol                                            | 2, 24         |
| mebendazole                                                  | 6       | paromomycin                                            | 21            |
| medroxyprogesterone acetate                                  | 43, 49  | _pegaspargase_                                         | 29            |
| mefloquine                                                   | 22, 23  | _pegylated interferon alfa 2a_                         | 21            |
| meglumine antimoniate                                        | 21      | penicillamine                                          | 4, 55         |
| _meglumine iotroxate_                                        | 40      | _pentamidine_                                          | 23            |
| melarsoprol                                                  | 24      | permethrin                                             | 39            |
| _melphalan_                                                  | 28      | pertussis vaccine                                      | 46            |
| meningococcal meningitis vaccine                             | 46      | phenobarbital                                          | 5             |
| _mercaptopurine_                                             | 28      | phenoxymethylpenicillin                                | 11            |
| _meropenem_                                                  | 14, 16  | phenytoin                                              | 5             |
| _meropenem + vaborbactam_                                    | 14      | phytomenadione                                         | 33            |
| _mesna_                                                      | 32      | pilocarpine                                            | 48            |
| metformin                                                    | 44      | piperacillin + tazobactam                              | 14            |
| _methadone_                                                  | 2, 52   | platelets                                              | 34            |
| methimazole                                                  | 44, 45  | _plazomicin_                                           | 14            |
| _methotrexate_                                               | 28, 55  | pneumococcal vaccine                                   | 46            |
| methyldopa                                                   | 37      | podophyllum resin                                      | 39            |
| _methylprednisolone_                                         | 32      | poliomyelitis vaccine                                  | 46            |
| methylthioninium chloride (methylene blue)                   | 4       | _polymyxin B_                                          | 14            |
| metoclopramide                                               | 3, 42   | potassium chloride                                     | 53, 54        |
| metronidazole                                                | 11, 21  | potassium ferric hexacyano-ferrate(II) -2H20 (Prussian |               |
| _micafungin_                                                 | 17      | blue)                                                  | 4             |
| miconazole                                                   | 38      | _potassium iodide_                                     | 17, 44, 45    |
| midazolam                                                    | 1, 3, 5 | potassium permanganate                                 | 39            |
| mifepristone – misoprostol                                   | 50      | povidone iodine                                        | 40            |
| miltefosine                                                  | 21      | praziquantel                                           | 6             |
| misoprostol                                                  | 50      | prednisolone                                           | 4, 32, 42, 48 |
| morphine                                                     | 1, 2    | primaquine                                             | 22            |
| moxifloxacin                                                 | 15, 16  | procaine benzylpenicillin                              | 11            |
| multiple micronutrient powder                                | 54      | _procarbazine_                                         | 29            |
| multiple micronutrient supplement                            | 50      | progesterone vaginal ring                              | 49            |
| mumps vaccine                                                | 47      | proguanil                                              | 23            |
| mupirocin                                                    | 39      | propofol                                               | 1             |
| naloxone                                                     | 4       | propranolol                                            | 24            |
| **WHO Model List of Essential Medicines – 22nd List (2021)** |         | **page 61**                                            |               |

**WHO Model List of Essential Medicines – 22nd List (2021)**

| propylthiouracil                       | 44, 45 | sulfamethoxazole + trimethoprim               | 11, 23   |
| -------------------------------------- | ------ | --------------------------------------------- | -------- |
| _prostaglandin E1_                     | 51     | sulfasalazine                                 | 42, 55   |
| protamine sulfate                      | 33     | sumatriptan                                   | 24       |
| pyrantel                               | 6      | suramin sodium                                | 23       |
| pyrazinamide                           | 15     | _surfactant_                                  | 51       |
| _pyridostigmine_                       | 47     | suxamethonium                                 | 47       |
| pyridoxine                             | 54     | _tacrolimus_                                  | 25       |
| pyrimethamine                          | 23     | _tamoxifen_                                   | 32       |
| quinine                                | 22     | telmisartan + amlodipine                      | 37       |
| rabies vaccine                         | 47     | telmisartan + hydrochlorothiazide             | 37       |
| raltegravir                            | 19     | tenofovir disoproxil fumarate                 | 18, 20   |
| ranitidine                             | 41     | terbinafine                                   | 38       |
| _rasburicase_                          | 32     | _testosterone_                                | 43       |
| _realgar-Indigo naturalis formulation_ | 29     | tetanus vaccine                               | 46       |
| red blood cells                        | 34     | tetracaine                                    | 48       |
| retinol                                | 54     | tetracycline                                  | 48       |
| ribavirin                              | 19, 21 | _thalidomide_                                 | 31       |
| riboflavin                             | 54     | thiamine                                      | 54       |
| rifabutin                              | 15     | tick-borne encephalitis vaccine               | 46       |
| rifampicin                             | 15     | timolol                                       | 48       |
| rifapentine                            | 15     | _tioguanine_                                  | 29       |
| risperidone                            | 51     | tiotropium                                    | 53       |
| ritonavir                              | 18     | tranexamic acid                               | 34, 50   |
| _rituximab_                            | 30     | _trastuzumab_                                 | 30       |
| rotavirus vaccine                      | 46     | triclabendazole                               | 6        |
| rubella vaccine                        | 46     | trimethoprim                                  | 12       |
| salbutamol                             | 53     | tropicamide                                   | 40       |
| salicylic acid                         | 39     | tuberculin, purified protein derivative (PPD) | 45       |
| selenium sulfide                       | 38     | typhoid vaccine                               | 47       |
| senna                                  | 3, 42  | ulipristal                                    | 49       |
| silver diamine fluoride                | 55     | urea                                          | 39       |
| silver sulfadiazine                    | 39     | valganciclovir                                | 19, 20   |
| simvastatin                            | 38     | valproic acid (sodium valproate)              | 5, 6, 52 |
| _sodium calcium edetate_               | 4      | vancomycin                                    | 14       |
| sodium chloride                        | 54     | varenicline                                   | 52       |
| sodium hydrogen carbonate              | 54     | varicella vaccine                             | 47       |
| sodium lactate                         | 54     | vecuronium                                    | 47       |
| sodium nitrite                         | 4      | verapamil                                     | 35       |
| _sodium nitroprusside_                 | 37     | _vinblastine_                                 | 29       |
| sodium stibogluconate                  | 21     | _vincristine_                                 | 29       |
| sodium thiosulfate                     | 4, 38  | _vinorelbine_                                 | 29       |
| sofosbuvir                             | 20     | voriconazole                                  | 17       |
| sofosbuvir + velpatasvir               | 20     | warfarin                                      | 34       |
| spectinomycin                          | 11     | water for injection                           | 54       |
| spironolactone                         | 38, 41 | whole blood                                   | 34       |
| _streptokinase_                        | 38     | xylometazoline                                | 55       |
| _streptomycin_                         | 16     | yellow fever vaccine                          | 46       |
| _succimer_                             | 4      | zidovudine                                    | 18       |
| sulfadiazine                           | 23     | zinc sulfate                                  | 43       |
| sulfadoxine + pyrimethamine            | 22, 23 | _zoledronic acid_                             | 32       |

**WHO Model List of Essential Medicines – 22nd List (2021)** **page 62**
